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1THE IMPORTANCE OF BETA CELL IMAGING
Beta cells are located in the pancreas and form, together with alpha, delta and polypeptide 
cells, clusters known as the islets of Langerhans. Beta cells produce insulin, which regulates 
glucose uptake by other cells. When beta cells are functioning correctly and target cells are 
sensitive to bind insulin, there is a normal blood glucose balance. However, in type 1 diabetes, 
the beta cell mass is reduced, because the immune system attacks and destroys the beta cells, 
leading to an imbalance of glucose levels in blood. In type 2 diabetes, cells in the peripheral 
organs are resistant to insulin, also leading to elevated blood glucose levels. The precise role 
of beta cells during the development and progression of diabetes is still unknown. To study the 
role of beta cells in the pathophysiology of diabetes, to monitor new treatment options, or to 
develop more personalized treatment strategies, a non-invasive method to determine beta cell 
mass is needed.
Uncontrolled focal growth of beta cells in the pancreas could lead to an insulinoma. Currently, 
the most widely used molecular imaging strategies to diagnose insulinomas are based on 
either somatostatin receptor scintigraphy or glucagon-like peptide-1 receptor scintigraphy.
Although the developments for the detection of neuroendocrine tumors have expanded, the 
search for new tracers for imaging neuroendocrine tumors is ongoing. The fi rst part of this 
thesis describes the development, improvement and characterization of new radiotracers 
for beta cell (tumor) imaging. The second part focusses on studies to validate the use of 
radiolabeled exendin to determine the beta cell mass non-invasively in two animal models of 
diabetes.
Chapter 2 | General introduction
In this chapter a brief overview of two beta cell related diseases, diabetes and insulinomas, is 
presented. Possible tracer candidates for visualizing beta cells in both diseases are described, 
as well as the requirements that an imaging agent should preferably meet, and challenges that 
we are facing when imaging beta cells in diabetes and insulinomas.
Chapter 3 | Preclinical evaluation of PAC1 targeting with radiolabeled maxadilan
In this chapter the evaluation of a new radiotracer, maxadilan, to image insulinomas is 
described. Maxadilan targets the PAC1 receptor that is expressed on insulinomas. Radiolabeled 
maxadilan was able to visualize subcutaneous insulinomas in vivo using SPECT.
Chapter 4 | Characterization of 111In-labeled glucose-dependent insulinotropic polypeptide 
as a radiotracer for neuroendocrine tumors
The feasibility of targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), 
that is expressed on neuroendocrine tumors, using a radiolabeled GIP analog is investigated 
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in this chapter. Subcutaneous GIPR-expressing tumors could be visualized in vivo using 
radiolabeled GIP and SPECT.
Chapter 5 | Enhanced specific activity by multi-chelation of exendin-3 leads to improved in 
vivo beta cell imaging
Of the tracers that we have tested during the last years, radiolabeled exendin seems to best 
fulfill the criteria for an adequate tracer for both beta cell and insulinoma imaging. To further 
improve the sensitivity of radiolabeled exendin and broaden its applicability, we have modified 
exendin by adding six lysine residues and six DTPA moieties. This new exendin-based compound 
is able to complex more radiometal atoms and as such delivers more activity to a single cell.
Chapter 6 | Efficient reduction of renal uptake of radiolabeled exendin
Using radiolabeled exendin is not only champagne and caviar. One of the challenges when 
performing SPECT imaging is the high kidney uptake of radiolabeled exendin, which could 
hamper the visualization of insulinomas. In chapter 6 we have described how to successfully 
reduce the kidney uptake by modifying exendin by introducing a methionine-isoleucine linker 
between NOTA and the peptide. This could open a window for exendin as a peptide receptor 
radionuclide therapeutic.
Chapter 7 | Strain differences determine the suitability of animal models for non-invasive 
in vivo beta cell mass determination with radiolabeled exendin
The second part of the thesis starts with an evaluation which animal model would be most 
optimal to reliably quantify the beta cell mass non-invasively. In this chapter, a comparison of 
the behavior of radiolabeled exendin in different animal models and strains is presented. The 
study showed that rat models are more suitable to study exendin-based beta cell determination 
than mouse models, because in mice there is significant exendin uptake in the exocrine 
pancreas as well.
Chapter 8 | Measuring the pancreatic beta cell mass in vivo with exendin SPECT during 
hyperglycemia and severe insulitis
In this chapter the performance of radiolabeled exendin in a type 1 diabetic mouse model 
under stress conditions has been investigated. Hyperglycemia and severe insulitis do not have 
a major impact on the determination of the beta cell mass using exendin.
Chapter 9 | Validation of [111In]In-exendin SPECT for the determination of the beta cell 
mass in BioBreeding Diabetes Prone rats
In chapter 9 radiolabeled exendin was applied to quantitatively assess the beta cell mass 
non-invasively in a rat model for spontaneous type 1 diabetes. A good correlation between the 
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1pancreatic uptake of radiolabeled exendin and the beta cell mass was found, which was not 
infl uenced by insulitis.
Chapter 10 | General discussion and future perspectives
In this fi nal chapter the obtained results are discussed, and a future outlook is given.
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According to the International Diabetes Federation, worldwide 464 million people are suffering 
from diabetes in 2019, of which more than 1 million are children with type 1 diabetes. The 
estimated number of adults living with diabetes is expected to rise to 578 million within ten 
years1. These huge numbers and the immense estimated increase underline the need for 
proper treatment, early diagnosis or even better, prevention.
Diabetes is a chronic disease in which either the islets of Langerhans in the pancreas are 
no longer able to produce insulin due to autoimmune destruction of the beta cells (type 1 
diabetes (T1D)), or in which cells in peripheral tissue become resistant to insulin. In the latter 
case, the beta cells are unable to produce enough insulin to overcome the resistance, leading 
to failure of the beta cells as a consequence of endoplasmic reticulum (ER) stress (type 2 
diabetes (T2D)). As the function of beta cells is to guard a normal blood sugar level, failure 
of these cells results in elevated blood glucose levels, called hyperglycemia. For both types 
of diabetes, acute or chronic elevation of the blood glucose levels can lead to complications, 
which can be very severe and even life-threatening. Acute complications are acute elevation of 
blood glucose levels leading to ketoacidosis, and coma as a result of low blood glucose, which 
can eventually lead to death. Chronic complications include microvascular diseases, such as 
retinopathy, nephropathy and neuropathy and macrovascular diseases, like cardiovascular 
diseases2. Currently, the most commonly used treatment for T1D is daily administration of 
insulin, either by subcutaneous injections or via an insulin pump. This is in contrast to T2D, 
where the main treatment starts with changing to a healthy lifestyle by increasing exercise 
or by dietary restrictions. The fi rst-line pharmacological treatment is blood glucose lowering 
medications (such as metformin), which can be complemented with drugs that stimulate 
insulin secretion (such as GLP-1 analogs) or drugs that stimulate elimination of glucose (such 
as SGLT-2 inhibitors)3.
Currently, most information about beta cell mass in humans is based on autopsy or biopsy 
studies, which do not show the dynamics in beta cell mass during the progression of diabetes. 
Functional studies are based on measuring glucose metabolism, (c-peptide levels, oral glucose 
tolerance tests) and are used as a surrogate to obtain dynamic data. However, these are based 
on beta cell function rather than on beta cell mass. Measuring only functional beta cells can 
underestimate the total amount of beta cells. Recently, it was shown that even in longstanding 
type 1 diabetes, there are still (functional) beta cells present4, 5. With this evidence, the 
dogma that in longstanding type 1 diabetes there is total depletion of beta cells was rebutted. 
Discrepancies between beta cell function and mass can occur as a result of the presence of 
dysfunctional beta cells as well as differences in beta cell sensitivity to stimuli. Therefore, a 
method to accurately measure the beta cell mass in vivo would provide a better insight in the 
pathophysiology of diabetes, and other beta cell related diseases.
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Neuroendocrine tumors (NETs) are a heterogeneous group of tumors which can arise 
throughout the body, but are most commonly found in the intestines, pancreas or lungs6. 
Insulinomas are the most common type of functioning pancreatic neuroendocrine tumors, 
which originate from the beta cells in the islets of Langerhans. Although the incidence of 
insulinomas is very low (1-3 per million per year), and >90% of the insulinomas are benign, 
the clinical symptoms, namely hypoglycemia, are severe and require immediate treatment7, 
8. Biochemical diagnosis of insulinomas is based on low blood glucose levels or elevated 
proinsulin, insulin and C-peptide levels in plasma and these tests can be complemented with 
fasting tests (which result in hypoglycemia if insulinoma is present)9-11.
Accurate diagnosis and localization of insulinomas to guide therapeutic intervention is 
essential. Currently, the treatment of choice for insulinomas is surgical removal of the lesion 
or partial pancreatectomy. Since 10 to 27% of insulinomas are not detected intraoperatively8, 
preoperative and/or intraoperative localization of insulinomas is crucial to identify the tumor 
lesion and to minimize unnecessary surgical interventions.
In this thesis, we describe the development and characterization of new agents to image beta 
cells in the pancreas as well as to detect insulinomas. Furthermore, we have investigated 
possibilities to improve glucagon-like peptide 1 receptor (GLP-1R) imaging with GLP-1 analogs, 
a technique that is currently in clinical use for imaging of insulinomas.
TRACERS FOR BETA CELL IMAGING
The ideal tracer
Nowadays, radionuclide imaging is indispensable for the diagnosis and treatment of tumors 
and other diseases. Peptide targeted molecular imaging is based on a targeting peptide, which 
recognizes specific binding sites (such as receptors, antigens) on a certain cell type, being 
for example tumor cells or immune cells. Labeling of peptides with a radiometal is done 
via a chelating moiety. After binding of the radiolabeled peptide to the receptor, the whole 
receptor-peptide-complex can be internalized into the cell, where the chelated radioisotope 
will be trapped in lysosomes. The peptide will be degraded and the receptor is degraded or can 
translocate to the cell membrane again, where it is able to bind a new radiolabeled peptide. This 
process can lead to a high accumulation of the radioisotope in tissues that express the targeted 
receptor12. One of the characteristics of cancer cells is high expression of tumor-associated 
receptors. This high expression is an advantage for targeted molecular imaging, because it 
can result in high uptake of the radiolabeled peptide. Ideally, a targeting agent should meet the 
following criteria: 1) high and specific uptake in tissue of interest, 2) low uptake in non-target 
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tissue, 3) high affi nity for the receptor, 4) fast blood clearance, 5) suffi cient metabolic stability, 
6) low or no toxicity, and in the case of an agonist 7) a minimal pharmacological effect.
Since insulinomas have high abundance of the GLP-1 receptor, it is reasonable that high 
amounts of GLP-1 analogs could accumulate into these tumors, and with that it should be 
relatively easy to detect insulinomas using PET and SPECT. On the contrary, native beta cells in 
the pancreas are ‘healthy’ cells and have lower GLP-1 receptor expression. Furthermore, beta 
cells, together with alpha, delta and polypeptide cells, form the islets of Langerhans which are 
spread throughout the pancreas and only represent 1-2% of the total pancreatic mass. Hence, 
imaging of these pancreatic beta cells is much more challenging than imaging tumor cells13, 
since tumors consist of more cells than the islets of Langerhans and have increased receptor 
expression. Thus, the perfect tracer for native beta cell imaging should even meet more 
requirements. As there are less receptors available for binding, a low peptide dose should 
be administered to prevent saturation of the receptors. Along with a low peptide dose, a high 
molar activity is warranted in order to get a suffi cient amount of radioactive signal in the organ 
of interest, to allow detection with SPECT or PET.
Tracers for beta cell imaging
Currently, the most widely used imaging technique for the detection of insulinomas is 
somatostatin receptor scintigraphy (SRS). Different ligands targeting the somatostatin receptor 
have been tested, all based on octreotide. For example, a study using [111In]In-DTPA-D-Phe
1-
octreotide reported a detection rate of 53%14. A study of Antwi described a detection rate of 33% 
for [68Ga]DOTATOC15 and in another study using [68Ga]Ga-DOTA-TATE and [68Ga]Ga-DOTATOC, a 
sensitivity of 85% has been described for detecting insulinomas16.
Interestingly, a technique to visualize the pancreatic beta cells in diabetic patients does not 
exist to date. 
Several targets for beta cell imaging have been evaluated, based on their expression pattern 
in beta cells or in beta-cell derived tumors17. Incretins are hormones that are secreted after 
nutrient intake and stimulate insulin secretion in a glucose-dependent manner18, 19. As incretins 
are key players in controlling the glucose balance, these present interesting targets for beta 
cell imaging. Two incretin hormones, the glucose-dependent insulinotropic polypeptide (or 
gastric inhibitory polypeptide (GIP)) and glucagon-like peptide 1 (GLP-1) will be discussed in 
more detail18, 19. Furthermore, as PAC1 also seems to be involved in insulin secretion20 , this 
receptor will be discussed as well (Figure 1).
GIP
The GIP receptor (GIPR) belongs to the G-protein coupled receptor family and is expressed 
in several rodent tissues, like stomach, lung and most important in pancreatic islets18. 
Furthermore, abundant expression of the GIPR has been found in different neuroendocrine 
tumors, such as gastrointestinal and bronchial tumors, and the highest expression was found 
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in pancreatic tumors, including insulinomas21, 22. The natural GIP ligand has a short biological 
half-life and is rapidly cleaved by enzymes after release in the circulation23. The fi rst pre-
clinical study using different radiolabeled GIP analogs was performed by Gourni et al. They 
described high uptake of a GIP ligand, labeled with either 111In or 68Ga, in GIPR-transfected 
tumors, and the uptake in the pancreas could be blocked by an excess of unlabeled GIP24. As 
the kidneys are the main excretion route of radiolabeled GIP, high kidney uptake was observed, 
which could be partially reduced by co-injection of Gelofusine. Autoradiography using iodinated 
GIP confi rmed specifi c uptake in the islets of Langerhans in the pancreas, as well as specifi c 
uptake in pancreatic and bronchial NETs22. However, mRNA expression of GIPR has been 
detected in alpha and beta cells in rats by Moens et al. Nevertheless, it must be noted that they 
did not study the expression of GIPR on protein level25. 
Figure 1. An overview of beta cell specifi c receptors investigated in the next chapters. Abbreviations: GIP, 
glucose-dependent insulinotropic polypeptide; PAC1, pituitary adenylate cyclase-activating polypeptide 
type I; max, maxadilan; GLP-1, glucagon-like peptide 1; ex, exendin.
PAC1
Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase activating polypeptide (PACAP), 
and their receptors PAC1, VPAC1 and PAC2, being members of the G-protein coupled 
receptor family, have emerged as important factors in islet cell function (insulin secretion)20. 
Furthermore, they are involved in growth and differentiation of neuroendocrine tumors, 
including insulinomas. As these receptors are expressed at high levels in insulinomas and 
beta cells, they are potential targets for beta cell and insulinoma imaging26-28.
The natural mammalian ligands of PAC1, PACAP38 and the truncated form PACAP27, also 
bind VAPC1 and VPAC2. Because these ligands are not selective for the PAC1 receptor and 
are unstable in plasma29, they are not suited for in vivo targeting of PAC1 receptors. More than 
two decades ago it was demonstrated that the stable analog maxadilan shared features with 
ligands of the PACAP family30, 31. Maxadilan is a 61-amino acid vasoactive peptide, derived from 
sand fl ies32, 33, and has been demonstrated to bind specifi cally and with high affi nity to the PAC1 
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receptor, but not to VPAC1 or VPAC233. Thus far, it was unknown whether the PAC1 receptor 
is an appropriate target for imaging (healthy) beta cells. To the best of our knowledge, no 
studies were carried out using the PAC1 receptor for imaging insulinomas or for correlating 
the beta cell mass with uptake of PAC1 receptor targeting ligands. Also, the specifi city for 
beta cells is still unknown. So far, PACAP has been found in glucagon producing alpha cells 
and insulin producing beta cells, and was expressed in both normal and diabetic islets from 
rats and humans34. However, the specifi c expression pattern of the PAC1 receptor for beta or 
other endocrine cells was not explored. Contradictory results have been found by Filipsson et 
al., who were not able to demonstrate PACAP expression in insulin producing cells35. Yet, via 
in situ hybridization they did show PAC1 receptor expression in pancreatic endocrine cells, but 
the signal was equal in the exocrine pancreatic tissue. Nevertheless, the PAC1 receptor may 
be an interesting target for imaging insulinomas, but its potential for both pancreatic beta cell 
and insulinoma imaging needs to be investigated.
GLP-1R
The glucagon-like peptide 1 receptor (GLP-1R) is also a member of the G-protein coupled 
receptor family and is involved in beta cell proliferation and insulin secretion upon glucose 
stimulation. In human, the GLP-1R is mainly expressed in the pancreatic islets, duodenum 
and neuropituitary36. In mice and rats, high expression of the GLP-1R was also found in the 
lungs37, 38. As the GLP-1R is highly expressed on beta cells39, it is a promising target for imaging 
beta cells. Exendin is a stable analog of the natural GLP-1R ligand, the hormone GLP-1, and 
was isolated from the saliva of the Heloderma suspectum (Gilamonster)40. The feasibility of 
exendin-4 as an imaging agent was fi rst demonstrated by Gotthardt et al. in a preclinical study. 
Specifi c uptake of [111In]In-DTPA-exendin-4 was found in GLP-1R expressing organs, such as 
lungs and pancreas41. In addition, in a Rip1Tag2 mouse model insulinomas in the pancreas 
were visualized using [111In]In-DTPA-exendin-4 and SPECT/CT42. Over the years, several 
groups described exendin-based beta cell imaging using a variety of radioligands43, 44 or other 
molecular imaging strategies, like fl uorescently labeled exendin45. Recently, it was shown that 
the uptake of exendin in the pancreas was decreased in chemically induced diabetic animals46, 47.
Radiolabeled exendin has shown great potential to image native beta cells in diabetes. A study 
of Brom et al. showed a signifi cantly lower pancreatic uptake of [111In]In-DTPA-exendin in 
T1D patients as compared to healthy volunteers, although some individuals with T1D showed 
pancreatic uptake reaching into the lower range of uptake in healthy volunteers. Furthermore, 
the signal of the tracer in the pancreas of half of the T1D patients declined to almost the 
background level, suggesting that small amounts of beta cells can be detected and nonspecifi c 
uptake is neglectable46.
While exendin is a promising tracer for beta cell imaging, its specifi city for beta cells varies 
between species. In mice and pigs there is considerable uptake of exendin in the exocrine 
pancreas, but the tracer uptake in rats and humans is restricted to the endocrine cells39, 48. As 
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was demonstrated by Brom et al., uptake of exendin correlated with beta cell mass and not 
with alpha cell mass, indicating the specificity of exendin for beta cells49.
Challenges of GLP-1R-based beta cell imaging
As mentioned before, to be an ideal tracer, a targeting agent should meet various criteria. 
Exendin does meet some of these requirements, as it is stable, has high and specific uptake 
in the beta cells, has high affinity for the GLP-1R, fast blood clearance, and at low doses 
shows minimal toxicity or pharmacological effects49, 50. However, there is GLP-1R expression in 
non-target organs, like the duodenum, and exendin shows high accumulation in the kidneys. 
Furthermore, the extent to which the GLP-1R expression changes upon metabolic stress is 
unknown.
High kidney uptake
The main excretion route of hydrophilic small molecules, such as radiolabeled peptides is via 
the kidneys (Figure 2). Small molecules enter the kidneys via the bloodstream and are filtered 
through the glomeruli. Although part of the administered molecules is excreted via the urine, 
generally a significant part is reabsorbed in the proximal tubules, where different mechanisms 
of transport can be involved in the reabsorption of these peptides. Exendin is most probably 
reabsorbed via endocytic receptors that are located near the brush border membrane, as 
a recent study showed that the uptake of exendin in the kidneys could be reduced in mice 
that lack megalin, a particular endocytic receptor51, 52. After endocytic reabsorption of the 
radiolabeled peptide, it will be degraded in lysosomes, where the chelated radiometal will 
residualise, leading to high kidney accumulation.
The high kidney accumulation is a problem mainly for two reasons. First, high renal 
accumulation of radiolabeled exendin could hamper visualization of insulinomas that are in 
the vicinity of the kidneys. Second, because of the high kidney uptake, the prolonged radiation 
burden to the kidneys precludes the applicability of exendin for PRRT. Several successful 
attempts to reduce the kidney uptake have been described, for example by co-injection with 
the plasma expander Gelofusine53, 54. Also, the use of linkers that are cleaved by lysosomal 
enzymes, resulting in release of the radiometal-chelator complex into the urine have been 
described55. However, for exendin the use of Gelofusine is not as efficient as for octreotide for 
example56. Therefore, future research on minimizing the renal retention of tracers for beta cell 
and insulinoma imaging is warranted.
High molar activity
Whereas insulinomas have overexpression of the GLP-1R, the native beta cells in the pancreas 
have lower GLP-1R expression levels. As there are less binding sites for exendin in these 
endocrine beta cells, a very low peptide dose is needed to prevent saturation of the receptor. 
Furthermore, as the amount of beta cells declines in diabetic subjects and the amount of 
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Figure 2. Overview of glomerular and proximal tubular handling of proteins and peptides. AA = amino 
acid transporter, OCT = organic cation transporter, PEPT = oligopeptide transporter. This fi gure was 
originally published in JNM. Vegt et  al. Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: 
Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention. J Nucl Med. 2010; 51: 1049-
1058. © SNMMI.
beta cells between diabetic and healthy subjects partly overlaps, it is important to deliver high 
amounts of radiotracer to each single beta cell. Obviously, to be able to detect a suffi cient 
amount of radioactive signal associated with these cells, a tracer with a high molar activity 
is needed. This can be achieved for example by optimizing the labeling conditions57 or by 
introducing peptide modifi cations that could facilitate a higher molar activity.
Hyperglycemia
One concern when studying the beta cell mass using exendin is a potential infl uence of 
hyperglycemia on the GLP-1R expression. Hyperglycemia is one of the main characteristics 
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of diabetes. It is important that the influence of hyperglycemia on the GLP-1R expression is 
limited, as the determination of the beta cell mass using radiolabeled exendin depends on the 
expression of the GLP-1R. Chronic hyperglycemia has been demonstrated to down-regulate 
GLP-1R expression58, 59. This suggests that during development of diabetes the expression of 
the GLP-1R could change and with that the determination of the beta cell mass would be 
underestimated. It is therefore important to study the effects of elevated blood glucose levels 
on beta cell mass measurements using radiolabeled exendin.
Insulitis
Insulitis could also change the expression of the GLP-1R, inherent to the influence of blood 
glucose levels. Insulitis has been described as infiltration of the islets of Langerhans by 
lymphocytes, leading to inflammation of the islets and finally destruction of the beta cells60. 
During insulitis, several cytokines (IL-1, IFN-γ, a.o.) are released by immune cells. As not all 
diabetic patients have autoantibodies against beta cells (ICA, GADA, and IA-2-Ab) and not every 
patient has insulitis, it is important to unravel whether pro-inflammatory cytokines (e.g. IL-1β 
and IFN-γ) alter the expression of the GLP-1R. This is important, as the determination of the 
beta cell mass using radiolabeled exendin depends on the expression of GLP-1R. It has been 
demonstrated that upon treatment with cytokines the GLP-1R was down-regulated in vitro61. 
Similar to hyperglycemia, this might lead to an underestimation of the beta cell mass and 
thus it needs to be explored to which extend insulitis does have an influence on beta cell mass 
measurements using exendin.
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ABSTRACT
There is an ongoing search for new tracers to optimize imaging of beta cell-derived tumors 
(insulinomas). The PAC1 receptor, expressed by insulinomas, can be used for targeting of these 
tumors. Here, we investigated whether radiolabeled maxadilan could be used for insulinoma 
imaging. Maxadilan was C- or N-terminally conjugated with DTPA (termed maxadilan-DPTA or 
DTPA-maxadilan respectively). BALB/c nude mice bearing subcutaneous INS-1 tumors were 
injected with either 111In-labeled maxadilan-DTPA or DTPA-maxadilan. Biodistribution studies 
were carried out at 1, 2 and 4 hours after injection and SPECT/CT imaging 1 and 4 hours 
after injection of maxadilan-DTPA-[111In]In. Radiolabeling of maxadilan-DTPA (680 MBq/nmol) 
was more efficient than of DTPA-maxadilan (55 MBq/nmol). Conjugation with DTPA slightly 
reduced receptor binding affinity in vitro: IC50 values were 3.2, 21.0 and 21.0 nM for maxadilan, 
[natIn]In-DTPA-maxadilan and maxadilan-DTPA-[natIn]In respectively. Upon i.v. injection 
maxadilan-DTPA-[111In]In accumulated specifically in INS-1 tumors (7.30 ± 1.87%ID/g) and 
in the pancreas (3.82 ± 0.22%ID/g). INS-1 tumors were clearly visualized by small animal 
SPECT/CT. In conclusion, this study showed that the high affinity of maxadilan to the PAC1 
receptor was maintained after DTPA conjugation. Furthermore, radiolabeled maxadilan-DTPA 
accumulated specifically in INS-1 tumors and, therefore, may qualify as a useful tracer to 
image insulinomas.
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The most common pancreatic neuroendocrine tumors (NETs) are insulinomas. Insulinomas 
are tumors derived from the insulin-producing beta cells located in the islets of Langerhans in 
the pancreas. Clinical symptoms include symptomatic hypoglycemias as well as weight gain 
(due to increased food intake to compensate for hypoglycemia) and neurological symptoms1. 
Biochemical diagnosis is based on low blood glucose levels or elevated proinsulin, insulin and 
C-peptide levels in plasma and these tests can be complemented with fasting tests (which 
results in hypoglycemia if insulinoma is present) 1-3. The most widely used nuclear medicine 
imaging strategy for detecting insulinomas is somatostatin receptor scintigraphy (SRS) using 
111In-labeled octreotide. SRS is based on targeting somatostatin receptors (SSTR), which 
are over-expressed in sixty percent of insulinomas4. Because the remaining forty percent 
has either low or no expression of this receptor, many insulinomas are not being detected 
by scintigraphy based on somatostatin receptor targeting 2-4. More preferably, PET (Positron 
Emission Tomography) imaging with octreotide analogs can be used, since PET is more 
sensitive than SPECT imaging, due to the higher spatial resolution of clinical PET scanners 
and higher sensitivity in detection of emitted gamma photons. A few promising studies were 
conducted using SSTR PET/CT, although these studies showed that a small percentage of 
insulinomas remain undetected 5-8.
More than ten years ago, it was demonstrated that almost all insulinomas express several 
neuropeptide receptors, including CCK2 (cholecystokinin), VPAC1 (vasoactive intestinal peptide/
PACAP receptor subtype 1) and GLP-1 (glucagon-like peptide 1) receptors 4. Several preclinical 
SPECT and PET studies in RipTag2 mouse models using the GLP-1 analogs exendin-3 and 
exendin-4, showed specifi c tracer accumulation in insulinomas via the GLP-1 receptor 9-11. 
In the fi rst pioneering clinical PET/CT and SPECT/CT studies with exendin-4 in insulinoma 
patients, small insulinomas, which could not be detected by conventional imaging methods 
(endoscopic ultrasound, MRI (Magnetic Resonance Imaging), CT (Computed Tomography), 
SRS) 12-17, were accurately diagnosed. The success of visualizing neuroendocrine tumors is 
partially dependent on the type of receptors expressed in the tumors, as was shown previously 
by Baumann et al 5. For example, malignant insulinomas have a low incidence and expression 
density of the GLP-1 receptor, but show high expression of the somatostatin receptor, where 
in benign insulinomas the expression profi le is more favorable for the GLP-1R 4, 18, 19. Therefore, 
to improve the diagnostic tool box, the search for new tracers for detection of insulinomas is 
ongoing.
Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase activating polypeptide (PACAP), 
and their receptors PAC1, VPAC1 and PAC2 have emerged as important factors in islet cell 
function (insulin secretion) and growth and differentiation of neuroendocrine tumors including 
insulinomas. As these receptors are highly expressed in insulinomas and beta cells, they are 
potential targets for beta cell and insulinoma imaging 20-22.
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Using in vitro receptor autoradiography with VPAC1 and VPAC2 subtype-selective ligands, 
insulinomas have been demonstrated to bind high levels of radiolabeled selective VPAC1 
receptor ligands, although substantially less than GLP-1 selective ligands 4. As PAC1, VPAC1 
and VPAC2 mRNAs were detected in a rat insulinoma cell line with PAC-1 binding prevailing 
over that of VPAC1 and VPAC2 23, the PAC1 receptor seemed to be a promising alternative for 
targeting insulinomas. The natural mammalian ligands at the PAC1 receptor are PACAP38 and 
the truncated form PACAP27. They bind to PAC1, VPAC1 and VPAC2, whereas VIP only binds to 
VPAC1 and VPAC2. Since PACAP38 and PACAP27 are non-selective PAC1/VPAC1/VPAC2 ligands 
and unstable in plasma 24, they are not suited for in vivo targeting of PAC1 receptors. More than 
two decades ago it was demonstrated that the stable analog maxadilan shared features with 
ligands of the PACAP family 25, 26. Maxadilan is a 61-amino acid vasoactive peptide, derived from 
sand flies 27, 28, and has been demonstrated to bind specifically and with high affinity to the PAC1 
receptor but not to either VPAC1 or VPAC2 28.
In the present study we have examined the ability of 111In-labeled maxadilan to image rat 
insulinoma xenografts  (INS-1) in a nude mouse model. For this purpose maxadilan was either 
C- or N-terminally conjugated with DTPA to allow labeling with 111In. These compounds were 
evaluated for their radiolabeling properties and in vitro and in vivo binding characteristics.
MATERIALS AND METHODS
Peptides 
DTPA-conjugated and native maxadilan were purchased from Think Peptides (ProImmune 
Limited, Oxford, United Kingdom). N-terminal conjugation of DTPA (DTPA-maxadilan) was 
performed with isothiocyanate-DTPA (Macrocyclics, Dallas, TX, USA) via a beta-alanine 
spacer and C-terminal conjugation (maxadilan-DTPA) with p-NH2-Bn-DTPA via an extra 
C-terminal glutamic acid. The quality and purity of the peptides was determined using RP-
HPLC (reversed-phase high performance liquid chromatography) and mass spectrometry (MS) 
by the manufacturer. RP-HPLC showed a purity of 95.35%, 93.9% and 100% and a retention 
time of 15.18 min, 15.81 min and 14.46 for maxadilan, DTPA-maxadilan and maxadilan-DTPA 
respectively. With MS the expected mass of the peptides was confirmed (6870, 7537 and 7641 Da 
for maxadilan, DTPA-maxadilan and maxadilan-DTPA respectively). The amino acid sequences 
of the peptides are shown in Table 1. 
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Table 1. Amino acid sequence of maxadilan, DTPA-maxadilan and maxadilan-DTPA. Cysteine residues that 
form disulfi de bonds are underlined and indicated by the dotted lines30.





DTPA-maxadilan and maxadilan-DTPA were labeled with 111In by adding 111InCl3 to 1 µg peptide 
in 0.1 M MES buffer, pH 5.5. After incubation at room temperature for 20 min, 50 mM EDTA 
(ethylenediaminetetraacetic acid) (Sigma Aldrich, St. Louis, MO, USA) was added to a fi nal 
concentration of 5 mM. Quality control was performed by Instant Thin Layer Chromatography 
(ITLC) on silica gel ITLC strips (Pall Corporation Life Sciences, New York, NY, USA). As a mobile 
phase 0.1 M EDTA in 0.1 M NH4Ac, pH 5.5 was used (Rf
111In-maxadilan = 0, Rf
111In-EDTA = 1). 
The reaction mixture was purifi ed on a disposable PD-10 desalting column (GE Life Sciences, 
Diegem, Belgium), which was eluted with 10 ml PBS, 0.5% (v/w) bovine serum albumin (BSA) 
and fractions containing radiolabeled maxadilan were pooled.
Serum stability
Maxadilan-DTPA was labeled with 5 MBq 111InCl3 as previously described and incubated with 
human serum (1:10) at 37°C. Before addition of human serum and 1, 2, 4 and 24 hours after 
incubation with human serum, samples were taken, mixed with acetonitrile (1:1) and centrifuged 
for 5 min at 5000g to precipitate serum proteins. The supernatant was analyzed using RP-HPLC 
on a C18 reversed-phase column (Alltima; 4.6 mm x 25 cm; Grace, Breda, The Netherlands) and 
ITLC. The column was eluted with a linear gradient of 0.1% TFA (trifl uoroacetic acid, Lab-Scan, 
Analytical Sciences, Brussels, Belgium) in acetonitrile (3% to 100% over 10 min) with a fl ow 
rate of 1 ml/min. ITLC was performed as described above.
Cell culture
The rat insulinoma cell line INS-147 was maintained in RPMI-1640 medium supplemented with 
10% fetal bovine serum, 2 mM glutamine, 10 mM HEPES, 50 µM β-mercaptoethanol, 1 mM 
sodium pyruvate, 100 units/ml penicillin and 100 µg/ml streptomycin, in a humidifi ed 5% CO2
atmosphere at 37 °C. The cells were harvested by trypsinization with trypsin/EDTA.
Competitive binding assay
The 50% inhibitory concentration (IC50) of maxadilan, DTPA-maxadilan, maxadilan-DTPA, [
natIn]
In-DTPA-maxadilan and maxadilan-DTPA-[natIn]In was determined using suspensions of INS-1 
cells. Labeling of DTPA-maxadilan and maxadilan-DTPA with natIn was performed as previously 
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described9, 48. Unlabeled and natIn-labeled peptides were added to the cells (approximately 10 x 
106 cells in a final volume of 0.5 mL) in Eppendorf tubes to final concentrations ranging from 
0.1 to 300 nmol (n=3) together with 1,000 Bq maxadilan-DTPA-[111In]In. After 4 hours incubation 
on ice, the cells were centrifuged at 3,000 x g, the supernatant was removed and the cells were 
washed with 1 ml ice-cold PBS and the radioactivity in the cell pellet was determined in a well-
type gamma counter (Wallac 1480-Wizard, Perkin-Elmer, Boston, MA, USA). The IC50 value 
was calculated by one-site competition analysis with Graphpad Prism (version 5.03, GraphPad 
Software, San Diego, CA USA).
Biodistribution studies 
All experiments were performed in accordance with Radboud University guidelines. Animal 
experiments were approved by the Animal Ethical Committee of the Radboud University, 
Nijmegen, The Netherlands.
In order to assess the feasibility of targeting insulinomas with radiolabeled maxadilan, female 
BALB/c nude mice (6-8 weeks old) were injected subcutaneously with INS-1 cells (1x107 cells 
in 200 µl). When the tumors had grown to approximately 5 mm in diameter, groups of five 
mice were injected with either 370 kBq [111In]In-DTPA-maxadilan or maxadilan-DTPA-[111In]In 
(peptide dose: 13 pmol). For both peptides, an additional group of 5 mice was co-injected with 
an excess (1,300 pmol) of unlabeled maxadilan to determine the nonspecific binding of the 
peptides to the cells. Mice were euthanized 2 hours p.i. and blood, muscle, tumor, heart, lung, 
spleen, pancreas, stomach, intestine, adrenals, kidney and liver were dissected, weighed and 
the radioactivity concentration was determined.
To examine the pharmacokinetics of maxadilan-DTPA-[111In]In, BALB/c nude mice (n=4/group) 
were injected with 370 kBq maxadilan-DTPA-[111In]In and mice were euthanized at 1, 2 or 4 
hours p.i.. The radioactivity concentration in the organs was measured in a gamma counter.
SPECT of BALB/c nude mice bearing subcutaneous INS-1 tumors
BALB/c nude mice bearing subcutaneous INS-1 tumors were injected intravenously with 9 MBq 
maxadilan-DTPA-[111In]In (13 pmol). A separate group of tumor-bearing mice was co-injected 
with an excess of unlabeled maxadilan (1,300 pmol). One and four hours p.i. SPECT/CT images 
were acquired using a dedicated small animal SPECT scanner (U-SPECT-II, MILabs, Utrecht, 
The Netherlands). SPECT images were acquired with a 0.6 mm pinhole mouse collimator with an 
acquisition time of 50 min. The images were reconstructed with OSEM (3 iterations, 16 subsets, 
voxel size 0.375) using the U-SPECT-Rec software (MILabs, Utrecht, The Netherlands). The 
settings for the CT were as follows: spatial resolution, 160 µm; 40 kV; 612 µA.
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Statistical analysis was done using GraphPad Prism version 5.03 for Windows. The unpaired t test 
was used for determination of signifi cance. A p-value below 0.05 was considered as signifi cant. 
For the competitive binding assay the F-test was used to manually calculate signifi cance.
RESULTS
Radiolabeling
[111In]In-DTPA-maxadilan and maxadilan-DTPA-[111In]In could be labeled with a molar activity 
of 55 and 680 MBq/nmol, respectively. The radiochemical purity after purifi cation exceeded 
95%.
Serum stability
The stability of maxadilan-DTPA-[111In]In was analyzed in human serum. The radiochemical 
purity directly after labeling was >95% (Figure 1A). The radiolabeled peptide remained intact 
up to 24 hours after incubation in human serum, as is shown in Figure 1B. [111In]In-EDTA and 
radiolabeled maxadilan have a retention time of 3-4 min and 14.6 min, respectively.
Figure 1. Stability of maxadilan-DTPA-[111In]In in human serum. A) HPLC profi le of maxadilan-DTPA-[111In]In
directly after labeling. B) Stability analysis of maxadilan-DTPA-[111In]In before and 1, 2, 4 and 24 hours after 
incubation in human serum at 37°C.
Competitive binding assay
The results of the IC50 determination of labeled and unlabeled maxadilan analogs are 
summarized in Figure 2 and Table 2. Unlabeled maxadilan had the highest affi nity (IC50 value: 
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3.2 nM) for the receptor. DTPA conjugation resulted in a somewhat lower affinity as indicated 
by slightly higher IC50 values: 18.3 and 13.2 nM (p<0.001 and p<0.001) for DTPA-maxadilan and 
maxadilan-DTPA, respectively. Labeling of DTPA-maxadilan or maxadilan-DTPA with natIn did 
not significantly reduce the affinity (p=0.07 and p=0.12 respectively) compared to the unlabeled 
compounds.
Figure 2. Competitive binding assay (IC50) on INS-1 cells of unlabeled maxadilan, maxadilan-DTPA and 
DTPA-maxadilan, either unlabeled, or labeled with natIn. 111In-labeled maxadilan-DTPA was used as 
radioligand.
Table 2. IC50 values and 95% confidence intervals (in nM) of the competitive binding assay on INS-1 cells. 
Peptide IC50 (nM) 95% confidence interval (nM)
Maxadilan 3.2 2.1 – 4.9
Maxadilan-DTPA 13.2 8.8 – 19.8
DTPA-maxadilan 18.3 13.2 – 25.3
Maxadilan-DTPA-[NatIn]In 21.0 13.7 – 32.2
[NatIn]In-DTPA-maxadilan 21.0 11.8 – 37.3
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The results of the in vivo PAC1 receptor targeting study with 111In-labeled maxadilan in BALB/c 
nude mice bearing subcutaneous INS-1 tumors are summarized in Figure 3. Uptake of 
maxadilan-DTPA-[111In]In in the tumor was 7.76 ± 1.37 %ID/g, which was signifi cantly higher 
than that of [111In]In-DTPA-maxadilan (4.82 ± 0.87 %ID/g) (p=0.0037). Also, pancreatic uptake 
was signifi cantly higher for maxadilan-DTPA-[111In]In compared to [111In]In-DTPA-maxadilan, 
(3.87 ± 0.56 %ID/g and 2.73  ± 0.35 %ID/g respectively, p=0.0048). Accumulation in both tumor 
and pancreas could be blocked by an excess of unlabeled maxadilan, demonstrating specifi c 
uptake of the peptides via the PAC1 receptor (1.54 ± 0.49 %ID/g and 1.24 ± 0.48 %ID/g for 
maxadilan-DTPA-[111In]In and [111In]In-DTPA-maxadilan respectively in tumor tissue and 
0.59 ± 0.07 %ID/g and 0.43 ± 0.04 %ID/g respectively for pancreatic uptake). Renal uptake 
was very high and similar for both peptides (148 ± 3 and 145 ± 19 %ID/g for [111In]In-DTPA-
maxadilan and maxadilan-DTPA-[111In]In, respectively), which could not be blocked with an 
excess of unlabeled maxadilan. Furthermore, in all other dissected organs, except for blood 
and spleen, receptor-mediated uptake of maxadilan was observed. Since these results showed 
that maxadilan-DTPA-[111In]In has higher accumulation in tumor and pancreatic tissue than 
[111In]In-DTPA-maxadilan, this peptide was used to study the pharmacokinetics. Figure 4 shows 
the fast clearance of the peptide from the blood. Furthermore, tumor accumulation peaked at 
one hour after injection (7.30 ± 1.87 %ID/g) and decreased slightly over time (5.85 ± 1.17 %ID/g 
and 5.49 ± 0.66 %ID/g after 2 and 4 hours (not signifi cant)). A similar trend was observed for 
the uptake in the pancreas: 3.82 ± 0.22 %ID/g at 1 hour p.i., 2.71 ± 0.36 %ID/g at 2 hours p.i. 
and 2.55 ± 0.07 %ID/g at 4 hours p.i.. Renal uptake increased over time, while the specifi c 
accumulation in the liver decreased. Table 3 gives an overview of the tumor-to-normal-organ 
ratios for 111In-labeled maxadilan-DTPA.
Table 3. Tumor-to-normal-organ ratios for 111In-labeled maxadilan-DTPA. Mean ± SD are shown.
Time p.i. (h) Tumor-to-Blood Tumor-to-Muscle Tumor-to-Pancreas Tumor-to-Kidney
1 44.62 ± 10.63 11.45 ± 3.75 2.01 ± 0.35 0.06 ± 0.02
2 139.65 ± 24.28 10.59 ± 2.25 2.34 ± 0.35 0.04 ± 0.01
4 314.74 ± 40.82 11.83 ± 1.91 2.04 ± 0.23 0.04 ± 0.01
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Figure 3. Biodistribution of 111In-labeled DTPA-maxadilan and maxadilan-DTPA in BALB/c nude mice 
bearing subcutaneous INS-1 tumors. Values are expressed as a percentage of the injected dose per gram 
of tissue (n=5 mice per group, error bars SD). Blocking was performed by coinjection of a 100-fold excess 
of unlabeled maxadilan. Mice were dissected 2 hours after injection.
Figure 4. Biodistribution of 111In-labeled maxadilan-DTPA in BALB/c nude mice bearing  subcutaneous 
INS-1 tumors. Values are expressed as a percentage of the injected dose per gram of tissue (n=4 mice per 
group, error bars SD). Mice were dissected 1, 2 and 4 hours after injection to study the pharmacokinetics.
548546-L-bw-Joosten
Processed on: 22-9-2020 PDF page: 45
PAC1 TARGETING WITH RADIOLABELED MAXADILAN
45
3
SPECT of BALB/c nude mice bearing subcutaneous INS-1 tumors
SPECT/CT images of BALB/c nude mice bearing subcutaneous INS-1 tumors are shown in 
Figure 5.
Images were acquired one and four hours after injection of 111In-labeled maxadilan-DTPA and 
INS-1 tumors in the right shoulder were clearly visualized. In addition to tumor and kidney, 
accumulation of the tracer in the liver was observed. Figure 5C shows the image of a mouse 
which was co-injected with an excess of unlabeled maxadilan. The tumor on the right shoulder 
was not visualized with SPECT/CT, demonstrating specifi c uptake via the PAC1 receptor.
Figure 5. Fused SPECT/CT images of BALB/c nude mice bearing subcutaneous INS-1 tumors on the 
right shoulder (green arrow), obtained one and four hours p.i.. Image of a mouse injected with 9 MBq of 
maxadilan-DTPA-[111In]In, 1 hour (A), 4 hours (B), and a mouse with 9 MBq of maxadilan-DTPA-[111In]In
and a 100 fold excess of unlabeled maxadilan (C). Kidneys are indicated with red arrows. Uptake in the 
abdomen is also seen, mainly in liver (A and B).
DISCUSSION
We demonstrate here for the fi rst time that indeed radiolabeled maxadilan is a promising new 
tool to image subcutaneously transplanted insulinomas in mice. 
We were able to radiolabel maxadilan with 111In with high specifi c activity while preserving the 
affi nity for the PAC1 receptor. High and specifi c uptake of this tracer in both subcutaneous INS-
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1 tumors and pancreas was found. SPECT imaging clearly visualized the s.c. INS-1 xenografts. 
Both pancreatic as well as tumor uptake were receptor mediated, as was demonstrated by 
blocking experiments with unlabeled maxadilan.
Since the conjugation of a DTPA moiety can affect the affinity of the peptide for the receptor, the 
peptide was conjugated with DPTA at either the C- or the N-terminus and the molecules were 
compared. The maximum molar activity of maxadilan-DTPA-[111In]In was at least twelve times 
higher than that of [111In]In-DTPA-maxadilan. This could possibly be explained by hindrance of 
the radiometal incorporation into the DTPA molecule, due to either the secondary or tertiary 
structure of maxadilan or a conformational change in the peptide as a result of the conjugation.
Conjugation of DTPA to either the C-or N-terminus of maxadilan influenced the receptor 
binding affinity significantly. Maxadilan contains four cysteine residues, which form two 
disulfide bridges, one of which is located close to the N-terminus. Furthermore, it is known 
that the N-terminal residues of maxadilan are important for receptor binding 23, 29. Therefore, 
it was thought likely that conjugation of DTPA to the N-terminus could influence the binding 
affinity. However, it has also been shown in previous studies that when the disulfide bridge 
at the N-terminal part of maxadilan is removed or changed, the receptor binding capacity 
of maxadilan is preserved29, 30. Nevertheless, as was determined in our in vivo biodistribution 
studies, the C-terminally modified maxadilan-DTPA-[111In]In analog showed higher uptake in 
the tumor, therefore this compound was used for further characterization. 
The biodistribution shows specific accumulation of maxadilan in most organs. This is in line 
with the widespread PAC1 receptor expression and function in the pituitary, adrenal medulla, 
pancreas, stomach, colon, lung, and heart 31, 32. As demonstrated in the SPECT images, 
maxadilan-DTPA-[111In]In clearly visualized the subcutaneous INS-1 tumors and they were 
easily distinguished from the specific accumulation of radiolabeled maxadilan in various other 
tissues.
Other preclinical studies using INS-1 tumor-bearing mice have shown that GLP-1 receptor 
targeting ligands, labeled either with 111In, 68Ga or 18F, show a more favorable biodistribution 
compared to this maxadilan tracer. Although those previously-studied tracers show high tumor 
and kidney uptake similar to maxadilan, the tumor-to-normal-organ ratios are more optimal, 
which can be correlated with expression levels of the different receptors that are targeted9, 33, 34. 
Future studies need to be conducted to compare radiolabeled maxadilan with existing relevant 
PET agents in animals, before moving to clinical trials.
Recently, clinical imaging techniques such as 68Ga-labeled somatostatin receptor imaging and 
radiolabeled GLP-1 receptor imaging were introduced for diagnosis of insulinomas. These 
tracers would be useful for differentiating benign from malignant tumors or in diagnosis of 
metastatic NETS. However, the sensitivity is not optimal and false positive or false negative 
cases continue to be described using somatostatin receptor targeting 8, 19, 35. False negative-
SSTR PET/CT could be explained by small lesions (missed because the resolution of the 
scanner is not sufficient to detect them) or low somatostatin receptor expression (leading to 
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a low signal which cannot be detected as the sensitivity of the scanner is not suffi cient). A 
solution to the latter problem would be the use of a combination of different radiotracers, 
thus targeting alternative receptors. This was also suggested by Reubi et al., who conducted 
an elegant in vitro study proving that a cocktail of three different ligands was able to detect all 
tested NETs 36. Tumors with no or low receptor density, which would be missed in vivo when 
using only one radiotracer, have a higher probability of being detected when multiple receptors 
are targeted. In addition, if one of the tracers had a very high uptake in the tumor, this high 
uptake could help to overcome the limited spatial resolution and also visualization of small 
lesions.
In addition to diagnostic imaging, some somatostatin analogs, when radiolabeled with a 
beta emitter, are used as therapeutic agents37. Due to the high accumulation of radiolabeled 
maxadilan in the kidneys, and to a lesser extent in other organs, the feasibility of peptide 
receptor radionuclide therapy with maxadilan would be questionable. Insulinomas may not 
be the only NETs in which radiolabeled maxadilan could play a diagnostic role. In a study 
carried out by Pisegna et al. high expression levels of the PAC1 receptor in rat gastric ECL 
(enterochromaffi n-like) cells were observed 38, 39. Currently, [111In]In-DTPA-octreotide or [68Ga]
Ga-DOTATOC/[68Ga]Ga-DOTA-octreotide are used for the detection of gastric neuroendocrine 
tumors, which originate from ECL cells 40. Furthermore, PAC1 receptor expression has been 
demonstrated in Lewis lung tumor transplants 41. Radiolabeled maxadilan could therefore be 
a possible candidate for detecting both ECL derived tumors and a subtype of small cell lung 
cancer, in addition to somatostatin receptor tomography.  Moreover, there is evidence that 
there is high expression of PAC1 in human tumors such as paragangliomas, neuroblastomas, 
pituitary adenomas and endometrial cancers 42-45 with expression found also in human lung 
cancers46. Importantly, most of these studies were conducted in vitro, so in vivo studies are 
needed to explore the ratio between peptide uptake in PAC1 receptor positive tumors and that 
in normal tissues where PAC1  is widely expressed. 
In conclusion, radiolabeled maxadilan accumulates effi ciently and specifi cally in INS-1 tumors 
and could potentially be used for in vivo PAC1targeting in patients with insulinoma. Radiolabeled 
maxadilan, therefore, represents a new tracer to image insulinomas using SPECT in addition 
to or in combination with octreotide and exendin for the identifi cation of benign or malignant 
insulinoma. Furthermore, the expression of PAC1 in other human tumors indicates a broader 
application for the usage of radiolabeled maxadilan. Thus, the newly generated PAC1 selective 
high affi nity radiopeptide maxadilan can be employed for multireceptor tumor targeting in vivo.
548546-L-bw-Joosten
Processed on: 22-9-2020 PDF page: 48
PAC1 TARGETING WITH RADIOLABELED MAXADILAN
48
ACKNOWLEDGEMENTS
We would like to thank J. K. Sosabowski (Centre for Molecular Oncology, Barts Cancer Institute, 
Queen Mary University of London) for her help with editing the manuscript.
AUTHOR CONTRIBUTIONS
L.J., M.B., O.B. and M.G. contributed in the design of the study, M.S. and E.W. contributed to the 
new compound, L.J. and M.B. performed the experiments and analyzed the data, L.J. wrote the 
manuscript, M.S., E.W., and M.B. contributed to the introduction and discussion. All authors 
reviewed and edited the manuscript.
ADDITIONAL INFORMATION
Competing financial interests
No potential conflict of interest relevant for this article was reported.
548546-L-bw-Joosten
Processed on: 22-9-2020 PDF page: 49




1. Iglesias P, Diez JJ. Management of endocrine disease: a clinical update on tumor-induced 
hypoglycemia. European journal of endocrinology / European Federation of Endocrine Societies. 2014;
170 (4): R147-157.
2. Granberg D, Oberg K. Neuroendocrine tumours. Cancer chemotherapy and biological response 
modifi ers. 2005; 22 471-483.
3. Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). 
Gastroenterology. 1997; 112 (2): 583-590.
4. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: 
molecular basis for in vivo multireceptor tumour targeting. European journal of nuclear medicine and 
molecular imaging. 2003; 30 (5): 781-793.
5. Baumann T, Rottenburger C, Nicolas G, Wild D. Gastroenteropancreatic neuroendocrine tumours 
(GEP-NET) - Imaging and staging. Best practice & research. Clinical endocrinology & metabolism. 
2016; 30 (1): 45-57.
6. Bodei L, Sundin A, Kidd M, Prasad V, Modlin IM. The status of neuroendocrine tumor imaging: from 
darkness to light? Neuroendocrinology. 2015; 101 (1): 1-17.
7. Prasad V, Sainz-Esteban A, Arsenic R, Plockinger U, Denecke T, Pape UF, et al. Role of (68)Ga 
somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative 
study. European journal of nuclear medicine and molecular imaging. 2016; 43 (9): 1593-1600.
8. Sharma P, Arora S, Karunanithi S, Khadgawat R, Durgapal P, Sharma R, et al. Somatostatin receptor 
based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically 
suspected insulinoma. The quarterly journal of nuclear medicine and molecular imaging : offi cial 
publication of the Italian Association of Nuclear Medicine. 2016; 60 (1): 69-76.
9. Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC. 68Ga-labelled exendin-3, a new agent for 
the detection of insulinomas with PET. European journal of nuclear medicine and molecular imaging. 
2010; 37 (7): 1345-1355.
10. Wild D, Behe M, Wicki A, Storch D, Waser B, Gotthardt M, et al. [Lys40(Ahx-DTPA-111In)NH2]
exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. Journal of 
nuclear medicine : offi cial publication, Society of Nuclear Medicine. 2006; 47 (12): 2025-2033.
11. Wild D, Wicki A, Mansi R, Behe M, Keil B, Bernhardt P, et al. Exendin-4-based radiopharmaceuticals 
for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. Journal of nuclear medicine : offi cial 
publication, Society of Nuclear Medicine. 2010; 51 (7): 1059-1067.
12. Christ E, Wild D, Ederer S, Behe M, Nicolas G, Caplin ME, et al. Glucagon-like peptide-1 receptor 
imaging for the localisation of insulinomas: a prospective multicentre imaging study. The lancet. 
Diabetes & endocrinology. 2013; 1 (2): 115-122.
13. Christ E, Wild D, Forrer F, Brandle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor 
imaging for localization of insulinomas. The Journal of clinical endocrinology and metabolism. 2009;
94 (11): 4398-4405.
548546-L-bw-Joosten
Processed on: 22-9-2020 PDF page: 50
PAC1 TARGETING WITH RADIOLABELED MAXADILAN
50
14. Sowa-Staszczak A, Pach D, Mikolajczak R, Macke H, Jabrocka-Hybel A, Stefanska A, et al. Glucagon-
like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the 
detection of insulinoma. European journal of nuclear medicine and molecular imaging. 2013; 40 (4): 
524-531.
15. Wild D, Macke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize 
occult insulinomas. The New England journal of medicine. 2008; 359 (7): 766-768.
16. Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, et al. Localization of Hidden Insulinomas 
with (6)(8)Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. Journal of nuclear medicine : official publication, 
Society of Nuclear Medicine. 2015; 56 (7): 1075-1078.
17. Eriksson O, Velikyan I, Selvaraju RK, Kandeel F, Johansson L, Antoni G, et al. Detection of metastatic 
insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. The Journal of 
clinical endocrinology and metabolism. 2014; 99 (5): 1519-1524.
18. Christ E, Wild D, Reubi JC. Glucagonlike peptide-1 receptor: an example of translational research in 
insulinomas: a review. Endocrinology and metabolism clinics of North America. 2010; 39 (4): 791-800.
19. Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brandle M, et al. Glucagon-like peptide-1 
versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. Journal of 
nuclear medicine : official publication, Society of Nuclear Medicine. 2011; 52 (7): 1073-1078.
20. Inagaki N, Kuromi H, Seino S. PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin 
secretion. Annals of the New York Academy of Sciences. 1996; 805 44-51; discussion 52-43.
21. Moody TW, Nuche-Berenguer B, Jensen RT. Vasoactive intestinal peptide/pituitary adenylate cyclase 
activating polypeptide, and their receptors and cancer. Current opinion in endocrinology, diabetes, and 
obesity. 2016; 23 (1): 38-47.
22. Tatsuno I, Uchida D, Tanaka T, Saeki N, Hirai A, Saito Y, et al. Maxadilan specifically interacts with 
PAC1 receptor, which is a dominant form of PACAP/VIP family receptors in cultured rat cortical 
neurons. Brain research. 2001; 889 (1-2): 138-148.
23. Borboni P, Porzio O, Pierucci D, Cicconi S, Magnaterra R, Federici M, et al. Molecular and functional 
characterization of pituitary adenylate cyclase-activating polypeptide (PACAP-38)/vasoactive intestinal 
polypeptide receptors in pancreatic beta-cells and effects of PACAP-38 on components of the insulin 
secretory system. Endocrinology. 1999; 140 (12): 5530-5537.
24. Ahren B. Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system. 
Annals of the New York Academy of Sciences. 2008; 1144 28-35.
25. Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of 
research. Regulatory peptides. 1992; 37 (3): 287-303.
26. Arimura A, Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: 
neuroendocrine and endocrine interaction. Frontiers in neuroendocrinology. 1995; 16 (1): 53-88.
27. Lerner EA, Ribeiro JM, Nelson RJ, Lerner MR. Isolation of maxadilan, a potent vasodilatory peptide 
from the salivary glands of the sand fly Lutzomyia longipalpis. The Journal of biological chemistry. 
1991; 266 (17): 11234-11236.
548546-L-bw-Joosten
Processed on: 22-9-2020 PDF page: 51
PAC1 TARGETING WITH RADIOLABELED MAXADILAN
51
3
28. Moro O, Lerner EA. Maxadilan, the vasodilator from sand fl ies, is a specifi c pituitary adenylate cyclase 
activating peptide type I receptor agonist. The Journal of biological chemistry. 1997; 272 (2): 966-970.
29. Lerner EA, Iuga AO, Reddy VB. Maxadilan, a PAC1 receptor agonist from sand fl ies. Peptides. 2007; 28 
(9): 1651-1654.
30. Moro O, Wakita K, Ohnuma M, Denda S, Lerner EA, Tajima M. Functional characterization of structural 
alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-
activating peptide type 1 receptor-specifi c antagonist. The Journal of biological chemistry. 1999; 274 
(33): 23103-23110.
31. Vamos Z, Ivic I, Cseplo P, Toth G, Tamas A, Reglodi D, et al. Pituitary Adenylate Cyclase-Activating 
Polypeptide (PACAP) Induces Relaxations of Peripheral and Cerebral Arteries, which are Differentially 
Impaired by Aging. Journal of molecular neuroscience : MN. 2014; 54 (3): 535-542.
32. Yada T, Sakurada M, Ihida K, Nakata M, Murata F, Arimura A, et al. Pituitary adenylate cyclase 
activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from 
islet beta-cells. The Journal of biological chemistry. 1994; 269 (2): 1290-1293.
33. Kiesewetter DO, Gao H, Ma Y, Niu G, Quan Q, Guo N, et al. 18F-radiolabeled analogs of exendin-4 for 
PET imaging of GLP-1 in insulinoma. European journal of nuclear medicine and molecular imaging. 
2012; 39 (3): 463-473.
34. Rylova SN, Waser B, Del Pozzo L, Tonnesmann R, Mansi R, Meyer PT, et al. Approaches to Improve 
the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic 
Tracers. Journal of nuclear medicine : offi cial publication, Society of Nuclear Medicine. 2016; 57 (8): 
1282-1288.
35. Prasad V, Sainz-Esteban A, Arsenic R, Plockinger U, Denecke T, Pape UF, et al. Role of Ga somatostatin 
receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study. 
European journal of nuclear medicine and molecular imaging. 2016;
36. Reubi JC, Waser B. Triple-peptide receptor targeting in vitro allows detection of all tested gut and 
bronchial NETs. Journal of nuclear medicine : offi cial publication, Society of Nuclear Medicine. 2015;
56 (4): 613-615.
37. van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ. GEPNETs 
update: Radionuclide therapy in neuroendocrine tumors. European journal of endocrinology / 
European Federation of Endocrine Societies. 2015; 172 (1): R1-8.
38. Zeng N, Athmann C, Kang T, Lyu RM, Walsh JH, Ohning GV, et al. PACAP type I receptor activation 
regulates ECL cells and gastric acid secretion. The Journal of clinical investigation. 1999; 104 (10): 
1383-1391.
39. Zeng N, Kang T, Lyu RM, Wong H, Wen Y, Walsh JH, et al. The pituitary adenylate cyclase 
activating polypeptide type 1 receptor (PAC1-R) is expressed on gastric ECL cells: evidence by 
immunocytochemistry and RT-PCR. Annals of the New York Academy of Sciences. 1998; 865 147-156.
40. Cavallaro A, Zanghi A, Cavallaro M, Lo Menzo E, Di Carlo I, Di Vita M, et al. The role of 68-Ga-DOTATOC 
CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report. 
International journal of surgery. 2014; 12 Suppl 1 S225-231.
548546-L-bw-Joosten
Processed on: 22-9-2020 PDF page: 52
PAC1 TARGETING WITH RADIOLABELED MAXADILAN
52
41. Kalmbach N, Krasel C, Schafer MKH, Bunemann M, Weihe E. Molecular and functional characterization 
of PACAP/VIP receptors in Lewis lung carcinoma cells. Pneumologie. 2012; 66 A604.
42. Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/
pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of 
origin. Cancer research. 2000; 60 (11): 3105-3112.
43. Robberecht P, Vertongen P, Velkeniers B, de Neef P, Vergani P, Raftopoulos C, et al. Receptors for 
pituitary adenylate cyclase activating peptides in human pituitary adenomas. The Journal of clinical 
endocrinology and metabolism. 1993; 77 (5): 1235-1239.
44. Robberecht P, Woussen-Colle MC, Vertongen P, De Neef P, Hou X, Salmon I, et al. Expression of 
pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors. 
Peptides. 1994; 15 (4): 661-665.
45. Vertongen P, Devalck C, Sariban E, De Laet MH, Martelli H, Paraf F, et al. Pituitary adenylate cyclase 
activating peptide and its receptors are expressed in human neuroblastomas. Journal of cellular 
physiology. 1996; 167 (1): 36-46.
46. Busto R, Prieto JC, Bodega G, Zapatero J, Fogue L, Carrero I. VIP and PACAP receptors coupled to 
adenylyl cyclase in human lung cancer: a study in biopsy specimens. Peptides. 2003; 24 (3): 429-436.
47. Asfari M, Janjic D, Meda P, Li G, Halban PA, Wollheim CB. Establishment of 2-mercaptoethanol-
dependent differentiated insulin-secreting cell lines. Endocrinology. 1992; 130 (1): 167-178.
48. Brom M, Joosten L, Oyen WJ, Gotthardt M, Boerman OC. Radiolabelled GLP-1 analogues for in vivo 
targeting of insulinomas. Contrast media & molecular imaging. 2012; 7 (2): 160-166.
548546-L-bw-Joosten
Processed on: 22-9-2020 PDF page: 53




Processed on: 22-9-2020 PDF page: 54
548546-L-bw-Joosten
Processed on: 22-9-2020 PDF page: 55
CHAPTER 4
Characterization of 111In-labeled 
glucose-dependent insulinotropic 
polypeptide as a radiotracer for 
neuroendocrine tumors
Lieke Joosten1*, Stefanie M. A. Willekens1,2*, Otto C. Boerman1, 
Maarten Brom1 & Martin Gotthardt1
1 Department of Radiology and Nuclear Medicine, 
Radboud University Medical Center, Nijmegen, The Netherlands
2 Division of Nuclear Medicine and Molecular Imaging, Department of Imaging and 
Pathology, University Hospitals and KU Leuven, Leuven, Belgium
* Lieke Joosten and Stefanie M. A. Willekens contributed equally to this work
Scientifi c Reports. 2018; 8 (1): 2948
548546-L-bw-Joosten
Processed on: 22-9-2020 PDF page: 56
GIPR TARGETING OF NEUROENDOCRINE TUMORS
56
ABSTRACT
Somatostatin receptor targeting is considered the standard nuclear medicine imaging 
technique for visualization of neuroendocrine tumors (NETs). Since not all NETs over-express 
somatostatin receptors, the search for novel targets to visualize these NETs is ongoing. 
Many NETs, expressing low somatostatin receptor levels, have been shown to express 
glucose-dependent insulinotropic polypeptide (GIP) receptors (GIPR). Here, we evaluated the 
performance of  [Lys37(DTPA)]N-acetyl-GIP1-42, a newly synthesized GIP analog to investigate 
whether NET imaging via GIPR targeting is feasible. Therefore, [Lys37(DTPA)]N-acetyl-GIP1-42 
was radiolabeled with 111In with a molar activity up to 1.2 TBq/µmol and both its in vitro and in 
vivo receptor targeting properties were examined. In vitro, 111In-labeled [Lys37(DTPA)]N-acetyl-
GIP1-42 showed receptor mediated binding to BHK-GIPR positive cells, NES2Y cells and isolated 
islets. In vivo, both NES2Y and GIPR-transfected BHK tumors were visualized on SPECT/CT. 
Furthermore, co-administration of an excess unlabeled GIP1-42 lowered tracer uptake from 0.7 ± 
0.2 %ID/g to 0.6 ± 0.01 %ID/g (p=0.78) in NES2Y tumors and significantly lowered tracer uptake 
from 3.3 ± 0.8 to 0.8 ± 0.2 %ID/g (p=0.0001) in GIPR-transfected BHK tumors. In conclusion, 
111In-labeled [Lys37(DTPA)]N-acetyl-GIP1-42 shows receptor mediated binding in various models. 
Furthermore, both GIPR-transfected BHK tumors and NES2Y tumors were visible on SPECT/
CT using this tracer. Therefore, 111In-labeled [Lys37(DTPA)]N-acetyl-GIP1-42 SPECT seems 
promising for visualization of somatostatin receptor negative NETs.
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Targeting of peptide hormone receptors, expressed on tumors, is a valuable tool for in vivo 
molecular imaging and radionuclide therapy of a variety of neuroendocrine tumors (NETs).
Successful tumor targeting relies on over-expression of target receptors on cancer cells when 
compared to their expression levels in healthy tissues 1, 2. Nowadays, somatostatin receptor 
targeting is a standard procedure for NET detection 3-6 and radionuclide therapy with 90Y- and 
177Lu-labeled somatostatin analogs was proven benefi cial to patients with NET 7. However, 
not all NETs show elevated somatostatin receptor expression levels. Therefore, false negative 
results may occur in all NET types and somatostatin receptor imaging displays limited 
sensitivity for some types of NET, such as insulinomas (80-90% on [68Ga]Ga-DOTA-TATE PET) 
3, 5, 8-10 and medullary thyroid carcinoma (MTC) for which the detection rate is below 40-60% 11.
A variety of alternative peptide receptors, such as cholecystokinin (CCK) receptors 12, vasoactive 
intestinal peptide (VIP) receptors 13 and glucagon-like peptide 1 (GLP-1) receptors (GLP-1R) 14
are expressed on NETs. Recent fi ndings showed glucose-dependent insulinotropic polypeptide 
(GIP) receptor (GIPR) expression in gastric, duodenal and bronchial NETs 15, 16. Furthermore, 
approximately 90% of somatostatin receptor negative NETs are GIPR positive 16. In 2013, 
Sherman et al. pointed out that GIPR is a promising target for NET imaging and therapy due 
to its favorable expression pattern 17 and the feasibility of GIPR targeting was shown in a GIPR 
over-expressing tumor model using a truncated GIP1-30 analog 
18. 
GIP is secreted from the intestinal K cells after nutrient ingestion 19 and together with GLP-1, 
it enhances glucose-induced insulin secretion upon receptor binding on pancreatic beta cells, 
the so-called incretin effect 20, 21. Since insulinomas are NETs derived from pancreatic beta 
cells, incretin receptors are expected to be ideal candidate receptors for insulinoma imaging. 
Indeed, GLP-1R targeting tracers, such as 68Ga- or 111In-labeled exendin, can be applied for 
non-invasive in vivo insulinoma detection 22-24. However, since malignant insulinomas display 
differential GLP-1R and somatostatin receptor expression patterns 25, detection rates of these 
tumors remain limited to 50% by scintigraphy. Interestingly, GLP-1R negative malignant 
insulinomas and a majority of somatostatin negative NETs express enhanced GIPR levels 16, 
rendering this receptor an interesting target for NET and insulinoma imaging.
Since it was described that GIP1-30 exhibits reduced receptor binding affi nity when compared 
to the full length peptide GIP1-42 
26, 27, we have investigated the potential of a newly synthesized 
GIP1-42 analog, 
111In-labeled [Lys37(DTPA)]N-acetyl-GIP1-42 (Figure 1) as a radiotracer for NET 
imaging, starting from the initial hypothesis that a full-length peptide-based tracer might 
show improved characteristics for in vivo NET imaging when compared to GIP1-30. Therefore, we 
optimized the radiolabeling procedure and investigated its binding and internalization kinetics 
using GIPR-positive tumor cells (BHK-GIPR). Furthermore, we have also explored the tracer 
binding characteristics to NES2Y cells (a human beta cell-derived cell line, representing a 
more realistic model in terms of receptor expression) 28 and isolated islets of Langerhans. 
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Finally, subcutaneous BHK-GIPR and NES2Y tumors were visualized by SPECT after injection 
of 111In-labeled [Lys37(DTPA)]N-acetyl-GIP1-42.




[Lys37(DTPA)]N-acetyl-GIP1-42 (MW = 5422 g/mol) (referred to as DTPA-GIP1-42 and GIP1-42 (MW = 
5046.7 g/mol) were purchased from Peptide Specialty Laboratories (PSL GmbH, Heidelberg, 
Germany). DTPA was conjugated to the ε-amino group of the Lysine (K37) and the N-terminal 
tyrosine was acetylated to reduce its susceptibility to endopeptidases (Figure 1). DTPA-GIP1-42 
was dissolved in 0.5 M MES (2-(N-morpholino)ethanesulfonic acid) buffer, pH 5.5 and stored 
at 4°C until use. 150 MBq 111InCl3 (Mallinckrodt Pharmaceuticals, ‘s Hertogenbosch, The 
Netherlands) was added to 1 µg DTPA-GIP1-42 together with 5 volumes of 0.5 M MES buffer (1:5 
relation 111In:buffer), pH 5.5 and incubated for 20 min at room temperature. After incubation, 
EDTA (Sigma Aldrich, St. Louis, MO, USA) and Tween-80 (Sigma Aldrich) were added to a final 
concentration of 5 mM and 0.1%, respectively. The labeling mixture was purified by solid-phase 
extraction using a hydrophilic-lipophilic balance (HLB) cartridge (30 mg, Waters Oasis, Milford, 
MA, USA), to eliminate unincorporated 111In. The cartridge was activated with 1 ml ethanol, 
washed with 2 ml water and conditioned with 1 ml of 0.5 M MES, pH 5.5. Subsequently, the 
cartridge was loaded with the labeling mixture, washed with 1 ml 0.5 M MES and 2 ml water and 
[111In]In-DTPA-GIP1-42 was eluted from the cartridge with 200 µL 100% ethanol. For in vivo use, 
purified labeled peptide was diluted in phosphate buffered saline (PBS), 0.5% bovine serum 
albumin (BSA) (w/v) to obtain a final ethanol concentration of less than 10%. Radiochemical 
purity of [111In]In-DTPA-GIP1-42 was determined by instant thin-layer chromatography (ITLC) 
(ITLC-SG, Agilent Technologies, Lake Forest, CA, USA), using 0.1 M EDTA in 0.1 M NH4Ac 
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(Sigma Aldrich), pH 5.5 as a mobile agent and by reversed-phase high performance liquid 
chromatography (RP-HPLC) using an Eclipse XDB C18 column (Agilent Technologies). The 
column was eluted with 0.1% trifl uoroacetic acid (TFA) in H2O (0-5 minutes) followed by a linear 
gradient from 3% to 100% acetonitrile with 0.1% TFA over 10 minutes (fl ow rate: 1 ml/minute). 
Serum Stability Analysis
For the serum stability analysis, DTPA-GIP1-42 was labeled with 
111InCl3 at a molar activity of 27 
GBq/µmol. Radiochemical purity of [111In]In-DTPA-GIP1-42 directly after labeling was determined 
by ITLC-SG (Agilent Technologies) and RP-HPLC as described above. A sample of the labeling 
mixture was incubated in human serum (1:10) at 37°C. After 1, 2, 4 and 24 hours, a sample 
was taken and serum proteins were precipitated by adding acetonitrile. This mixture was 
centrifuged and after dilution, the radiochemical purity of the compound in the supernatant 
was analyzed using ITLC and RP-HPLC as described above. 
Cell Culture 
Baby hamster kidney cells, transfected with the human GIPR (BHK-GIPR cells) were maintained 
in DMEM Glutamax (cat. Nr. 6195, GIBCO, BRL Life Sciences Technologies, Bleiswijk, The 
Netherlands) supplemented with 10% fetal bovine serum (FCS), (HyClone, Celbio, Logan, UT, 
USA) and 1 mg/ml G418, in a humidifi ed atmosphere containing 5% CO2 at 37°C. The human 
beta cell line NES2Y was cultured as described previously (28). Briefl y, cells were maintained in 
RPMI 1640 (R0883, GIBCO) supplemented with 10% FCS, (HyClone, Celbio), 2 mM L-glutamine 
(Sigma Aldrich), 100 U/ml penicillin (Sigma Aldrich) and 100 µg/ml streptomycin (Sigma 
Aldrich) (complete RPMI), in a humidifi ed atmosphere containing 5% CO2 at 37°C.
Competitive binding assay
The 50% inhibitory concentration (IC50) of [
111In]In-DTPA-GIP1-42 was determined using NES2Y 
cells. NES2Y cells were seeded at a density of 200,000 cells/well in 24-well plates and incubated 
overnight at 37°C. The cells were washed with binding buffer (RPMI + 0.5% BSA (w/v)) and 
DTPA-GIP1-42 was added at a fi nal concentration ranging from 1.0 ‒ 100 µM along with a trace 
amount of [111In]In-DTPA-GIP1-42 (4.6 kBq = 2.7 fmol). After o/n (15 hours) incubation at 37°C, 
cells were washed with binding buffer and cell-associated activity was measured in a well type 
gamma counter (Wallac 2480 wizard, Perkin Elmer). Under these conditions, internalization 
may occur. We therefore designate the results of this competitive binding assay as “apparent 
IC50” values rather than IC50.  
Internalization kinetics
The internalization kinetics of [111In]In-DTPA-GIP1-42 was determined as previously described 
38 
using BHK-GIPR transfected cells and NES2Y cells. BHK-GIPR transfected cells and NES2Y 
cells were seeded in 24-well plates with a density of 50,000 and 200,000 cells/well, respectively 
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and incubated overnight at 37°C. Cells were washed with binding buffer and incubated with 
approximately 1.6 kBq [111In]In-DTPA-GIP1-42  (2.7 fmol) for 1, 2, 4 and 24 hours at 37°C. After 
incubation, cells were washed twice with binding buffer. To determine the surface-bound 
fraction, ice-cold acid buffer (0.1 M acetic acid, 154 mM NaCl, pH 2.5) was added and cells 
were incubated for 10 minutes at 4°C. After washing the cells twice with binding buffer to make 
sure that all surface-bound tracer was removed from the cells, the cell-associated activity 
was measured in a well type gamma counter. After removal of the surface-bound activity, the 
internalized fraction was represented by the remaining cell-associated activity. The internalized 
fraction (remaining cell-associated activity after acid wash) and the receptor bound fraction 
(activity removed by acid wash) were determined in a well-type gamma counter.
Animals
All animal experiments were approved by the Animal Welfare Body of the Radboud University, 
Nijmegen, The Netherlands and carried out in accordance with their guidelines. Six to eight 
weeks old, female BALB/c nude mice and C3H mice were purchased from Janvier labs (Le 
Genest Saint Isle, France). For all in vivo experiments, 6-8 weeks old female BALB/c nude 
mice were injected subcutaneously in the right shoulder with 0.2 ml of a 2.5 x 107 cells/ml 
suspension of BHK-GIPR transfected cells or with 0.2 ml of a 2.5 x 107 cells/ml suspension 
of NES2Y cells mixed with matrigel (2:1) in the right shoulder. When the tumor reached a 
diameter of 2-5 mm, mice were randomly divided in groups.
Islet Isolation
Islets of Langerhans were isolated from donor C3H mice by collagenase digestion as follows. 
Mice were euthanized by CO2/O2 suffocation and 2 ml of ice cold RPMI 1640 containing 1 mg/ml 
collagenase type V (Sigma Aldrich) were infused via the pancreatic duct in situ. After dissection, 
the perfused pancreata were collected in serum free medium containing collagenase and kept 
on ice until digestion. Pancreata were digested for 12 min at 37°C. Digestion was stopped by 
adding RPMI medium containing 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin and 100 U/
ml streptomycin (complete RPMI). After washing, digested pancreata were passed through 
a mesh. Afterwards, islets were purified on a discontinuous Ficoll gradient (densities: 1.108; 
1.096; 1.037; Cellgro by Mediatech Inc, Manassas, VA, USA) by centrifugation at 625 x g for 16 
min without brake. Islets were collected from the intersection of the second and third layer and 
remaining Ficoll was removed by washing with complete RPMI. Isolated islets were cultured 
overnight in complete RPMI medium in a humidified atmosphere containing 5% CO2 at 37°C.
In Vitro Binding to Isolated Islets
After overnight recovery from the isolation procedure, islets from the donor C3H mice were 
collected, counted and resuspended in complete RPMI. After transwell saturation using binding 
buffer, islets were transferred to 24 well transwell plates (200 islets per transwell) (Corning 
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Inc. Tewksbury, MA, USA) and washed with binding buffer. Subsequently, approximately 8 kBq 
[111In]In-DTPA-GIP1-42 (13.5 fmol) was added followed by incubation for 24 hours at 37°C. To 
investigate the GIPR-mediated binding, 25 µg of unlabeled GIP1-42 was added together with [
111In]
In-DTPA-GIP1-42 in a separate set of wells. After incubation, islets were washed extensively with 
binding buffer and islet-associated radioactivity was measured in a well type gamma counter. 
Peptide Dose Escalation Study 
To determine the optimal peptide dose of DTPA-GIP1-42, BHK-GIPR transfected tumor bearing 
BALB/c nude mice (n=5/group) were injected intravenously with approximately 3 MBq [111In]
In-DTPA-GIP1-42 (0.05 µg) in the tail vein and were co-injected with escalating amounts of 
unlabeled DTPA-GIP1-42 (0.05 µg ‒ 1.95 µg), resulting in fi nal peptide doses ranging from 0.1 to 
2 µg/mouse (0.02 ‒ 0.4 nmol/mouse) (5 groups, n=5/group). Four hours after injection, mice 
were euthanized by CO2/O2 suffocation and tumors and other relevant tissues (heart, muscle, 
lung, spleen, pancreas, kidney, liver, stomach and duodenum) were dissected, weighed and 
measured in a well type gamma counter. The percentage injected dose per gram of tissue 
(%ID/g) was determined for each tissue.  
Biodistribution Studies
BALB/c nude mice bearing BHK-GIPR transfected tumors were injected intravenously with 
approximately 3 MBq (peptide dose 0.2 µg = 0.04 nmol) of [111In]In-DTPA-GIP1-42 via the tail 
vein. At various time points after injection (1, 4 and 24 hours), mice were euthanized by CO2/O2
suffocation and blood, tumor and other relevant tissues were dissected, weighed and measured 
in a well type gamma counter. The percentage injected dose per gram (%ID/g) was calculated 
for each tissue. To determine whether the GIP1-42 uptake was GIPR mediated, 25 µg of unlabeled 
GIP1-42 was co-injected in a separate group (n=5) and mice were euthanized four hours post-
injection. BALB/c nude mice bearing NES2Y tumors (n=5) were injected intravenously with 
approximately 3 MBq (peptide dose 0.2 µg = 0.04 nmol) of [111In]In-DTPA-GIP1-42 via the tail vein. 
One hour after injection, mice were euthanized by CO2/O2 suffocation and blood, tumor and 
other relevant tissues were dissected, weighed and measured in a well type gamma counter. 
The percentage injected dose per gram (%ID/g) was determined for each tissue. To determine 
whether the GIP1-42 uptake was GIPR mediated, 25 µg of unlabeled GIP1-42 was co-injected in a 
separate group (n=2) and mice were euthanized one hours post-injection.
SPECT/CT
One (BHK-GIPR tumors and NES2Y tumors) or four (BHK-GIPR tumors) hours (n=2/group) 
prior to SPECT imaging, BALB/c nude mice were injected intravenously in the tail vein with 
20.6 ± 0.7 MBq [111In]In-DTPA-GIP1-42 (peptide dose 0.2 µg (=0.04 nmol) in 200 µl injection fl uid). 
SPECT/CT scans were acquired on a dedicated small animal SPECT/CT scanner (U-SPECT-II, 
Milabs, Utrecht, The Netherlands) with a 1.0 mm mouse collimator, using 36 bed positions and 
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an acquisition time of 30 minutes (BHK-GIPR tumors) or 45 minutes (NES2Y tumors). After 
SPECT acquisition, CT (65 kV, 615 µA, 1 bed position) was acquired as an anatomical reference. 
SPECT scans were reconstructed using U-SPECT-II reconstruction software (U-SPECT-Rec, 
Milabs, Utrecht, The Netherlands) with the following settings: selection of the lower 111In 
photopeak (152-183 keV), corrected for two backgrounds (135-151 keV and 184-211 keV), pixel 
based OSEM, voxel size 0.4 mm3 and 1 iteration over 16 subsets.
Statistics  
All values are expressed as mean ± standard deviation (SD). Statistical analysis was performed 
using unpaired two-tailed t-test using GraphPad Prism v5.03 (GraphPad Software Inc., San 
Diego, CA, USA). The level of significance was set at p<0.05.
RESULTS
Radiolabeling and Serum Stability
DTPA-GIP1-42 could be labeled with 
111In with a molar activity of up to 1.2 TBq/µmol. 
Radiochemical purity exceeded 95% as determined by RP-HPLC and ITLC, resulting in a 
final molar activity exceeding 712.5 MBq/nmol when starting with 150 MBq 111InCl3. Figure 2A 
shows the HPLC analysis of the labeling mixture. [111In]In-EDTA eluted with a retention time 
of 3 minutes, whereas 111In-labeled DTPA-GIP1-42 had a retention time of 14 minutes. After 12 
minutes, a very small impurity (< 2%) eluted from the column. Since GIP is known to be prone 
to inactivation by dipeptidyl peptidase IV (DPP IV), the stability of [111In]In-DTPA-GIP1-42 was 
analyzed in human serum. The results of this stability analysis are shown in Figure 2B and 2C. 
Up to 4 hours of incubation in human serum, [111In]In-DTPA-GIP1-42 remained intact. After 24 
hours of incubation in human serum, 73% of the activity was still found as intact radiolabeled 
peptide, as determined by HPLC.
In vitro binding and internalization kinetics
The results of the apparent IC50 determination are shown in Figure 3A. The apparent IC50 of 
DTPA-GIP1-42 is 4.8 µM (95% confidence interval: 0.7 ‒ 32.8 µM). However, the low internalization 
rate described below, render the observed value more likely to be a true IC50 rather than an 
apparent IC50. Figure 3B summarizes the binding and internalization kinetics of [
111In]In-DTPA-
GIP1-42  by BHK-GIPR transfected cells and NES2Y cells as determined in vitro. Both cell lines 
displayed similar binding and internalization characteristics. After 1 hour, 0.6 ± 0.1% and 0.6 ± 
0.02% of the added [111In]In-DTPA-GIP1-42 was bound to BHK-GIPR transfected cells and NES2Y 
cells, respectively. At this time point, the internalized fractions were 1.1 ± 0.1% and 1.5 ± 0.3%, 
respectively. After 24 hours, the binding values had increased to 13.8 ± 1.7% and 8.6 ± 1.5%, 
respectively and the internalization values to 4.2 ± 0.6% and 4.7 ± 3.6% for BHK-GIPR and NES2Y 
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cells, respectively. All values were corrected for non-specifi c binding, as determined by the 
addition of 25 µg unlabeled GIP1-42 which signifi cantly reduced the binding and internalization at 
all time points indicating GIPR-mediated binding in both cell lines (p<0.05). Figure 4 shows the 
in vitro binding characteristics of [111In]In-DTPA-GIP1-42 to 200 isolated islets of C3H mice. After 
24 hours, 0.22 ± 0.01 fmol [111In]In-DTPA-GIP1-42 bound to the islets. Addition of 25 µg unlabeled 
GIP1-42 reduced the binding to 0.03 ± 0.01 fmol, indicating specifi c binding of the tracer to the 
GIPR on the islets of Langerhans.
Figure 2. a) Radiochemical purity analysis of [111In]In-DTPA-GIP1-42 as determined by HPLC, immediately 
after labeling. b) HPLC profi le of [111In]In-DTPA-GIP1-42 after 24 hours of incubation in human serum. c) 
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Figure 3. In vitro characterization a) Competition binding assay (apparent IC50) of DTPA-GIP1-42 on 
NES2Y cells. [111In]In-DTPA-GIP1-42 was used as a radiotracer b) binding and internalization kinetics of 
[111In]In-DTPA-GIP1-42 in BHK-GIPR positive cells and NES2Y cells. Cell bound and internalized fractions 
are corrected for non-specific binding and accumulation, as determined by co-incubation with an excess 
unlabeled GIP1-42.
Peptide Dose Escalation Study
The effect of the peptide dose on tumor targeting was studied in BALB/c nude mice with 
subcutaneous BHK-GIPR tumors and the results are summarized in Figure 5A. The DTPA-
GIP1-42  dose had a pronounced effect on tumor uptake, which decreased significantly at peptide 
doses exceeding 0.2 µg (Figure 5A and 5B). Highest tumor uptake of [111In]In-DTPA-GIP1-42 was 
observed at peptide doses <0.2 µg (0.04 nmol) per mouse: 5.2 ± 1.4 %ID/g at 4 hours post-
injection. Administration of 0.5 µg (0.1 nmol) as a peptide dose resulted in a significantly lower 
tumor uptake: 2.4 ± 0.7 %ID/g (p=0.008) (figure 5B). Four hours post-injection, [111In]In-DTPA-
GIP1-42 also showed uptake in various organs such as the lung, spleen, pancreas, liver, stomach 
and duodenum. The high uptake in the kidneys has been described as being the result of 
tubular reabsorption through the scavenger receptors cubilin and megalin, which is the case 
for many peptides 30. As the kidney uptake of radiolabeled DTPA-GIP1-42 cannot be inhibited by 
an excess of unlabeled peptide, tubular reabsorption indeed appears to be the cause of the 
high kidney uptake. Raw data of this biodistribution study are shown in Table 1.
A B
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Table 1. Raw data of the peptide dose escalation study in BALB/c nude mice with subcutaneous BHK-GIPR 
tumors shown in Figure 5A. Values are expressed as percentage injected dose per gram tissue (%ID/g) and 
presented as mean ± SD.
0.1 µg (n=5) 0.2 µg (n=5) 0.5 µg (n=5) 1.0 µg (n=5) 2.0 µg (n=5)
Blood 0.03 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 0.06 ± 0.02 0.07 ± 0.05
Tumor 0.15 ± 0.03 0.13 ± 0.02 0.14 ± 0.05 0.14 ± 0.03 0.16 ± 0.03
Muscle 4.69 ± 0.85 5.19 ± 1.36 2.36 ± 0.67 2.88 ± 0.34 1.92 ± 0.09
Heart 0.13 ± 0.03 0.16 ± 0.03 0.16 ± 0.02 0.18 ± 0.02 0.17 ± 0.02
Lung 0.36 ± 0.07 0.52 ± 0.12 0.58 ± 0.19 0.61 ± 0.08 0.56 ± 0.13
Spleen 0.65 ± 0.10 0.69 ± 0.18 0.59 ± 0.15 0.78 ± 0.08 0.71 ± 0.07
Pancreas 0.17 ± 0.03 0.23 ± 0.05 0.20 ± 0.05 0.26 ± 0.04 0.21 ± 0.04
Kidney 237.3 ± 17.75 265 ± 38.01 213.8 ± 41.68 287.25 ±  33.58 256.96 ± 28.78
Liver 1.60 ± 0.31 1.53 ± 0.32 1.55 ± 0.37 1.74 ± 0.24 1.83 ± 0.35
Stomach 0.41 ± 0.09 0.42 ± 0.09 0.41 ± 0.03 0.53 ± 0.10 0.44 ± 0.07
Duodenum 0.49 ± 0.10 0.57 ± 0.15 0.53 ± 0.07 0.75 ± 0.27 0.93 ± 0.66
Tumor/Blood 143.4 ± 15.75 109.8 ± 13.06 52.55 ± 18.37 50.28 ± 7.42 37.95 ± 16.30
Tumor/Muscle 33.69 ± 10.64 41.12 ± 5.16 19.08 ± 8.46 20.94 ± 5.02 12.23 ± 2.94
Tumor/Kidney 0.02 ± 0.01 0.02 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
Tumor/Heart 35.64 ± 2.05 33.10 ± 5.33 14.58 ± 4.15 16.45 ± 3.02 11.22 ± 1.42
Tumor/Lung 12.96 ± 1.16 10.04 ± 1.82 4.19 ± 0.72 4.81 ± 0.82 3.58 ± 0.83
Figure 4. Binding of [111In]In-DTPA-GIP1-42 to isolated islets. The solid bar represents binding of [
111In]
In-DTPA-GIP1-42. The white bar represents binding of [
111In]In-DTPA-GIP1-42 in the presence of an excess 
unlabeled GIP1-42.
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Figure 5. a) Peptide dose escalation study in BALB/c nude mice with subcutaneous BHK-GIPR tumors. 
Values are expressed as percentage injected dose per gram tissue (%ID/g) (n=5). b) Tumor uptake of 
[111In]In-DTPA-GIP1-42 using different peptide doses. Tumor uptake was significantly higher (**p=0.008) at 
peptide doses smaller than 0.5 µg (0.1 nmol).
Biodistribution Studies 
Figure 6A summarizes the biodistribution of [
111In]In-DTPA-GIP1-42 in BALB/c nude mice bearing 
a subcutaneous BHK-GIPR transfected tumor. One hour after injection, highest tumor uptake 
was observed: 4.7 ± 0.8 %ID/g. After 4 and 24 hours, tumor uptake decreased to 3.3 ± 0.8 
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Figure 6. a) Biodistribution study of [111In]In-DTPA-GIP1-42 in BALB/c nude mice bearing subcutaneous 
BHK-GIPR tumors at 1, 4 and 24 hours after tracer injection. Values are expressed as percentage injected 
dose per gram tissue (%ID/g) (n=5). Blocking was performed by co-injection of 25 µg unlabeled GIP1-42 
(n=5). b) Biodistribution study of [111In]In-DTPA-GIP1-42  in BALB/c nude mice bearing subcutaneous NES2Y 
tumors, 1 hour after tracer injection. Values are expressed as percentage injected dose per gram tissue 
(%ID/g) (n=5). Blocking was performed by co-injection of 25 µg unlabeled GIP1-42 (n=2).
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GIP1-42 significantly lowered tumor uptake to 0.8 ± 0.2 %ID/g (p=0.0001) 4 hours after injection, 
indicating GIPR-mediated tumor uptake. One hour after injection, tumor uptake in NES2Y 
tumors was 0.7 ± 0.2 %ID/g (Figure 6B). Co-administration of an excess unlabeled GIP1-42 
lowered tumor uptake to 0.6 ± 0.01 %ID/g (p=0.78) Raw data of these biodistribution studies are 
shown in Tables 2 and 3.
SPECT/CT
One and four hours after injection of [111In]In-DTPA-GIP1-42, BHK-GIPR transfected tumors were 
clearly visible on SPECT/CT (Figures 7A and 7B). Co-injection of an excess unlabeled GIP1-42 
completely blocked tracer uptake in the BHK-GIPR transfected tumor (Figure 7C). Also in mice 
bearing NES2Y tumors, clear tumor uptake was observed 1 hour after tracer injection (Figure 
8A and 8B). Furthermore, co-injection of an excess unlabeled GIP1-42 prevented tracer uptake 
in NES2Y tumors, suggesting GIPR-mediated tracer uptake in these tumors.
Table 2. Raw data of the biodistribution study of [111In]In-DTPA-GIP1-42 in BALB/c nude mice bearing 
subcutaneous BHK-GIPR tumors at 1, 4 and 24 hours after tracer injection shown in Figure 6A. Values are 
expressed as percentage injected dose per gram tissue (%ID/g) and presented as mean ± SD.
1 hour p.i. 
(n=5)
4 hours p.i. 
(n=5)




24 hours p.i. 
(n=5)
p-value
Blood 0.25 ± 0.12 0.05 ± 0.02 0.03 ± 0.01 0.02 ± 0.01
Tumor 4.69 ± 0.75 3.27 ± 0.77 0.86 ± 0.20 1.95 ± 0.21 0.0001
Muscle 0.14 ± 0.02 0.08 ± 0.01 0.07 ± 0.01 0.06 ± 0.20
Heart 0.20 ± 0.03 0.12 ± 0.02 0.10 ± 0.02 0.08 ± 0.03
Lung 0.55 ± 0.08 0.33 ± 0.08 0.33 ± 0.11 0.18 ± 0.60
Spleen 0.60 ± 0.09 0.53 ± 0.17 0.52 ± 0.12 0.49 ± 0.08
Pancreas 0.30 ± 0.04 0.19 ± 0.02 0.15 ± 0.02 0.14 ± 0.03 0.01
Kidney 210.9 ± 22.93 227.9 ± 15.46 227.1 ± 25.81 172.75 ± 21.28
Liver 1.10 ± 0.15 1.16 ± 0.26 1.09 ± 0.27 0.70 ± 0.16
Stomach 0.50 ± 0.12 0.36 ± 0.07 0.27 ± 0.02 0.26 ± 0.07
Duodenum 0.56 ± 0.09 0.45 ± 0.05 0.39 ± 0.07 0.38 ± 0.04
Tumor/Blood 21.76 ± 7.93 77.60 ± 21.65 29.76 ± 10.10 129.79 ± 68.35
Tumor/Muscle 34.97 ± 4.70 40.43 ± 11.33 12.45 ± 1.14 36.35 ± 11.38
Tumor/Kidney 0.02 ± 0.01 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00
Tumor/Heart 23.58 ± 3.41 29.00 ± 9.68 8.89 ± 0.83 25.51 ± 5.31
Tumor/Lung 8.64 ± 1.05 10.09 ± 2.91 2.68 ± 0.51 11.27 ± 2.95
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Table 3. Raw data of the biodistribution study of [111In]In-DTPA-GIP1-42 in BALB/c nude mice bearing 
subcutaneous NES2Y tumors shown in Figure 6B. Values are expressed as percentage injected dose per 
gram tissue (%ID/g) and presented as mean ± SD.
1 hour p.i. 
(n=5)
1 hour p.i. + excess 
unlabeled (n=5)
p-value
Blood 0.18 ± 0.07 0.21 ± 0.06
Tumor 0.65 ± 0.16 0.62 ± 0.01 0.70
Muscle 0.07 ± 0.01 0.06 ± 0.01
Heart 0.14 ± 0.02 0.10 ± 0.02
Lung 0.49 ± 0.04 0.47 ± 0.08
Spleen 0.46 ± 0.12 0.34 ± 0.01
Pancreas 0.20 ± 0.04 0.16 ± 0.04 0.20
Kidney 184.38 ± 17.56 180.17 ± 19.22
Liver 1.11 ± 0.11 0.83 ± 0.12
Stomach 0.34 ± 0.06 0.28 ± 0.04
Duodenum 0.42 ± 0.12 0.37 ± 0.04
Tumor/Blood 3.96 ± 0.76 3.01 ± 0.88
Tumor/Muscle 9.43 ± 1.12 11.09 ± 2.05
Tumor/Kidney 0.00 ± 0.00 0.00 ± 0.00
Tumor/Heart 4.83 ± 0.96 6.09 ± 1.14
Tumor/Lung 1.38 ± 0.45 1.33 ± 0.24
DISCUSSION
In this study, we investigated the potential of [111In]In-DTPA-GIP1-42 for NET detection. The tracer 
showed GIPR-mediated binding to BHK-GIPR positive cells and NES2Y cells, and to isolated 
islets in vitro. Optimal GIPR-mediated tumor targeting of BHK-GIPR positive tumors in vivo, 
was observed 1 hour post injection using a peptide dose of 0.2 µg (0.04 nmol). Furthermore, 
both BHK-GIPR transfected tumors and NES2Y tumors were visualized by SPECT.
It has been described that C-terminally truncated GIP analogs, such as GIP1-30, exhibit reduced 
receptor binding affi nity when compared to intact GIP1-42,while retaining their full insulinotropic 
effect 26, 27. Since the goal of this study was to apply the analog for in vivo imaging, high receptor 
affi nity should be preserved rather than biological activity. Therefore, we selected GIP1-42 as 
a basis for our radiotracer. Another point of consideration while designing a GIPR targeting 
radiotracer, is the susceptibility of the native peptide to DPP IV degradation 31. Since it was 
shown that several N-terminal modifi cations showed increased half-life in vitro 32, 33, we 
acetylated the N-terminal tyrosine residue to obtain a better DPP IV degradation-resistant 
tracer. Indeed, we observed that the tracer remained stable in serum for at least 4 hours after 
incubation and even after 24 hours of incubation 73% of the tracer remained intact.
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In order to obtain high quality images, high target-to-background ratios are required. Tracer 
metabolites labeled with a radiometal via a chelator, can be trapped in the lysosomes upon 
tracer internalization and degradation, resulting in enhanced tracer accumulation in the target 
cells 23, 34. Therefore, we investigated tracer internalization rates in vitro. Internalization kinetics 
of the tracer were comparable and relatively slow: after 24 hours, both BHK-GIPR positive 
and NES2Y cells showed similar internalization rates of 4.2 ± 0.6 %ID/g and 4.7 ± 3.6 %ID/g, 
respectively. Interestingly, the majority of the tracer was bound to the cell surface in both cell 
lines. These observations could be explained by very recent findings of Ismail et al. indicating 
that N-terminal acetylation of the peptide hampers receptor internalization 35. 
In BHK-GIPR positive tumors, GIP1-42 doses lower than 0.5 µg (0.1 nmol) resulted in maximal 
tumor accumulation. This indicates that administration of higher peptide doses results in 
partial saturation of the GIPR in vivo. However, since the tracer could be labeled with a molar 
activity up to 1.2 TBq/µmol, administration of an activity dose for imaging is still feasible. For 
in vivo SPECT imaging, high tumor-to-blood ratios are required. However, since tracer uptake 
in the blood was still very low at a peptide dose of 0.2 µg, we selected this dose as the optimal 
dose for in vivo imaging since it resulted in the highest absolute tumor uptake.
Although [111In]In-DTPA-GIP1-42 showed high and specific tumor uptake in GIPR-transfected 
GIPR tumors, tumor uptake in NES2Y tumors was lower and co-injection of an excess unlabeled 
GIP1-42 did not result in significantly lower tracer uptake. This clear difference in tracer uptake 
might be explained by the completely different origin and purpose of both cell lines. While the 
BHK-GIPR cell line was created to express artificially high receptor levels, the NES2Y cells are 
derived from patients with congenital hyperinsulinism of infancy (28). Since these cells do not 
overexpress the target receptor and it is known that the natural expression levels of the GIPR 
are much lower compared to its brother incretin peptide GLP-1 36, the lower uptake is to be 
expected. As for the blocking study, the small size of the blocking group (n=2) impairs generation 
of representative results. Therefore, the obtained significance level (p=0.78) might be distorted. 
On the SPECT images however, tracer accumulation was observed in NES2Y tumors but was 
no longer observed after co-injection of an excess unlabeled GIP1-42 (Figure 8C), suggesting 
specific tumor targeting. Nevertheless, several tracer characteristics might be optimized to 
further improve tumor targeting. Firstly, other N-terminal modifications than acetylation, such 
as glucitol or pyroglutamil insertion, have been shown to improve the half-life of the peptide 
in the presence of DPP IV 32, 33 and might also result in higher internalization rates. Secondly, 
receptor binding and internalization might increase with longer circulation times. As shown 
in our biodistribution studies, [111In]In-DTPA-GIP1-42 is cleared from the blood very rapidly, 
hampering longer tracer circulation and thus higher tumor uptake. Several methods such as 
PEGylation, multimerization or introduction of free fatty acid tails might increase circulation 
time 37 and thereby tracer accumulation in the tumor. However, a good balance between tracer 
retention in blood and tracer targeting dynamics has to be found in order to obtain favorable 
target-to-background ratios for in vivo imaging.
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[111In]In-DTPA-GIP1-42 was produced at a high molar activity and showed receptor mediated 
binding to various GIPR expressing cells in vitro. Subcutaneous BHK-GIPR positive tumors 
showed GIPR-mediated tracer accumulation with optimal in vivo targeting 1 hour post-
injection, at a peptide dose of 0.2 µg (0.04 nmol). Furthermore, although very low, uptake of 
a GIP-based tracer was demonstrated for the fi rst time in a human beta-cell derived tumor. 
Unfortunately, specifi city of tracer binding could not be shown due to the small size of the 
blocking group. In conclusion, [111In]In-DTPA-GIP1-42 shows promising results as a radiotracer 
for NET imaging. However, the initial working hypothesis that a full-length peptide-based 
tracer might show improved characteristics for in vivo NET imaging when compared to GIP1-30
could not be confi rmed.
Figure 7. Maximum intensity projection (MIP) SPECT/CT images of a BALB/c nude mouse bearing a 
subcutaneous BHK-GIPR tumor 1 hour after injection (a), 4 hours after injection (b) and 4 hours after 
injection and co-injection with 25 µg unlabeled GIP1-42 (c).
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Figure 8. SPECT/CT (a) and SPECT (b) of a BALB/c nude mouse bearing a subcutaneous NES2Y tumor, 1 
hour after injection and SPECT/CT (c) and SPECT (d) after co-injection with 25 µg unlabeled GIP1-42.
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Glucagon like peptide-1 receptor (GLP-1R) targeting using radiolabeled exendin is a promising 
approach to non-invasively visualize and determine beta cell mass (BCM), which could help 
to unravel the pathophysiology of diabetes. However, saturation of the GLP-1R on beta cells 
occurs at low peptide doses, since the number of receptors expressed under physiological 
conditions is low. Therefore, tracers with high molar activities are required to sensitively image 
small variations in BCM. Here, we describe a novel exendin-3-based radiotracer with multiple 
chelators and determined its potential for in vivo beta cell imaging.
Exendin-3 was modified by adding six lysine residues C-terminally conjugated with one, two 
or six DTPA moieties. All compounds were labeled with 111In and their GLP-1R affinity was 
determined in vitro using GLP-1R expressing cells. The in vivo behavior of the 111In-labeled 
tracers was examined in BALB/c nude mice with a subcutaneous GLP-1R expressing tumor 
(INS-1). Brown Norway rats were used for SPECT visualization of the pancreatic BCM.
Addition of six lysine and six DTPA residues (hexendin(40-45)) resulted in a seven-fold increase 
in molar activity (from 0.73 GBq/nmol to 5.54 GBq/nmol). IC50 values varied between 5.2 and 
69.5 nM. All compounds with two or six lysine and DTPA residues had a significantly lower 
receptor affinity than [Lys40(DTPA)]exendin-3 (4.4 nM, p < 0.05). The biodistribution in mice 
revealed no significant decrease in pancreatic uptake after addition of six lysine and DTPA 
molecules. Hexendin(40-45) showed a six-fold increase in absolute 111In uptake in the pancreas 
of Brown Norway rats compared to [Lys40(DTPA)]exendin-3 (182.7 ± 42.3 kBq vs. 28.8 ± 6.0 kBq, 
p<0.001). Visualization of the pancreas on SPECT was improved using hexendin(40-45), due to 
the higher count rate, achieved at the same peptide dose.
In conclusion, hexendin(40-45) showed an improved visualization of the pancreas with SPECT. 
This tracer holds promise to sensitively and specifically detect small variations in BCM.
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Currently, 422 million people worldwide are suffering from diabetes, and it is expected that 
this number will have doubled by 2030 1. These dramatic numbers underline the importance 
for research aiming to improve diagnosis and treatment of the disease. Gaining better insight 
into the pathophysiology of the different types of diabetes is therefore one of the major goals 
of current diabetes research. 
The diagnosis of diabetes is currently based on laboratory tests, such as blood glucose 
measurements and oral glucose tolerance testing. However, they do not provide information 
about the underlying pathophysiological processes and can only detect the downstream 
consequences (i.e. impaired glucose tolerance) of processes that have started years before 
diagnosis. Currently, the loss of beta cell mass (BCM) and beta cell function (not being directly 
related to mass) proceeding to overt hyperglycemia is gaining attention and determination of 
BCM has emerged as a fi eld of diabetes research 2. To date, biopsy and autopsy studies of 
diabetic patients are the only source of information regarding BCM. However, this only provides 
information at one time point 3 and pancreatic biopsies in T1D patients have been shown to 
be associated with a high rate of serious complications 4. Therefore, there is a clear need 
for a non-invasive method to measure the loss of BCM in individual patients. A promising 
approach addressing this urgent issue would be a sensitive, specifi c and non-invasive imaging 
method to detect viable beta cells in the pancreas, which would also enable determination of 
the exact relation between the BCM and beta cell function during the course of the disease 
5, 6. The high technological demands for in vivo beta cell imaging and the need for a highly 
sensitive and specifi c imaging method displaying a high target-to-background ratio have been 
discussed extensively in the literature 5, 7-10. Namely, the low amount of beta cells (only a few 
gram) and the diffuse distribution throughout the pancreas represent a major challenge for 
in vivo imaging 6. Recently, it has been shown that radiolabeled exendin is a promising tracer 
to visualize pancreatic beta cells in vivo in rodents and humans 6, 11. Exendin-3 is an analog of 
GLP-1 (glucagon-like peptide-1) and binds with high affi nity to the GLP-1 receptor (GLP-1R) 
which is specifi cally expressed on the pancreatic beta cells as well as on beta cell derived 
tumors 12, 13. In order to improve image quality, enabling better delineation of the pancreas 
(which can be hampered by the proximity of the kidneys accumulating radioactivity), higher 
uptake of radiolabeled exendin-3 in the pancreas is warranted to obtain optimal count rates 
and high signal-to-background ratios. Since the GLP-1R is expressed at relatively low levels on 
beta cells in healthy rodents (as compared to for example neuroendocrine tumors massively 
overexpressing somatostatin receptors) and the total BCM is decreased in diabetic animals, 
the receptor is saturated at comparably low peptide doses. It has been demonstrated that the 
maximum peptide dose for exendin imaging of pancreatic beta cells in mice and rats is 20 pmol 
per injection 14, 15. In order to achieve optimal SPECT image quality, labeling of exendin with very 
high molar activities is required.
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Previously, an exendin analog with six extra lysine residues at the C-terminus has been 
described (Table 1)16. The addition of lysine residues would theoretically allow the conjugation 
of multiple DTPA moieties to produce a tracer with a higher molar activity. In the present 
study, we have tested five novel variants of exendin-3 by adding multiple DTPA moieties to the 
C-terminal lysine residues and we evaluated whether 1) the molar activity would be enhanced, 
2) the modifications would influence the affinity for the GLP-1R, 3) targeting to beta cells would 
be increased (in terms of absolute radioactivity concentration) and 4) image quality would be 
improved.
Table 1. Amino acid sequence of ZP10A, exendin-4, exendin-3 and GLP1. Amino acids homologous to GLP-
1 are in bold.









111InCl3 was obtained from Mallinckrodt Medical (Petten, The Netherlands) and the DTPA-
exendin-3 peptides were purchased from Peptide Specialty Laboratories (PSL, Heidelberg, 
Germany). The exendin-3 compounds with 6 additional lysine residues are referred to as 
hexendin (hexa-lysine-exendin-3) hereafter. One or multiple DTPA molecules were conjugated 
to the ε-amino group of C-terminal lysines at different positions. The structure, names and 
molecular weights of the peptides are shown in Table 2. Exendin-3, with DTPA conjugated to 
lysine at position 40 ([Lys40(DTPA)]exendin-3), was used as the reference in this study.
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Table 2. Structure, name and molecular mass of exendin-3 derivatives. The lysine position to which DTPA 
is conjugated is indicated between parentheses (), the lysine residues and DTPA moieties attached are 
marked in bold.




















Radiolabeling of DTPA-exendin-3 analogs with 111In
The peptides were dissolved in metal-free 0.1 M MES (2-(N-morpholino) ethanesulfonic acid, 
Sigma Aldrich, St. Louis, MO, USA), pH 5.5 17. 111InCl3 was added to 0.1 M MES buffer, pH 5.5, 
containing the respective peptide: One volume of 111InCl3 was mixed with two volumes of MES 
buffer. After incubation for 20 min at room temperature, 50 mM EDTA (ethylenediaminetetraacetic 
acid) (Sigma Aldrich) was added to a fi nal concentration of 5 mM. Subsequently, 10% Tween-80 
(Sigma Aldrich) in PBS was added to a fi nal concentration of 0.1% to prevent sticking of the 
peptide to the reaction vial. The maximum specifi c activity of each analog was determined by 
performing a series of radiolabeling reactions ranging from 75 to 300 MBq for [Lys40(DTPA)]
exendin-3, hexendin(40), hexendin(45), and hexendin(40+45) (200 pmol of peptide was added to 
the reaction mixture) and 75 to 900 MBq for hexendin(40+41) and hexendin(40-45) (100 pmol of 
peptide was added to the reaction mixture). Radiochemical purity was determined by instant 
thin layer chromatography on silica-gel strips (ITLC-SG Biodex, Shirley, NY, USA) using 0.1 M 
EDTA in 0.1 M NH4Ac as a mobile phase (Rf
111In-labeled peptides = 0, Rf
111In-EDTA = 1).
The radiolabeled peptides were purifi ed by solid-phase extraction using an HLB (hydrophilic-
lipophilic balance reversed-phase sorbent) cartridge (Waters Oasis©, Milford, MA, USA) as 
described previously 18. For conditioning and washing of the cartridge, 1 ml 0.1 M MES was 
used.
Cell culture
For in vivo experiments the rat insulinoma cell line INS-1 was used 19. INS-1 cells were 
cultured in RPMI-1640 medium supplemented with 10% fetal calf serum, 2 mM glutamine, 
100 units/ml penicillin, 100 µg/ml streptomycin, 10 mM HEPES, 50 µM β-mercaptoethanol and 
1 mM sodiumpyruvate. CHL-cells transfected with the human GLP-1 receptor (a kind gift of 
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Brigitte Lankat-Buttgereit, Marburg) were used for the in vitro experiments. CHL-GLP-1R cells 
were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) GlutaMAX (Gibco, Invitrogen, 
Breda, The Netherlands), supplemented with 10% fetal calf serum, 100 units/ml penicillin, 100 
µg/ml streptomycin, Geneticin (G418) sulphate solution (0.5 mg/ml final concentration), 1 mM 
sodiumpyruvate and 0.1 mM non-essential amino acids. Cells were maintained in a humidified 
5% CO2 atmosphere at 37 °C.
Competitive binding assay
The relative affinity of the exendin analogs for the GLP-1R was determined in a competitive 
binding assay using CHL-GLP-1R cells. CHL-GLP-1R cells were seeded in six-well plates at 
1 x 106 cells/well 2 days prior to the experiment. All peptides were labeled with natIn. A five-
fold molar excess of natIn prepared in 0.02 M HCl was added to the peptides and two volumes 
of 0.1 M MES buffer. After incubation at room temperature for 20 min, 10% Tween-80 was 
added to a final concentration of 0.1%. Serial dilutions of these ‘cold-labeled’ compounds were 
prepared in DMEM GlutaMAX with 0.5% w/v BSA (bovine serum albumin). Cells were washed 
once with GlutaMAX with 0.5% w/v BSA and the ‘cold-labeled’ peptides were added at a final 
concentration ranging from 0.1-1000 nM along with 1 kBq (1.4 fmol) 111In-labeled [Lys40(DTPA)]
exendin-3. After incubation on ice for 4 hours, cells were washed with ice-cold GlutaMAX with 
0.5% w/v BSA and the cells were harvested with 0.1 M NaOH. Cell-associated radioactivity was 
determined in a γ-counter (Wallac 1480-Wizard, Perkin Elmer, Boston, MA, USA) and the IC50 
(half-maximal inhibitory concentration) was calculated using GraphPad Prism (version 5.03, 
GraphPad Software, San Diego California USA).
Biodistribution at equimolar doses
All animal experiments were performed according to national laws and regulations and 
approved by the animal welfare body of the Radboud University. To examine the in vivo GLP-1R 
targeting properties of the 111In-labeled exendin analogs, six to eight weeks old female BALB/
cRJ nu mice (Janvier, Saint-Berthevin, France) were inoculated subcutaneously with 1 x 107 
INS-1 cells in 200 µl RPMI medium. Mice were randomly divided into 12 groups (n=5 per group). 
Each group was injected intravenously with 0.1-0.7 MBq of one of the following 111In-labeled 
peptides: [Lys40(DTPA)]exendin-3, hexendin(40), hexendin(45), hexendin(40+45), hexendin(40+41) 
or hexendin(40-45)). Equimolar doses of the labeled analogs were administered (20 pmol) to 
the mice. For each analog, an additional group of 5 mice was co-injected with an excess (2 
nmol) of unlabeled Lys40exendin-3 to determine the biodistribution of the tracer while blocking 
the GLP-1 receptors in vivo. After two hours, mice were euthanized by CO2/O2 asphyxiation. 
Relevant organs were dissected, weighed and counted in a γ-counter. For each tissue sample 
the uptake was calculated and presented as the percentage of the injected dose per gram 
tissue (%ID/g).
548546-L-bw-Joosten




Biodistribution at different molar doses
Because hexendin(40+41) and hexendin(40-45) can be labeled at higher molar activities, it allows 
injection of a lower peptide dose. To investigate whether administering a lower peptide dose 
could lead to higher uptake of the tracer in the target tissue (in terms of %ID/g), BALB/c nude 
mice with a s.c. INS-1 tumor were injected with 4 pmol of hexendin(40+41) or hexendin(40-45) 
and compared to injection of 20 pmol of [Lys40(DTPA)]exendin-3. For all compounds 0.2 MBq of 
the 111In-labeled peptide was injected. To determine the non-GLP-1R mediated biodistribution 
of the tracers, for each peptide an additional group of 5 mice was co-injected with an excess 
(2 nmol) of unlabeled Lys40exendin-3. The ex vivo biodistribution was performed as described 
above. 
SPECT
To compare the ability of the tracers to visualize GLP-1R expressing cells in the pancreas, SPECT 
studies were carried out in male Brown Norway (BN) rats. Two groups of rats (n=5) received 
19.4 ± 1.3 MBq (20 pmol) of either 111In-labeled [Lys40(DTPA)]exendin-3 or hexendin(40-45). 
An additional group received [111In]In-hexendin(40-45) at a 7.5-fold higher activity dose (20 
pmol, 149.1 ± 3.8 MBq (n=4)) to investigate the effect of the activity dose on the image quality. 
SPECT scans were acquired under isofl urane/O2 anesthesia two hours after injection of the 
radiolabeled peptide using a dedicated small animal SPECT/CT scanner (U-SPECT-II, MILabs, 
Utrecht, The Netherlands). Images were acquired for 50 min, using a 1.0 mm multi-pinhole 
general purpose mouse and rat collimator. Rats were euthanized by CO2/O2 asphyxiation and 
the ex vivo biodistribution was determined as described above. Absolute uptake in the pancreas 
and kidneys was calculated by multiplying the injected dose (MBq) by the uptake in the organs 
(percent injected dose in the total dissected organ).
Images were reconstructed using the U-SPECT-Rec Software (MILabs, Utrecht, The 
Netherlands,). Inveon Research Workplace (Preclinical Solutions, Siemens Medical Solutions 
USA, Inc., Knoxville, TN, USA) was used to quantify the pancreatic uptake of the 111In-labeled 
peptides by drawing a volume of interest over the pancreas and in the abdomen (below the 
kidneys) as a background region. The image quality was determined quantitatively by calculating 
the ratio of the mean activity in  the pancreas region and the activity in the background region 
(signal-to-background ratio) 20.
Statistical analysis
Data were analyzed using GraphPad Prism software version 5.03 for Windows. One-way 
ANOVA followed by a Tukey test was used to determine signifi cance. A p-value below 0.05 
was considered signifi cant. For the competitive binding assay the F-test was used to manually 
calculate signifi cance.
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The maximum molar activity of the 111In-labeled exendin analogs and the theoretical maximum 
molar activity (assuming all DTPA-molecules chelating 111In) are summarized in Table 3. 
For all tracers the radiochemical purity exceeded 99% after purification. The molar activity 
of [Lys40(DTPA)]exendin-3 (0.73 GBq/nmol) was similar to that of the exendin-3 analogs with 
6 lysine residues and only one DTPA attached (hexendin(40) and hexendin(45): 0.69 and 0.67 
GBq/nmol). The molar activity of hexendin(40+41) and hexendin(40+45) was approximately two-
fold higher (1.66 and 1.32 GBq/nmol, respectively) compared to the reference peptide. Finally, 
hexendin(40-45) could be labeled with a molar activity of 5.54 GBq/nmol, which is 7.5-times 
higher than that of the reference peptide. Furthermore, the radiolabeling of [Lys40(DTPA)]
exendin-3 resulted in 42% of the theoretical maximum molar activity, whereas 54% of the 
theoretical maximum molar activity was reached for hexendin(40-45).
Table 3. Maximum and theoretical specific activity of exendin-3 derivatives. The maximum theoretical 
specific activity calculated for exendin-3, conjugated with one, two or six DTPA molecules, with the 
assumption that 1 nmol of 111In will be complexed in 1 nmol of DTPA.
Compound Maximum specific activity 
achieved (GBq/nmol)








* The labeling is not reproducible, and varies from 0.85 GBq/nmol to 4.24 GBq/nmol.
Competitive binding assay
In Figure 1 the results of the competitive binding assay on CHL-GLP-1R cells are shown. 
The IC50 values of all peptides were in the low nanomolar range. The IC50 of hexendin(40) and 
hexendin(45) were 5.2 and 6.3 nM respectively. The IC50 of hexendin(40+45), hexendin(40+41) and 
hexendin(40-45) were 10.1 , 19.2 and 69.5 nM, respectively. All peptides, except hexendin(40), 
had a significantly lower affinity for the receptor than the reference peptide (4.4 nM, p < 0.05).
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Figure 1. Curves of the competitive binding assay (IC50) on CHL-GLP-1R cells. 
111In-labeled [Lys40(DTPA)]-
exendin-3 was used as radiotracer. The IC50 values and 95% confi dence intervals in nM are given between 
parentheses ().
Biodistribution at equimolar doses
Figure 2 shows the biodistribution of all 111In-labeled exendin analogs (at a peptide dose of 20 
pmoles) in BALB/c nude mice with a subcutaneous INS-1 tumor two hours post injection. 111In-
labeled [Lys40(DTPA)]exendin-3 showed the highest uptake (33.8 ± 7.6 %ID/g) in the INS-1 tumor. 
C-terminal addition of six lysine residues (hexendin(40)) reduced the tumor uptake to 19.8 ± 
5.8 %ID/g (p<0.05). Conjugation of multiple DTPA molecules did not affect the tumor uptake 
signifi cantly compared to hexendin(40) (hexendin(40+45): 15.9 ± 1.3 %ID/g, hexendin(40+41): 
22.9 ± 7.3 %ID/g, hexendin(40-45): 19.9 ± 9.2 %ID/g). The pancreatic uptake of hexendin(40) (7.60 
± 1.50 %ID/g) was lower than that of [Lys40(DTPA)]exendin-3 (11.97 ± 4.04 %ID/g). Hexendin with 
two or more DTPA molecules showed similar pancreatic uptake as [Lys40(DTPA)]exendin-3: 
hexendin(40+41) (10.77 ± 2.87 %ID/g) and hexendin(40-45) (9.77 ± 2.72 %ID/g). Accumulation 
in the tumor and the pancreas could be blocked by an excess of unlabeled exendin-3, proving 
GLP-1R mediated uptake for all compounds. Furthermore, the lungs, stomach and duodenum 
also showed receptor-mediated uptake of exendin-3. Renal uptake of all peptides was high and 
could not be blocked by an excess of unlabeled exendin-3.
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Figure 2. Biodistribution of 111In-labeled exendin-3 derivatives in BALB/c nude mice bearing a subcutaneous 
INS-1 tumor. Values are expressed as a percentage of the injected dose per gram of tissue (n=5 mice per 
group, error bars SD).
Biodistribution at different molar doses
In order to assess whether the uptake of the tracer in the pancreas could be further enhanced 
by reducing the administered peptide dose, the biodistribution of 20 pmol of the reference 
peptide was compared to that of 4 pmol of hexendin(40+41) and hexendin(40-45) (Figure 3). 
When the standard [Lys40(DTPA)]exendin-3 dose of 20 pmol was given, the uptake in tumor was 
28.3 ± 12.2 %ID/g. A peptide dose of 4 pmol resulted in a tumor uptake of 23.7 ± 5.8 and 16.7 
± 3.3 %ID/g, respectively for hexendin(40+41) and hexendin(40-45), which was not significantly 
different. Pancreatic uptake was 13.3 ± 1.9 %ID/g for [Lys40(DTPA)]exendin-3 at the standard 
peptide dose, while this was 9.5 ± 1.7 and 9.8 ± 2.2 %ID/g for hexendin(40+41) (p<0.05) and 
hexendin(40-45) (p<0.05) respectively, at a peptide dose of 4 pmol. Renal uptake did not change 
significantly.
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Figure 3. Biodistribution of 111In-labeled [Lys40(DTPA)]exendin-3 (20 pmol), hexendin(40+41) (4 pmol) and 
hexendin(40-45) (4 pmol) in BALB/c nude mice with a subcutaneous INS-1 tumor. Values are expressed as 
%ID/g (n=5 mice per group, error bars SD).
SPECT
Addition of multiple DTPA molecules allowed for labeling at a higher molar activity. Therefore, in 
the fi nal experiment, we radiolabeled hexendin(40-45) at a high molar activity and we investigated 
whether visualization of the pancreas with SPECT could be improved by administering a 
higher activity dose (at equimolar peptide doses), compared to labeling of hexendin(40-45) or 
[Lys40(DTPA)]exendin-3 at a low molar activity. Figure 4 shows the biodistribution profi les of 
111In-labeled [Lys40(DTPA)]exendin-3 and hexendin(40-45) in BN rats. Pancreatic uptake was 
higher for [Lys40(DTPA)]exendin-3 (0.17 ± 0.05 %ID/g) than for hexendin(40-45), either labeled 
at a low (LA) or high (HA) molar activity (0.09 ± 0.01 (p<0.01) and 0.10 ± 0.02 %ID/g (p<0.05) 
respectively). The absolute uptake in pancreas and kidneys was assessed for all three tracers 
and is shown in Figure 5. The absolute pancreatic uptake of [Lys40(DTPA)]exendin-3 (28.8 ± 6.0 
kBq) and hexendin(40-45) (19.9 ± 1.5 kBq) did not differ signifi cantly, when labeled at the same 
molar activity. However, injection with a high activity dose of hexendin(40-45) resulted in an 
absolute uptake in the pancreas which was 9 times higher than injection of a low activity dose 
(182.7 ± 42.3 kBq compared to 19.9 ± 1.5 kBq, p<0.001). The absolute renal uptake was six-fold 
higher:  42.52 ± 2.68 MBq vs. 7.17 ± 3.16 MBq (p<0.001). Typical images of rats injected with 
[Lys40(DTPA)]exendin-3 or hexendin(40-45), labeled at a low molar activity are shown in Figure 
6A and 6B. The image quality improved when hexendin(40-45) with a high molar activity was 
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administered (Figure 6C). The pancreas-to-background ratio (Figure 7) increased to 18.8 ± 4.3 
for hexendin(40-45) (HA), compared to 6.6 ± 1.9 for [Lys40(DTPA)]exendin-3 (LA) and 10.9 ± 2.2 
for hexendin(40-45) (LA). (p<0.001).
Figure 4. Biodistribution of 111In-labeled [Lys40(DTPA)]exendin-3 and hexendin(40-45) in Brown Norway 
rats. Values are expressed as %ID/g (n=5 rats per group for the LA (low activity) and n=4 rats per group for 
the HA (high activity), error bars SD).
Figure 5. Absolute uptake of 111In-labeled [Lys40(DTPA)]exendin-3 and hexendin(40-45) in pancreas and 
kidney. 
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Figure 6. Coronal slices of SPECT images of Brown Norway rats, obtained two hours after injection of 
the peptide. (A) 20 pmol 111In-labeled [Lys40(DTPA)]exendin-3 (19.1 ± 2.4 MBq) (B) 20 pmol 111In-labeled 
hexendin(40-45) (18.4 ± 0.2 MBq) (C) 20 pmol 111In-labeled hexendin(40-45) (149.1 ± 3.8 MBq). Lungs are 
indicated with L, kidneys with K and the pancreas is delineated with a red circle.
Figure 7. Signal-to-background ratio.
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In this study, a novel exendin analog was presented that can be labeled at a seven-fold higher 
molar activity as compared to [Lys40(DTPA)]exendin-3. The relative pancreatic uptake of this 
new tracer with six lysine and DTPA moieties (expressed as %ID/g) in mice was comparable 
to that of the reference peptide, however, the absolute activity uptake of hexendin(40-45) in 
the pancreas was nine-fold higher. This increased pancreas activity resulted in an almost 
three-fold improvement of the signal-to-background ratio of the images and clearly improved 
pancreas visualization.
Breeman et al. optimized labeling conditions to reach higher molar activities to avoid receptor 
saturation or pharmacological (side)effects 21. When using optimal labeling conditions, like 
metal-free materials, appropriate temperatures or buffers still leaves room for improvement, 
a modification of the compound is an additional approach to enhance the molar activity.
Conjugation of five extra lysine residues to the C-terminus of [Lys40(DTPA)]exendin-3 allowed 
to attach multiple DTPA moieties. The 111InCl3 incorporation in hexendin(40-45) was twenty 
percent more efficient, relatively, than in the reference peptide, leading to a very clear absolute 
increase in molar activity from 0.73 GBq/nmol to 5.54 GBq/nmol. 
The increased molar activity obtained in this study allowed us to administer either lower 
amounts of peptide or higher amounts of radioactivity at equal peptide doses of the tracer. 
Although lowering the peptide dose  did not lead to an increased relative accumulation in target 
tissues, injecting a higher amount of radioactivity led to enhanced absolute accumulation of 
radiolabeled exendin. Background activity increased to a lesser extent, resulting in improved 
target-to-background ratios and improved visualization of the pancreas on SPECT. This 
represents a clear improvement for in vivo imaging as low peptide doses of exendin should 
be administered to avoid receptor saturation 14; as stated previously, this is of even more 
importance for beta cell quantification in the pancreas of diabetic individuals with lower BCM 
and thus a lower number of GLP-1R available for binding.
Although administration of higher ligand doses may be possible in clinical studies, also for 
peptides or antibodies which are biologically active, like exendin, it is of great interest to 
administer low pharmacological doses to limit the potential (biological) side-effects of the 
tracer. Using hexendin(40-45) for instance, the peptide dose administered to patients could be 
reduced almost seven times, thereby preventing side-effects, while maintaining a sufficient 
amount of radioactivity (150 MBq).
A disadvantage of multi-chelated compounds is the higher radioactivity accumulation in the 
kidneys. In preclinical imaging studies this is not a limiting factor, while in clinical studies this 
would result in unfavorably high radiation doses to the kidneys.
In our view, the multi-chelation approach presented here has high translational potential, 
because it is widely applicable, not only for different SPECT tracers, but also for PET tracers 
and other peptides or antibodies. When the labeling procedure of an antibody, for example, is 
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restricted to a low temperature, the multi-chelation approach could help to improve the molar 
activity. In addition, several antibody-based imaging agents are also limited by the protein dose 
that can be administered without saturating the tumor-associated receptor (e.g. PD-L1, IGF-
1R) 22, 23. Also, for evaluation of tracer molecules, this technology facilitates determination of 
optimal (low) tracer doses in vivo.
The concept of conjugating more than one chelator molecule to one mole of antibody was 
demonstrated almost three decades ago. In the respective study from Boniface et al., an 
increase in molar activity was found by increasing the cDTPA:MAb (monoclonal antibody) 
conjugation ratio 24. A major difference between their study and the study presented here, is 
the conjugation method. When conjugating antibodies, the chelator moieties are randomly 
bound to the antibody, possibly in the binding domain and thereby infl uencing the affi nity or 
immunoreactivity of the antibody. In the present study, the DTPA moieties were conjugated 
site-specifi cally to additional Lysine residues. By F-moc protection of the lysines that should 
not be conjugated, random conjugation interference in the binding domain was prevented.
Multi-chelated compounds should, at least theoretically, also be more sensitive in detecting 
tumors with a very low receptor density, or very small tumors or metastases, since more 
radioactivity can be delivered per receptor molecule while uptake in non-receptor expressing 
background remains low. In addition, this approach may help to make radiotracers suitable 
for autoradiography studies as the detection limit of autoradiography is dependent on target 
saturation and thus limits the tracer amount used. Finally, the potential of non-internalizing 
peptides with antagonistic features for tumor detection might be increased by improving 
radioactivity accumulation (which is lower due to lack of internalization) in the target tissue.
In conclusion, despite slightly decreased relative uptake of the tracer in the pancreas in rats, 
our multi-chelator approach led to an increase in signal-to-background ratio as a result of the 
improved molar activity. The higher target organ radioactivity accumulation led to improved 
visibility of pancreatic tissue in SPECT images in rodents. This technology may represent a 
major asset for reliable quantitative measurements of BCM in vivo for diabetes research. 
Moreover, this approach has great potential for translation to other peptides and chelators/
radionuclides, where it is essential to perform examination with high molar activity.
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ABSTRACT
PET/CT imaging of the glucagon-like peptide-1 receptor (GLP-1R) using radiolabeled exendin 
is a highly promising imaging method to detect insulinomas. However, high renal accumulation 
of radiolabeled exendin could hamper the detection of small insulinomas in close proximity to 
the kidneys. We report a new exendin analog with a cleavable methionine-isoleucine (Met-Ile-
Mal) linker to reduce renal uptake. We performed ex vivo biodistribution and PET/CT studies to 
assess uptake of this radiolabeled tracer in insulinomas, kidneys, and pancreas.
The C-terminus of exendin-4 was extended with a Met-Ile-linker, to which NOTA was conjugated 
(NOTA-MI-exendin-4). Exendin-4 with conjugated NOTA was used as control (NOTA-exendin-4). 
The affinity of both peptides for the GLP-1R was determined in a competitive binding assay using 
GLP-1R transfected CHL cells. The renal retention of 68Ga-labeled compounds was compared in 
non-tumor bearing C3H mice. Subsequently, the tumor uptake in INS-1 tumor-bearing BALB/c 
nude mice was determined with ex vivo biodistribution and visualized by PET/CT.
The affinity for the GLP-1R was 9.6 and 4.0 nM for NOTA-exendin-4 and NOTA-MI-exendin-4, 
respectively. In C3H mice, a significantly lower uptake of 68Ga-labeled NOTA-MI-exendin-4 in the 
kidneys 4 hours post injection (72.7 ± 3.9 %ID/g) was observed, compared to NOTA-exendin-4 
(207.7 ± 17.4 %ID/g) (p<0.0001). [68Ga]Ga-NOTA-MI-exendin-4 uptake in INS-1 tumors was 
stable over time (29.3 ± 6.9 %ID/g at 1 hour and 25.0 ± 8.0 %ID/g at 4 hours p.i.) and was similar 
to tumor uptake of [68Ga]Ga-NOTA-exendin-4 (27.8 ± 4.9 %ID/g at 1 hour and 24.9 ± 9.3 %ID/g 
at 4 hours p.i.). For both tracers, INS-1 tumors were clearly visualized using PET/CT, while 
kidney uptake was significantly lower for [68Ga]Ga-NOTA-MI-exendin-4 in comparison to [68Ga]
Ga-NOTA-exendin-4.
 [68Ga]Ga-NOTA-MI-exendin-4 showed reduced renal retention, while preserving INS-1 tumor 
uptake. Therefore, this promising new tracer might improve the sensitivity of PET/CT to detect 
insulinomas.
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Insulinomas are functioning neuroendocrine tumors, which originate from the beta cells in 
the pancreatic islets of Langerhans. Although the incidence of insulinomas is very low (0.4%), 
and only a small percentage of insulinomas are malignant (>90% of the insulinomas is benign), 
the clinical symptoms, namely hypoglycemia, are severe and require adequate treatment1, 2. 
Accurate localization of insulinomas to guide therapeutic intervention is essential. Currently, the 
treatment of choice for insulinomas is surgical removal of the lesion or partial pancreatectomy. 
Since 10% to 27% of insulinomas are not detected intraoperatively2, preoperative and/or 
intraoperative localization of insulinomas is of pivotal importance to identify the tumor lesion 
and to minimize unnecessary surgical intervention. A highly promising recently developed 
clinical imaging strategy to visualize insulinomas and native beta cells in the pancreas is 
based on glucagon-like peptide-1 receptor (GLP-1R) targeting using radiolabeled exendin 
and either SPECT/CT or PET/CT3-5. The GLP-1R is highly and specifi cally expressed on beta 
cells and is therefore the most promising target for the detection of (benign) insulinomas. 
Furthermore, recent studies suggest that this imaging method is preferred over somatostatin 
receptor scintigraphy (SRS)4. Exendin-4 is a stable analog of the natural, unstable GLP-1 ligand 
and binds with high affi nity to the GLP-1R. In addition to high accumulation in insulinomas, 
radiolabeled exendin-4 also shows high renal uptake, as a result of tubular reabsorption in 
the kidneys.
In certain cases, high renal uptake may be of concern as insulinomas are often very small in 
size (≤ 2 cm)1, 2 and located in close proximity to the kidneys, especially lesions located in the 
pancreatic tail, as demonstrated by several clinical trials 3, 4, 6, 7. This may hamper visualization 
of these lesions. Another concern is that [68Ga]Ga-exendin PET scans of patients can display a 
white halo around the kidneys, a serious reconstruction artefact as a result of the high kidney 
uptake8. Obviously, these artefacts can hamper the detection of tumor lesions, but cannot be 
solved currently by using different reconstruction algorithms.
Over the past years, several successful strategies to reduce renal uptake of radiolabeled 
peptides have been described. For example, van Eerd et al., were the fi rst to show reduced renal 
uptake of 111In-labeled octreotide by pre-injection of Gelofusine9. Likewise, Vegt et al. obtained 
the same results in human volunteers10. Furthermore, Hammond et al., used the amino acids 
lysine and arginine to block the tubular re-uptake of [111In]In-DTPA-octreotide11, which was also 
shown to be effective in patients with neuroendocrine tumors12. In a rat study, Gelofusine was 
shown to reduce renal uptake of 111In-labeled exendin by almost 19%13. A similar effect was 
found in human volunteers14. Blocking the tubular reabsorption of radiolabeled exendin using 
amino acids is, however, not effective13. Thus, in order to further reduce the kidney uptake of 
radiolabeled exendin, a new approach is demanded. 
Wu et al. have shown that a methionine conjugate, labeled with gallium-67, was rapidly 
excreted from the kidneys15. Based on the conclusions of the latter study, Uehara et al. 
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reported a methionine-isoleucine linker between NOTA and a Fab fragment of a mAb against 
HER2. They observed a reduction in kidney uptake of almost 88%, which could be attributed 
to the additional linker that was introduced16. These two studies evoked the question whether 
the translation of the methionine-isoleucine linker to exendin-4 could help to reduce the renal 
uptake of exendin.
The purpose of this study is to develop and characterize a novel exendin analog, which is based 
on NOTA-exendin-4, with an additional methionine-isoleucine linker between the chelator and 
the peptide (NOTA-MI-exendin-4). The peptide has been labeled with gallium-68 and its uptake 
in kidneys, pancreas and GLP-1R-expressing tumors in mice was compared to 68Ga-labeled 
NOTA-exendin-4 by ex vivo biodistribution and PET/CT studies. Furthermore, this concept was 
validated using a different chelator (NODAGA) and a different radiometal (indium-111).
MATERIALS AND METHODS
Peptides and radionuclides
NOTA-exendin-4, Lys40[Mep((S-)NOTA-Met-Ile-Mal-)] exendin-4 (referred to as NOTA-MI-
exendin-4), NODAGA-exendin-4, Lys40[Mep((S-)NODAGA-Met-Ile-Mal-)]exendin-4 (referred to 
as MI-NODAGA-exendin-4) and [Lys40(DTPA)]exendin-3  were purchased from piCHEM (Graz, 
Austria).
Control peptides [Lys40(DTPA)]exendin-3, [Lys40(NOTA)]exendin-4 and [Lys40(NODAGA)]exendin-4 
(piCHEM) were conjugated with p-NCS-benzyl-functionalized DTPA, NOTA or NODAGA to the 
ε-amino group of the lysine at position 40.
To obtain NOTA-MI-exendin-4 and NODAGA-MI-exendin-4, exendin-4 was modified with a 
Mep (mercapto-proionic acid) at the lysine side chain at position 40. The spacer molecule, 
methionyl-isoleucine was modified at the C-terminus with N-(2-aminoethyl)maleimide as the 
thiol reactive cross-linker, whereas the corresponding chelator (NOTA-Bn-SCN or NODAGA-
Bn-SCN) was attached at the N-terminus of methionine. Finally, the chelator-spacer group 
was conjugated via the maleimide to the mercapto-propionyl moiety at the lysine of exendin-4 
at position 40. An overview of the structure of these peptides is given in Figure 1 and Table 1.
111InCl3 was obtained from Mallinckrodt Medical (Petten, The Netherlands) and 
68Ga was 
eluted from a 68Ge/68Ga generator (GalliaPharm Generator, Eckert & Ziegler Eurotope, Berlin, 
Germany) with 0.1 M HCl (Rotem GmbH, Israel) at a flow rate of 1mL/min.
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Figure 1. Structures of NOTA-MI-exendin (A) and NODAGA-MI-exendin-4 (B).
Radiolabeling of exendin-4 analogs with 68Ga
The peptides were labeled with 68Ga by adding 2.5 M HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, Sigma Aldrich) to 35-100 MBq 68Ga in Ultrapure 0.1 M HCl 
and 1 µg of peptide. After incubation at 95°C for 5 min, EDTA and Tween-80 were added to 
a final concentration of 5 mM and 0.1%, respectively. Quality control was performed by RP-
HPLC (reversed-phase high performance liquid chromatography) and ITLC (instant thin layer 
chromatography). RP-HPLC was done using a C18 reversed-phase column (Alltima; 4.6 mm x 25 
cm; Grace, Breda, The Netherlands). For elution a linear gradient of 0.1% TFA (trifluoroacetic 
acid, Lab-Scan, Analytical Sciences, Brussels, Belgium) in acetonitrile (3% to 100% over 10 
min) with a flow rate of 1 ml/min was used. 68Ga-colloid content was determined with ITLC: 
1.25 M NH4Ac, pH 5.5: dimethylformamide (DMF) (1:1) (Rf 
68Ga-hydroxide = 0, Rf 
68Ga-labeled 
peptide and 68Ga-EDTA = 1)17. Purification was performed by solid-phase extraction using an 
HLB (hydrophilic-lipophilic balance reversed-phase sorbent) cartridge (Waters Oasis©, Milford, 
MA, USA). Activation and washing of the cartridge was done with 100% ethanol and water, 
respectively.
Radiolabeling of DTPA-exendin-3, NOTA-exendin-4 and NOTA-MI-exendin-4 with 111In
DTPA-exendin-3, NOTA-exendin-4 and NOTA-MI-exendin-4 were labeled with 111In by mixing 
150, 30 and 30 MBq of 111InCl3, respectively, with 0.5 M MES (2-(N-morpholino) ethanesulfonic 
acid, Sigma Aldrich, St. Louis, MO, USA), pH 5.5 and 1 µg of the respective peptide, followed 
by incubation at room temperature for 20 min. After labeling, Tween-80 and 50 mM EDTA 
(ethylenediaminetetraacetic acid) (Sigma Aldrich) were added to a final concentration of 0.1% 
and 5 mM, respectively. Purification was performed by solid-phase extraction using an HLB 
column and washing and conditioning of the cartridge was done with 1 ml 0.5 M MES. The 
labeling efficiency was analyzed using instant thin layer chromatography on silica-gel strips 
(ITLC-SG Biodex, Shirley, NY, USA) using 0.1 M EDTA in 0.1 M NH4Ac as a mobile phase (Rf 
111In-
labeled peptide = 0, Rf 
111In-EDTA = 1).
Serum stability of 68Ga-labeled exendin-4 analogs
NOTA-MI-exendin-4, NOTA-exendin-4, NODAGA-MI-exendin-4 and NODAGA-exendin-4 were 
labeled with 68Ga at a specific activity of 60, 35, 100 and 35 MBq/µg respectively and quality 
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control and purifi cation was performed as described above. The radiolabeled compounds 
were incubated in human serum (1:10) at 37°C and samples were taken after 1 and 2 hour 
incubation. Supernatant was analyzed using RP-HPLC after acetonitrile precipitation of the 
proteins. RP-HPLC was performed as described previously.
Cell culture
CHL-cells transfected with the human GLP-1R (a kind gift of Brigitte Lankat-Buttgereit, 
Marburg, Germany) were maintained in Dulbecco’s Modifi ed Eagle’s Medium (DMEM) GlutaMAX 
(Gibco, Invitrogen, Breda, The Netherlands), supplemented with 10% fetal calf serum, 100 
units/ml penicillin, Geneticin (G418) sulphate solution (0.5 mg/ml fi nal concentration), 100 
µg/ml streptomycin, 1 mM sodiumpyruvate and 0.1 mM non-essential amino acids. The INS-
1 cell line (rat insulinoma) was maintained in RPMI-1640 medium supplemented with 10% 
fetal bovine serum, 2 mM glutamine, 10 mM HEPES, 50 µM β-mercaptoethanol, 1 mM sodium 
pyruvate, 100 units/ml penicillin and 100 µg/ml streptomycin18. Cells were maintained in a 
humidifi ed 5% CO2 atmosphere at 37 °C.
Competitive binding assay (IC50)
A competitive binding assay using CHL-GLP-1R cells was performed to compare the affi nity 
of both MI-peptides with their respective control peptides. Cells were grown to confl uency 
overnight at 37°C, after plating 1x106 cells per well in a 6-wells plate. Cells were washed 
with binding buffer (DMEM GlutaMAX + 0.5% bovine serum albumin) and a trace amount of 
111In-labeled DTPA-exendin-3 (150 MBq/µg, as previously described) (0.8 kBq, 0.9 fmol) was 
added to the cells, together with increasing amounts of unlabeled NOTA-exendin-4, NOTA-
MI-exendin-4, NODAGA-exendin-4 or NODAGA-MI-exendin-4, ranging from 0.1 to 1000 nM. 
After incubation for 4 h at 0°C, cells were washed twice with binding buffer, harvested with 
0.1 M NaOH and cell associated activity was measured in a gamma counter (WIZARD, 2480 
Automatic Gamma Counter, Perkin Elmer, Boston, MA, USA). The IC50 value (half-maximal 
inhibitory concentration) was calculated usi ng GraphPad Prism using one-site competition 
(version 5.03, GraphPad Software, San Diego California USA).
Animal studies
The project (2015-0071) was approved by the Nijmegen Medical Center animal ethics committee 
(RUDEC) and the Dutch animal ethics comittee (CCD) of the Radboud University and performed 
according to the Institute of Laboratory Animal Research Guidelines.
C3H mice were purchased from Charles River Laboratories (L’Arbresle, France) and BALB/cRJ 
nu mice from Janvier (Saint-Berthevin, France).
Mice were housed in a pathogen-free environment in ventilated fi lter-topped cages (5 mice 
per cage), had ad libitum access to water and chow and were allowed to adapt to laboratory 
conditions for 1 week before the start of the experiments.
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Biodistribution of [68Ga]Ga-NOTA-exendin-4 and [68Ga]Ga-NOTA-MI-exendin-4 in healthy 
mice
The distribution of 68Ga-labeled NOTA-exendin-4 and NOTA-MI-exendin-4 were compared in 
female healthy C3H mice of 8-13 weeks old. Mice were randomized into 8 groups (n = 4-5 
per group,) and received an intravenous injection with 20 pmol of either [68Ga]Ga-NOTA-MI-
exendin-4 (1.7 MBq) or [68Ga]Ga-NOTA-exendin-4 (1,4 MBq). At 1, 2 and 4 hours after injection 
mice were euthanized by CO2/O2 asphyxiation and relevant organs were dissected, weighed, 
and measured in a gamma-counter. For each tissue sample, the uptake was calculated and 
presented as the percentage of the injected dose per gram tissue (%ID/g).
Two additional groups of mice (n = 2/group) received an excess of unlabeled (2 nmol) peptide 
(the same peptide as the tracer) to determine non-specific uptake at 4 hours after injection.
Biodistribution and PET/CT of [68Ga]Ga-NOTA-exendin-4 and [68Ga]Ga-NOTA-MI-exendin-4 
in mice with a subcutaneous INS-1 tumor
To assess the influence of the Met-Ile-linker on the uptake of the radiolabeled exendin-4 in 
tumor tissue, an experiment was conducted in male BALB/cRJ nu mice (13 weeks old) with 
subcutaneous INS-1 tumors. Mice were inoculated subcutaneously with 3 x 106 INS-1 cells in 
200 µl RPMI medium and after growth of the tumor to appropriate size (approx. 0.1 cm3) assigned 
randomly into groups of five animals. One, 2 and 4 hours after injection of [68Ga]Ga-NOTA-
MI-exendin-4 or [68Ga]Ga-NOTA-exendin-4 (1.6 MBq), mice were anesthetized by isoflurane/
O2 and underwent PET/CT. Two additional groups of mice received a co-injection of the tracer 
with an excess of unlabeled peptide (n=2/group). PET/CT images were acquired for 30-40 min 
with a small-animal PET/CT scanner (Inveon™; Preclinical Solutions, Siemens Medical 
Solutions USA, Inc., Knoxville, TN, USA). After PET/CT acquisition, the biodistribution of the 
radiolabeled peptides was determined as described above. Reconstruction of the images was 
performed as follows: OSEM3D/SPMAP reconstruction, 256 x 256 matrix, 2 OSEM3D iterations, 
18 MAP iterations and a resolution of 0.075 mm uniform variance. The settings for the CT were 
as following: spatial resolution 113 µm, 80 kV, 500 µA, exposure time 300 msec.
Biodistribution of [68Ga]Ga-NODAGA-exendin-4 and [68Ga]Ga-NODAGA-MI-exendin-4 in 
healthy mice
We have evaluated the combination of the methionine-isoleucine linker with NODAGA-
exendin-4 in female C3H mice of 8-13 weeks old as well. The molar activity obtained with 
both NODAGA-conjugated peptides is higher than that of the NOTA-conjugated peptides. If 
there is a comparable biodistribution of NOTA-MI-exendin-4 and NODAGA-MI-exendin-4, the 
higher molar activity for the NODAGA-MI-peptide could be beneficial in PET/CT studies. A 
higher molar activity allows the injection of a higher radioactive dose at the standard peptide 
dose, which could lead to and enhanced absolute uptake. Mice (n = 4-5 per group) received 
an intravenous injection with 20 pmol of either [68Ga]Ga-NOTA-MI-exendin-4 (1,7 MBq), 
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[68Ga]Ga-NOTA-exendin-4 (1,4 MBq), [68Ga]Ga-NODAGA-MI-exendin-4 (4,1 MBq) or [68Ga]Ga-
NODAGA-exendin-4 (3.7 MBq). At one, two and four hours after injection the biodistribution 
was performed as described previously. Four additional groups of mice (n = 2) received an 
excess of unlabeled (2 nmol) peptide (the same peptide as the tracer) to determine receptor-
mediated binding and their biodistribution was determined four hours after injection.
Biodistribution of [111In]In-NOTA-exendin-4 and [111In]In-NOTA-MI-exendin-4 in healthy 
mice
The biodistribution of 111In-labeled NOTA-MI-exendin-4 and NOTA-exendin-4 was determined 
in female C3H mice (Charles River Laboratories, Calco, Italy) of 9-10 weeks old. Mice were 
injected intravenously with 20 pmol of either [111In]In-NOTA-MI-exendin-4 or [111In]In-NOTA-
exendin-4 (3,7 MBq) (n=3 per group). To determine receptor-mediated binding additional 
groups of mice received an excess of unlabeled NOTA-MI-exendin-4 or NOTA-exendin-4 (2 
nmol) together with the labeled peptide (n=2 per group).
Four hours after injection the biodistribution was performed as described previously.
Dosimetry
Biodistribution data of [68Ga]Ga-NOTA-exendin-4 and [68Ga]Ga-NOTA-MI-exendin-4 in mice with 
a subcutaneous INS-1 tumor were used for dosimetric calculations. The kidney self-dose was 
calculated based on the radioactivity distribution in the kidneys. The time-integrated activity 
coeffi cients (MBq-h/MBq) were calculated using mono-exponential curve-fi tting between the 
imaging time points. As last data point, an extrapolation of the remaining uptake value within 
the kidneys of 10 times the radioactive half-life of 68Ga was used for NOTA-exendin-4, and 10 
times the biological half-life of the peptide for NOTA-MI-exendin-4. OLINDA/EXM application 
(version 2.1) was used to calculate the absorbed kidney dose in mice using the 25 g RADAR 
model. The mice data was then used to calculate the expected absorbed kidney doses per 
injected activity in humans using the equation19, 20:
 � %IA
organ
� human = � � %IA
g
mouse × Mmouse (kg) � × � m (g)
M (kg)
� human
with %IAg and 
%IA
organ  the percentage of the injected activity concentration and per organ, 
respectively, and m the organ mass and M the total human or mouse body weight. Subsequently, 
the extrapolated human residence times were used as input in an 80 kg male reference model 
in OLINDA/EXM application (Version 2.1).
Statistical analysis
All data were analyzed using GraphPad Prism software version 5.03 for Windows. The Student’s 
t-test or the One-way ANOVA followed by a Tukey’s test were used to determine signifi cance. 
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For the IC50 binding assay the F-test was used to manually calculate significance. A p-value 
below 0.05 was considered significant. All data are presented as mean ± standard deviation.
RESULTS
Radiolabeling
Labeling of NOTA-exendin-4 and NOTA-MI-exendin-4, with 68Ga resulted in a maximum specific 
activity up to 275 GBq/µmol and 242 GBq/µmol, respectively. After purification, radiochemical 
purity exceeded 98%. Labeling of NODAGA-exendin-4 and NODAGA-MI-exendin-4 with 68Ga 
resulted in a maximum specific activity up to 457 GBq/µmol and 667 GBq/µmol, respectively. 
After purification, the radiochemical purity exceeded 95% for [68Ga]Ga-NODAGA-exendin-4 and 
85% for [68Ga]Ga-NODAGA-MI-exendin-4.
Serum stability
Two hours after incubation in serum, >94% of the gallium-68 was still coupled to NOTA-MI-
exendin-4 and had the most favourable stability compared to [68Ga]Ga-NODAGA-exendin-4 
(93%), [68Ga]Ga-NOTA-exendin-4 (92%) and [68Ga]Ga-NODAGA-MI-exendin-4 (47%) (Figure 2).
Competitive binding assay (IC50)
The IC50 values of NOTA-exendin-4 and NOTA-MI-exendin-4 were 4.0 nM (2.5 – 6.3 nM) and 9.6 
nM (7.0 – 12.8), respectively. The IC50 values of NODAGA-Exendin-4 and NODAGA-MI-exendin-4 
were 4.7 nM (3.4 – 6.4 nM) and 5.2 nM (3.8 – 7.2 nM) respectively. A significant difference in 
affinity was found between NOTA-exendin-4 and NOTA-MI-exendin-4 and between NODAGA-
MI-exendin-4 and NOTA-MI-exendin-4 ( p < 0.01). The competitive binding curves and their 
respective 95% confidential intervals are presented in Figure 3.
Biodistribution of [68Ga]Ga-NOTA-exendin-4 and [68Ga]Ga-NOTA-MI-exendin-4 in healthy 
mice
The biodistribution of 68Ga-labeled NOTA-MI-exendin-4 was compared to that of the reference 
peptide NOTA-exendin-4 in healthy mice (Figure 4). The overall distribution pattern of the 
radiolabeled compounds was similar, with very rapid clearance of the peptides from the 
circulation. A significant difference in renal uptake of 68Ga-labeled NOTA-MI-exendin-4 one 
hour post injection (151.7 ± 17.0 %ID/g), compared to NOTA-exendin-4 (203.2 ± 15.3 %ID/g) 
(p<0.0001) was found, which was even more pronounced (up to 65% difference) four hours p.i. 
(72.7 ± 3.9 %ID/g vs 207.7 ± 17.4 %ID/g respectively, p<0.0001) (Figure 4B).
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Figure 2. Stability of 68Ga-labeled NODAGA-exendin-4 (A), NOTA-exendin-4 (B), NODAGA-MI-exendin-4 (C) 
and NOTA-MI-exendin-4 (D) before purifi cation, and before and 1 and 2 h after incubation in human serum 
at 37°C. Graphs show HPLC profi les.
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Figure 3. Competitive binding assay (IC50) of NOTA-exendin-4, NOTA-MI-exendin-4, NODAGA-exendin-4 
and NODAGA-MI-exendin-4 on CHL cells transfected with the GLP-1R. 111In-labeled DTPA-exendin-4 was 
used as tracer.
Similarly, pancreatic uptake of [68Ga]Ga-NOTA-MI-exendin-4 also decreased over time (22.2 
± 2.3% and 11.6 ± 1.4% at 1 hour and 4 hours p.i., respectively, while that of [68Ga]Ga-NOTA-
exendin-4 remained stable (21.5 ± 1.2% and 18.3 ± 3.4% at 1 hour and 4 hours. p.i., respectively 
(Figure 4A)). However, the difference in kidney uptake (65%) between both peptides was higher 
than the difference in pancreatic uptake (37%) at four hours p.i. (Figure 4D). These findings led 
to a more favourable pancreas-to-kidney ratio for [68Ga]Ga-NOTA-MI-exendin-4 (0.16 ± 0.01) than 
for [68Ga]Ga-NOTA-exendin-4 (0.09 ± 0.01) at four hours after injection (p<0.0001) (Figure 4C).
Co-injection of unlabeled exendin-4 showed that the uptake of the radiolabeled peptides in 
the pancreas, lungs and duodenum (transition from stomach to duodenum) could be blocked 
by an excess unlabeled peptide and therefore was GLP-1 receptor mediated. Raw data of this 
biodistribution study is shown in Table 2.
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Figure 4. Biodistribution of 68Ga-labeled NOTA-exendin-4 and NOTA-MI-exendin-4 in healthy C3H mice, 
1, 2 and 4 hours after injection. Pancreatic uptake (A), kidney uptake (B), pancreas-to-kidney-ratio (C), 
difference in kidney and pancreatic uptake between both peptides (D). Receptor saturation was performed 
by coinjection of a 100-fold excess of unlabeled peptide 4 hours after injection (dotted bars). Values are 
expressed as percentage injected dose per gram of tissue (%ID/g) (n=4-5 mice per group, error bars SD).
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Biodistribution and PET/CT of [68Ga]Ga-NOTA-exendin-4 and [68Ga]Ga-NOTA-MI-exendin-4 
in mice with a subcutaneous INS-1 tumor
Figure 5A shows that the high accumulation of both [68Ga]Ga-NOTA-exendin-4 and [68Ga]Ga-
NOTA-MI-exendin-4 in INS-1 tumors was stable over time ([68Ga]Ga-NOTA-MI-exendin-4: 29.3 
± 6.9 %ID/g at 1 h and 25.0 ± 8.0 %ID/g at 4 h p.i.; [68Ga]Ga-NOTA-exendin-4: 27.8 ± 4.9 %ID/g 
at 1 h and 24.9 ± 9.3 %ID/g at 4 h p.i.). Furthermore, a remarkably reduced kidney uptake up to 
66% for [68Ga]Ga-NOTA-MI-exendin-4 was seen over 4 h (Figure 5B), which was not observed 
for [68Ga]Ga-NOTA-exendin-4. The tumor-to-kidney ratio was 0.20 ± 0.10 for [68Ga]Ga-NOTA-
exendin-4, compared to 0.80 ± 0.30 for [68Ga]Ga-NOTA-MI-exendin-4 (p<0.001) and was most 
optimal four hours after injection (Figure 5C). Raw data of this biodistribution study are shown 
in Table 3.
Figure 5. Biodistribution of 68Ga-labeled NOTA-exendin-4 and NOTA-MI-exendin-4 in BALB/c nude mice 
bearing subcutaneous CHL-GLP1R tumors 1, 2 and 4 hours after injection. Tumor uptake (A), kidney 
uptake (B), tumor-to-kidney-ratio (C), Tumor-to-pancreas ratio (D). Receptor saturation was performed 
by coinjection of a 100-fold excess of unlabeled peptide 4 hours after injection (dotted bars). Values are 
expressed as percentage injected dose per gram of tissue (%ID/g) (n=4-5 mice per group, error bars SD).
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The images in Figure 6F reveal reduced renal uptake and improved discrimination between 
the left and right kidney when using 68Ga-labeled exendin-4 with the Met-Ile-linker, while 
maintaining a signifi cant signal in the INS-1 tumor. This in contrast to the images of [68Ga]
Ga-NOTA-exendin-4, where the kidneys could not be discriminated from each other due to the 
high renal retention (Figure 6C).
Figure 6. Fused PET/CT images of BALB/c nude mice bearing subcutaneous CHL-GLP-1R tumors (green 
arrow). Mice were injected with 1.6 MBq of either [68Ga]Ga-NOTA-exendin-4 (A, B and C) or [68Ga]Ga-NOTA-
MI-exendin-4 (D, E and F). Images were obtained 1 hour (A and D), 2 hours (B and E) and 4 hours (C and F) 
after injection. Kidneys are indicated with K.
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Dosimetry
The estimated absorbed doses per injected activity for mice were 266 and 232 mSv/MBq for 
[68Ga]Ga-NOTA-exendin-4 and [68Ga]Ga-NOTA-MI-exendin-4, respectively. For human, the 
estimated absorbed doses were 0.20 and 0.17 mSv/MBq respectively. The use of [68Ga]Ga-
NOTA-MI-exendin-4 reduced the estimated absorbed kidney dose in both mice and human by 
12%.
Biodistribution of [68Ga]Ga-NODAGA-exendin-4 and [68Ga]Ga-NODAGA-MI-exendin-4 in 
healthy mice
The complete biodistribution of [68Ga]Ga-NODAGA-exendin-4 and [68Ga]Ga-NODAGA-MI-
exendin-4 in healthy C3H mice is presented in Table 4. The overall distribution pattern of these 
compounds is similar with very rapid elimination from the blood. 
The addition of the cleavable linker lowers renal uptake by almost 40% at 4 hours after injection 
of [68Ga]Ga-NODAGA-MI-exendin-4. When comparing the renal retention of [68Ga]Ga-NODAGA-
MI-exendin-4 with [68Ga]Ga-NODAGA-exendin-4, a difference of almost 58% was found (109.3 
± 7.0 %ID/g vs 257.9 ± 21.2 %ID/g respectively, p<0.0001) four hours after injection. Similarly, 
uptake in the pancreas also decreased over time. Four hours after injection, pancreatic uptake 
of [68Ga]Ga-NODAGA-MI-exendin-4 was 53% less than the pancreatic uptake of [68Ga]Ga-
NODAGA-exendin-4 (p<0.0001). A significant difference in pancreas-to-kidney ratio was found 
only 2 h after injection (0.11 ± 0.01 for [68Ga]Ga-NODAGA-MI-exendin-4 and 0.09 ± 0.01 for 
[68Ga]Ga-NODAGA-exendin-4, p=0.01). Furthermore, co-injection of an excess of unlabeled 
exendin-4 showed that the uptake of all radiolabeled peptides in the pancreas, lungs and 
duodenum could be blocked by coinjection of an excess unlabeled peptide and was therefore 
GLP-1 receptor mediated. Overall, a higher pancreas-to-kidney ratio was found for [68Ga]Ga-
NOTA-MI-exendin-4 (0.17 ± 0.01) compared to [68Ga]Ga-NODAGA-MI-exendin-4 (0.11 ± 0.01) 
(p<0.0001).
Biodistribution of [111In]In-NOTA-exendin-4 and [111In]In-NOTA-MI-exendin-4 in healthy 
mice
Table 5 presents the total biodistribution of 111In-labeled NOTA-exendin-4 and NOTA-MI-
exendin-4 four hours after injection. The overall distribution of both compounds is similar. 
However, a significantly higher lung uptake was found for [111In]In-NOTA-MI-exendin-4 
compared to [111In]In-NOTA-exendin-4 (p<0.01), in contrast to the other GLP-1R expressing 
organs (pancreas, stomach/duodenum), were the uptake did not significantly differ. Interestingly, 
the renal clearance as observed for the 68Ga-labeled peptides was not found for [111In]In-NOTA-
MI-exendin-4. At four hours post injection, kidney uptake was 175.2 ± 23.0 %ID/g and  202.6 ± 
3.9 %ID/g for [111In]In-NOTA-MI-exendin-4 and [111In]In-NOTA-exendin-4, respectively (p=0.11).
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Complete surgical resection of insulinomas remains challenging. Pre-operative imaging 
with radiolabeled exendin can be used to identify and localize tumor lesions, however some 
lesions (namely in the pancreatic tail close to the left kidney) may be missed because they are 
masked by the high kidney uptake. The present study demonstrated a signifi cantly lower renal 
uptake of radiolabeled exendin, after introducing a methionine-isoleucine linker. The high 
accumulation in subcutaneous GLP-1R-expressing INS-1 tumors was preserved. Therefore, 
this new compound may enable an improved visualization of small insulinomas located in the 
vicinity of the kidneys.
The mechanism behind high renal uptake is not fully understood. Tubular reabsorption of 
radiolabeled exendin-4 has been described as one of the major causes13, but expression of the 
GLP-1R on porcine proximal tubular cells has been reported as well21. However, exendin uptake 
in the kidneys cannot be blocked by an excess of unlabeled exendin, thus the contribution of 
GLP-1R mediated uptake in the tubules seems to play only a minor role. In general, peptides 
enter the kidneys via the bloodstream and are fi ltered through the glomeruli. Instead of being 
excreted, the peptides are reabsorbed in the proximal tubules22, most probably via endocytic 
receptors that are located near the brush border membrane23. After endocytosis, the peptides 
will fi nally end up in lysosomes, where they are cleaved into amino acids by enzymes22. As 
radiolabeled exendin-4 is a residualizing compound, it will get trapped in the lysosomes instead 
of excreted, leading to high accumulation of the tracer.
In this study, high kidney uptake of [68Ga]Ga-NOTA-exendin-4 was observed at early time 
points after injection, which did not decrease over time. On the contrary, [68Ga]Ga-NOTA-MI-
exendin-4 showed rapid clearance from the kidneys (a difference of 66% between 1 and 4 hours 
in the BALB/c nude mice) and therefore had a much shorter renal retention time. This is in 
line with the fi ndings as reported by Uehara et al. They have shown a reduced kidney uptake 
when introducing a methionine-isoleucine linker between the chelator and the compound16. 
Furthermore, they published an antibody fragment with a newly designed cleavable linker, 
Methionine-Valine-Lysine (MVK). This new compound displayed an even lower renal uptake 
than the antibody with the methionine-isoleucine linker. More recently, an exendin-4 analog 
containing the MVK-linker was developed. Similar to our study, they reported a stable tumor 
uptake (around 25 %ID/g at 1 and 2 hours p.i.) of the 68Ga-labeled compound, but found a striking 
decrease in renal accumulation. Two hours p.i., the uptake of [68Ga]Ga-NOTA-MVK-Cys40-Leu14-
Exendin-4 was 33% of the control. Similarly, the kidney uptake of our ligand was 36% of the 
control, which was even more pronounced 4 hours after injection (73% of the control)24.
Both studies using the MVK-linker showed that the main radiometabolite in the urine was 
radiolabeled NOTA-Met and the ligand was cleaved between Methionine and Valine by the renal 
brush border membrane enzyme, neutral endopeptidase (NEP)24, 25. Uehara et al. performed a 
direct comparison between both linkers and postulated that the methionine-isoleucine linker 
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is cleaved during lysosomal proteolysis rather than cleavage at the brush border membrane, 
due to higher retention in the kidneys25. The exact mechanism and location behind the cleavage 
of the methionine-isoleucine linker remains to be unravelled.
Importantly, [68Ga]Ga-NOTA-MI-exendin-4 already showed less kidney uptake one hour after 
injection, in contrast to [68Ga]Ga-NOTA-exendin-4, whereas uptake in the other GLP-1R 
expressing organs was similar at this time point. Furthermore, uptake in the INS-1 tumor did 
not change over time, showing that binding to and retention in tumor tissue was not impaired. 
These findings suggest that degradation of the peptide was restricted to the kidneys, but we 
did find lower uptake over time in other GLP-1R mediated organs, like the pancreas, lungs 
and duodenum as well. This cannot be explained by a difference in binding capacity, since the 
baseline uptake (1 hour p.i.) was similar for both tracers. Also, the in vitro binding affinity for 
the GLP-1R was very high for both tracers. A different internalization rate of the peptide in 
different organs, the abundance of the GLP-1R in tumor tissue, or absence of the cleavable 
enzyme might explain the different retention times. Of course, a lower uptake in the pancreas 
can even improve the detection of insulinomas, as almost all insulinomas are located in the 
pancreas. Accordingly, the tumor-to-pancreas ratio could also be improved.
In addition, the pancreas-to-kidney and tumor-to-kidney ratio of [68Ga]Ga-NOTA-MI-exendin-4 
were almost three and four times higher (respectively) than for [68Ga]Ga-NOTA-exendin-4, 4 
hours after injection. Even 4 hours after injection of 68Ga-labeled exendin-4 PET scans can be 
acquired of patients with an insulinoma with a very good image quality. 
Other attempts in decreasing renal exendin uptake based on cleavable linkers have been 
reported, but were not successful so far. Jodal et al.26 introduced a meprin ß (a protease 
on the brush border membrane of the kidneys) cleavable linker to exendin-4. After labeling 
with 111In they did not find a reduced kidney uptake in CD1 nu/nu mice. Whether this could be 
explained by exendin-4 not being recognized by the targeted protease for cleavage or by the 
use of the radiometal that was used is not known. Interestingly, when comparing [111In]In-
NOTA-exendin-4 and [111In]In-NOTA-MI-exendin-4 in C3H mice (Table 5), we also did not find a 
decreased renal uptake. The same was reported for [111In]In-DTPA-Met-octreotide27. Moreover, 
Yim et al. reported that the addition of an NƐ-maleoyl-L-lysyl-glycine (MAL) linker between 
[64Cu]Cu-NODAGA and exendin-4 did not prove effective in reducing the kidney uptake in rats28. 
Again, whether this is a matter of animal model, radionuclide or cleavable linker used, remains 
unknown. Although the approach of the above mentioned studies were unsuccessful, many 
other studies showed that cleavable linkers can be effective in reducing kidney retention29.
To date, the best approach for reducing kidney uptake is co-injection of Gelofusine or amino 
acids. Gotthardt et al. used Gelofusine to inhibit the renal uptake of [111In]In-DTPA-exendin-4. 
They found a reduction of 19% in the kidneys of Wistar rats13. In healthy volunteers, Gelofusine 
reduced kidney uptake of [111In]In-DTPA-exendin-4 by 18.1 ± 4.2%14. Both approaches, 
coinjection of Gelofusine or the introduction of a cleavable linker are a step forward towards 
the use of radiolabeled exendin for peptide receptor radionuclide therapy (PRRT), which could 
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be an alternative treatment for patients that are not eligible for surgery (i.e. metastasized 
insulinomas or insulinomas near vessels or ducts).
Another approach to prevent renal retention of exendin-4 is by a different radiolabeling 
approach which is not based on radiometals. For example [18F]-exendin-4 demonstrated rapid 
clearance from the kidneys in Sprague-Dawley rats; 17 ± 3 %ID/g at 1 hour p.i. to 2.8 ± 0.4 %ID/g 
at 4 hours p.i., which is benefi cial regarding visualization of lesions in close proximity to the 
kidneys. However, they also observed decreased uptake in the pancreas (0.18 ± 0.02 %ID/g at 1 
h p.i. to 0.13 ± 0.004 %ID/g at 4 h p.i.)30. The absorbed kidney dose was 0.3 mSv/MBq (based on 
extrapolation of rat data). This makes [18F]-exendin-4 promising for safely visualizing beta cells 
and insulinomas, which is however, restricted for diagnostic purposes as this radiolabeling 
technique does not allow coupling of therapeutic radionuclides.
In our study, a kidney-to-kidney absorbed dose in human of 0.17 mSv/MBq was estimated 
for [68Ga]Ga-NOTA-MI-exendin-4, which was twelve percent lower than for [68Ga]Ga-NOTA-
exendin-4 (0.20 mSv/MBq). Although [68Ga]Ga-NOTA-MI-exendin-4 showed a much more 
favorable biodistribution than [68Ga]Ga-NOTA-exendin-4, this was not refl ected in the estimated 
kidney absorbed dose values. This might be explained by the short physical half-life of 68Ga as 
the main contributor for the absorbed doses for both peptides. Importantly, the reduced uptake 
of our new compound in pancreas and kidney, and the preserved high uptake in tumor tissue, 
improves the ratio between target and non-target organs and could therefore be important 
in the next step towards PRRT. Whether the absorbed kidney dose could be reduced when a 
(therapeutic) radiometal with a longer half-life will be used, needs to be further investigated. If 
NOTA-MI-exendin-4, labeled with a therapeutic radiometal, would show a low absorbed dose 
in the kidneys, this might enable PRRT with exendin-4.
Like exendin, most radiolabeled peptides show rapid clearance from blood and are 
predominantly excreted via the kidneys31. High renal uptake due to tubular reabsorption is 
not only seen for exendin, but for other low molecular weight tracers (e.g. minigastrin or 
octreotide) as well22. This makes them less suitable as therapeutic agents or even precludes 
PRRT, because accumulation of highly radioactive compounds in the kidneys can cause serious 
nephrotoxicity. Kidneys could therefore be the dose-limiting organs in PRRT32. In this regard, it 
would be interesting to apply this cleavable linker to other peptides or nanobodies in order to 
reduce the kidney uptake and possibly radiation burden to the kidneys.
Future studies should elucidate the effect of the linker in combination with other (therapeutic) 
radionuclides and clinical trials are needed to explore the translational value of this new 
compound.
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CONCLUSION
To summarize, [68Ga]Ga-NOTA-MI-exendin-4 showed more than 70% lower renal uptake than 
[68Ga]Ga-NOTA-exendin-4 in BALB/c nude mice, while uptake in the INS-1 tumor is preserved 
and might therefore increase the sensitivity of PET/CT to detect insulinomas. Additional 
studies are required to explore whether this could also apply for therapeutic radionuclides, 
which would then provide new possibilities for safe and effective use of NOTA-MI-exendin-4 as 
therapeutic agent for insulinoma treatment. 
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ABSTRACT
Non-invasive beta cell mass (BCM) quantification is a crucial tool to understand diabetes 
development and progression. [111In]In-DTPA-exendin is a promising agent for in vivo beta cell 
imaging, but tracer testing has been hampered by the lack of well-defined rodent models. 
Biodistribution and pancreatic uptake of [111In]In-DTPA-exendin were compared in rats and 
mice. In selected models, the amount of [111In]In-DTPA-exendin accumulation in the pancreas 
and other organs was determined using a model of alloxan-induced beta cell loss. GLP-1R 
expression levels were analyzed by RT-PCR and immunohistochemistry.
Namely Brown Norway rats showed beta cell specific tracer accumulation and favorable 
pancreas-to-background ratios for non-invasive BCM determination. Mice displayed receptor 
mediated [111In]In-DTPA-exendin uptake in endocrine and exocrine pancreas, in spite of very 
low GLP-1R expression in exocrine tissue.  
Rats display better characteristics for in vivo BCM determination than mice, and are suggested 
as a more adequate model for humans.
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Diabetes mellitus is characterized by defective glucose homeostasis and consequent chronic 
hyperglycemia. Maintenance of glycemic control by daily insulin injections or anti-diabetogenic 
drugs is diffi cult and patients affected by both type 1 and type 2 diabetes are at risk for severe 
complications, such as cardiovascular disease, blindness and kidney failure, increasing the 
risk for premature death. Changes in beta cell mass (BCM) occur in both forms of diabetes 1-3, 
but the mechanisms and evolution underlying these BCM changes are poorly understood 4, 5.
Beta cell function is usually monitored by measurements of insulin secretion, such as insulin 
and C-peptide, analyzed in parallel to glucose levels. However, it was shown that beta cell 
function and BCM do not diminish equally during disease progression 5, 6, indicating that beta 
cell function is not an adequate measure for BCM. A reliable and reproducible method to 
monitor BCM dynamics over time, such as longitudinal quantitative imaging, could unravel the 
importance of BCM during the course of diabetes. 
During the past decade, major efforts have been made to image BCM in vivo in animal models 
using a variety of imaging methodologies 7, such as near infrared optical projection tomography 
(OPT) 8, bioluminescence 9 or magnetic resonance imaging (MRI) 10-12. While MRI offers the 
highest resolution (still not allowing resolution of single islets in vivo), nuclear medicine imaging 
modalities, such as single photon emission computed tomography (SPECT) and positron 
emission tomography (PET) have the potential to reach suffi cient sensitivity to detect small 
numbers of beta cells when targeted with a radiolabeled beta cell specifi c tracer. Importantly, 
the fi rst clinical trial results show that SPECT and PET are the most likely approaches to reach 
human translation at this point in time 13-15.
A variety of antibodies, such as IC2 16, small molecules, such as 18F-fl uorodeoxyglucose 
([18F]FDG) 17, neurotransmitter precursors, such as 11C-5-hydroxytryptophan ([11C]5-HTP) 18, 
organic compounds, such as dihydrotetrabenazine (DTBZ) targeting the vesicular monoamine 
transporter 2 (VMAT2) 19 and peptides, such as exendin targeting the glucagon-like peptide 1 
(GLP-1) receptor 13 have been evaluated as tracers for BCM determination. Very recent fi ndings 
indicate that [11C]5-HTP can successfully discriminate between rats with severe or moderate 
beta cell loss 15, 18, while radiolabeled exendin, a stable GLP-1R agonist specifi cally targeting the 
pancreatic beta cells 20, was shown to successfully detect small changes in BCM in a preclinical 
model for beta cell loss 14. In order to further validate the use of GLP-1R radionuclide imaging 
to evaluate the dynamics of BCM changes in diabetes, further studies in animal models are 
required. 
A variety of preclinical models have been used to investigate BCM dynamics, but the results 
obtained showed differences in biodistribution and in tracer uptake in relation to BCM 14, 21-24. 
We hypothesize that the observed differences in these studies can be related to the use of 
animal models. Therefore, in the present study we aimed to evaluate the differences between 
various animal models to select the most suitable model for preclinical, non-invasive BCM 
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determination using [111In]In-DTPA-exendin. Ideally, this optimal model should allow accurate, 
quantitative BCM determination and its features should reflect the human situation. We 
compared the biodistribution and pancreatic uptake of [111In]In-DTPA-exendin in various rat and 
mouse strains and compared their specific GLP-1R expression pattern. Finally, we determined 
the specificity of [111In]In-DTPA-exendin accumulation in beta cells using an alloxan-induced 
model for beta cell loss.
MATERIALS AND METHODS
Radiolabeling 
[Lys40(DTPA)]exendin-3 (Peptides Specialty Laboratories, Heidelberg, Germany) was 
radiolabeled as previously described (Brom 2012). Briefly, 150 MBq 111InCl3
 was added to 1 
µg [Lys40(DTPA)]exendin-3 dissolved in 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES), pH 
5.5 (Sigma Aldrich, St. Louis, MO, USA) and incubated for 20 minutes at room temperature. 
After incubation, EDTA (Sigma Aldrich) and Tween-80 (Sigma Aldrich) were added to a final 
concentration of 5 mM and 0.1%, respectively. The radiochemical purity of [111In]In-DTPA-
exendin-3 was determined by instant thin-layer chromatography (ITLC) (ITLC-SG, Agilent 
Technologies, Lake Forest, CA, USA), using 0.1 M EDTA in 0.1 M NH4Ac (Sigma Aldrich), pH 5.5 
as a mobile agent.
Animals 
All animal experiments were approved by the Animal Welfare Committee of the Radboud 
University, Nijmegen and carried out in accordance with the local and national guidelines. Six 
to eight weeks old, male animals were used for all experiments. For the experiments in mice, 
BALB/c, DBA, CBA and C57Bl/6J mice were purchased from Janvier Labs (Le Genest Saint 
Isle, France) and the NMRI mice from Harlan (Horst, The Netherlands). For the experiments 
in rats, Brown Norway, F344, WAG/Rij and Sprague Dawley rats were purchased from Harlan. 
Alloxan treatment 
To determine the specificity of [111In]In-DTPA-exendin accumulation in the beta cells, animals 
were injected with various doses (25 – 75 mg/kg) of alloxan monohydrate (Sigma chemicals, St 
Louis, MO, USA) to deplete the beta cells. Alloxan was dissolved in ice cold 10 mM HCl with a 
concentration of 0,1 mg/µl and diluted with ice cold PBS. During storage and dilution, alloxan 
was protected from light and kept on ice. Animals were injected intravenously with 200 µl 
alloxan solution within five minutes after dilution. Control animals were injected with vehicle 
(10 mM HCl diluted with PBS). Blood glucose concentrations were monitored for one week 
after alloxan injection using a blood glucose meter (Accu-Chek Sensor, Roche Diagnostics, 
Almere, The Netherlands). 
548546-L-bw-Joosten
Processed on: 22-9-2020 PDF page: 131




Biodistribution studies were performed to compare the [111In]In-DTPA-exendin uptake in 
different mouse and rat strains. Based on the pancreatic uptake, endocrine-to-exocrine 
ratio, pancreas-to-stomach ratio and pancreas-to-duodenum ratio, one strain was chosen to 
determine the specifi city of [111In]In-DTPA-exendin accumulation in the beta cells, as described 
above. To determine the effect of alloxan over time, biodistribution studies were performed 
on day one, three, fi ve and seven after alloxan injection. All animals used for biodistribution 
studies were injected intravenously with 15 MBq [111In]In-DTPA-exendin-3 (peptide dose: 20 
pmol/rat, mouse). Non-GLP-1R mediated exendin uptake was determined in a separate group 
of animals that were co-injected with an excess of unlabeled exendin (25 µg/animal). Four 
hours after injection of the radiolabeled exendin, animals were euthanized  and the pancreas 
and other relevant tissues (blood, muscle, heart, lung, spleen, kidney, liver, stomach and 
duodenum) were dissected, weighed and counted in a well type gamma counter (Wallac 1480 
Wizard, Perkin Elmer, Boston, MA, USA). The percentage injected dose per gram tissue (%ID/g) 
was determined for each tissue.
Digital autoradiography
Ex vivo autoradiography was performed to visualize the uptake in the islets and the exocrine 
pancreas. After dissection, pancreata were fi xed in 4% formalin (w/v), dehydrated and embedded 
in paraffi n. Sections of the pancreas (4 µm) were prepared and exposed to a phosphorimaging 
plate (Fuji Film BAS-SR 2025, Raytest, Straubenhardt, Germany) for seven days. Images were 
acquired with a radioluminography laser images (Fuji Film BAS 1800 II system (Raytest) and 
analyzed using Aida Image Analyzer software (Raytest). 
Endocrine-to-exocrine ratio determination 
To quantitatively compare tracer uptake in the islets and the exocrine pancreas, endocrine-
exocrine uptake ratios were determined in the autoradiographs of pancreatic sections. The 
digital images were analyzed using imageJ, a public domain software (http://imagej.nih.gov/
ij/). Three pancreatic sections were analyzed per mouse and rat strain. Per pancreatic section, 
three regions of interest (ROI) were drawn in both the exocrine and endocrine pancreas and 
the mean density values (photostimulated luminescence) were determined. These values were 
used to calculate the endocrine-exocrine uptake ratio. 
Immunohistochemistry
Pancreatic sections (4 µm) of C57Bl/6 mice, Brown Norway rats and humans were stained 
for the presence of GLP-1R. Antigen retrieval was performed in 10 mM sodium citrate, pH 6.0 
for 10 minutes at 96 oC. Subsequently, sections were incubated for 10 minutes with 3% H2O2
in PBS at RT in the dark, to block endogenous peroxidase activity. Non-specifi c binding was 
blocked by incubation for 30 minutes with 5% normal swine serum. The primary anti-GLP-1R 
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antibody (ab39072, Abcam, Cambridge, UK) was diluted in PBS containing 1% BSA (1:500). 
Primary antibody incubation for 90 minutes was followed by incubation with swine-anti-rabbit 
peroxidase (1:50) (p0271, DAKO, Copenhagen, Denmark) for 30 min at RT in the dark. Finally, 
3,3’diaminobenzidine (DAB) was used to develop the pancreatic sections.
Pancreatic islet isolation, mRNA extraction and real time PCR 
mRNA extraction and real time PCR was performed as described previously 25. Briefly, poly(A)+ 
mRNA was isolated from pancreatic islets (rat islets were isolated by collagenase digestion 
and handpicking and mouse islets using the Histopaque method 26) or exocrine tissue (the 
tissue remaining after islet isolation) from C57Bl/6 mice and Wistar rats using the Dynabeads 
mRNA DIRECTTM kit (Invitrogen, Merelbeke, Belgium) and reversely transcribed. Exocrine 
mRNA samples used in the study were evaluated with Biodrop (Cambridge, United Kingdom) 
and showed a 260/280 ratio >1.9, suggesting that the mRNA was well preserved. Real time 
PCR amplification of Glp-1r was performed using IQ SyBR Green Supermix on iCycler MyiQ 
Single Color (BIO-RAD, Hercules, CA, USA) and compared to a standard curve. amy2 was 
calculated with the deltaCT method 27. In all assays the geometrical means of the house 
keeping genes β-actin and gapdh was used as a reference. The pancreatic islet and exocrine 
tissue preparations were selected based on the expression levels of respectively the endocrine 
marker pdx1 and the exocrine marker amy2. The primers used are listed in Table 1. Standard 
curves of the reference genes (β-actin and gapdh) and Glp1r mRNA expression assays of both 
rat and mouse are provided in Figure 1.
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Figure 1. mRNA estimation of glucagon-like peptide 1 receptor (Glp-1r) expression was performed by 
quantitative PCR where beta actin (actb) and glyceraldehyde-3-phosphate dehydrogenase (gapdh) were 
used as reference genes. Standard curves of actb, gapdh and Glp-1r genes for both mouse (Mm, Mouse 
musculus, A, C, E) and rat (Rn, Rattus norvegicus, B, D, F) (mRNA expression assays, with plotted CT 
values of pancreatic islets samples (red squares) and exocrine tissue (black circles).
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Table 1. Primers used for quantitative PCR on rat and mouse cDNA with the length of amplification in base 
pairs.
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[111In]In-DTPA-exendin uptake in various mouse strains 
Figure 2 shows the biodistribution (2 mice per strain) of [111In]In-DTPA-exendin in fi ve mouse 
strains. As reported previously 28, tracer uptake was observed not only in the pancreas but 
also in various other organs, such as the lung, stomach, duodenum and the kidneys. Based on 
these results, BALB/c mice showed favorable features for in vivo beta cell targeting, namely: 
high pancreatic uptake (36.8 %ID/g) and relatively low uptake in lung (26.4 %ID/g), stomach 
(7.37 %ID/g) and duodenum (9.42 %ID/g). Therefore, BALB/c mice were selected to determine 
the specifi city of tracer accumulation in the beta cells. C57Bl/6 mice, a strain often used in 
diabetes research, was also evaluated.
Table 2. Endocrine-exocrine ratio of [111In]In-DTPA-exendin uptake in BALB/c and C57Bl/6 mice calculated 
from autoradiography of pancreatic sections.
Mouse strain Endocrine-exocrine ra� o
BALB/c 4.11 ± 0.93
C57Bl/6 4.56 ± 0.91
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Figure 2. Biodistribution of [111In]In-DTPA-exendin in C57Bl/6, BALB/c, NMRI, CBA and DBA mice. Values 
are expressed as percentage injected dose per gram tissue (n=2). Mice were dissected four hours after 
injection.
Beta cell specificity of [111In]In-DTPA-exendin uptake in BALB/c and C57Bl/6 mice
In BALB/c mice, the pancreatic uptake did not decline after injection of 25, 32.5, 50 and 62.5 
mg/kg alloxan (Figure 3A). Mice treated with even higher doses of alloxan (75, 100, 150 and 
200 mg/kg) showed increased total pancreatic tracer uptake. In animals treated with high 
alloxan doses, elevated tracer levels in the blood were observed and thus, higher uptake in 
all other tissues, including the exocrine pancreas (Figure 3A and B). This is most probably the 
result of dehydration secondary to severe hyperglycemia, leading to slower blood clearance. 
In addition, direct toxic effects of alloxan cannot be excluded at high doses. Co-injection of an 
excess unlabeled exendin decreased the pancreatic uptake from 7.9 ± 0.6  %ID/g to 0.23 ± 0.04 
%ID/g (Figure 3A) which was also reflected by the autoradiographic images (Figure 3C). Due to 
the high uptake in exocrine tissue, the endocrine-exocrine ratio in these mice was only 4.11 ± 
0.93 (Table 2) which is very low when compared to rats. These results - especially the reduced 
uptake after co-injection of unlabeled exendin - indicate specific, receptor mediated tracer 
binding in the exocrine pancreas of BALB/c mice.
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Figure 3. a) Biodistribution of [111In]In-DTPA-exendin in control and alloxan treated BALB/c mice. Values 
are expressed as percentage injected dose per gram tissue (n=5 mice). Blocking was performed by co-
injection of 25 µg unlabeled exendin (n=5). b) Pancreatic uptake of [111In]In-DTPA-exendin in BALB/c mice 
treated with 100 mg/kg (n=5), 150 mg/kg (n=4) and 200 mg/kg (n=3) of alloxan. Values are expressed as 
percentage injected dose per gram tissue. c) Ex vivo autoradiography of pancreatic sections of BALB/c 
mice treated with PBS (control) and 50 mg/kg alloxan. Blocking was performed by co-injection of 25 µg 
unlabeled exendin. 
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Because of this high exocrine uptake, [111In]In-DTPA-exendin uptake after alloxan treatment 
was further investigated in C57Bl/6 mice for validation of the results described above. Figure 
4A summarizes pancreatic uptake of [111In]In-DTPA-exendin in C57Bl/6 mice on various days 
after alloxan treatment. After three days, a clear decrease in pancreatic uptake was observed, 
while the maximum decrease was observed seven days after alloxan treatment. However, the 
decrease did not exceed 40% compared to control mice injected with vehicle. Furthermore, 
similar to the findings observed in BALB/c mice, tracer uptake in the exocrine pancreas 
of C57Bl/6 mice could be blocked with an excess of unlabeled exendin (Figure 4B and C). 
Additionally, the calculated endocrine-to-exocrine uptake ratio in these mice (4.56 ± 0.91) 
(Table 2) was in the same range as the ratio observed in BALB/c mice.
Figure 4. a) Pancreatic uptake of [111In]In-DTPA-exendin in C57Bl/6 mice (n=2) on different days after 
alloxan treatment (50 mg/kg). b) Pancreatic uptake of [111In]In-DTPA-exendin in C57Bl/6 mice treated 
with vehicle (control) (n=2) and 50 mg/kg alloxan (n=2). Blocking was performed by co-injection of 25 µg 
unlabeled exendin (n=1). c) Autoradiography of pancreatic sections of C57Bl/6 mice treated with vehicle 
(control) and 50 mg/kg alloxan. Blocking was performed by co-injection of 25 µg unlabeled exendin.
[111In]In-DTPA-exendin uptake in different rat strains 
Figure 5A summarizes the biodistribution (2 rats per strain) of [111In]In-DTPA-exendin in four 
rat strains. In all rat strains there was very high lung uptake (> 10%ID/g), which was even 
higher than the uptake observed in the kidneys. The biodistribution profiles indicated that WAG/
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Rij rats have the highest pancreatic [111In]In-DTPA-exendin uptake (0.45%ID/g). In addition, the 
endocrine-to-exocrine uptake ratio, calculated from the autoradiographs shown in Figure 5B, 
was highest for WAG/Rij rats as well (Table 3). The uptake in the stomach (1.7 %ID/g) of WAG/
Rij rats is relatively high (Figure 5B), resulting in a pancreas-to-stomach uptake ratio of 0.27 ± 
0.02 (Table 4). Since high stomach uptake might hamper BCM visualization in vivo, we selected 
Brown Norway rats to investigate the beta cell specifi city of pancreatic [111In]In-DTPA-exendin 
accumulation due to their higher pancreas-to-stomach (1.39 ± 0.11) and acceptable pancreas-
to-duodenum (0.70 ± 0.1) ratios (Table 4) despite their lower pancreatic uptake (0.27 %ID/g) 
(Figure 4A) and endocrine-to-exocrine ratio (57.1 ± 12.5) (Table 3).
Table 3. Overview of the endocrine-exocrine ratios of [111In]In-DTPA-exendin uptake in various rat strains 
calculated from autoradiography of pancreatic sections.
Rat strain Endocrine-exocrine ratio
WAG/Rij 105.66 ± 29.84
Brown Norway 57.06 ± 12.53
Sprague Dawley 44.00 ± 13.33
F344 44.83 ± 2.85
Table 4. Overview of the pancreas-to-stomach and pancreas-to-duodenum ratios of [111In]In-DTPA-exendin 
uptake in the different rat strains.
Rat strain Pancreas-to-stomach ratio Pancreas-to-duodenum ratio
Sprague Dawley 0.08 ± 0.02 0.33 ± 0.02
F344 0.11 ± 0.00 0.31 ± 0.07
Wag/Rij 0.27 ± 0.02 1.15 ± 0.78
Brown Norway 1.39 ± 0.11 0.70 ± 0.10
Beta cell specifi city of [111In]In-DTPA-exendin uptake in Brown Norway rats
In Brown Norway rats, treated with 60 mg/kg alloxan (2 rats), pancreatic uptake was reduced by 
more than 80% compared to control rats, that were injected with vehicle (PBS) (2 rats) (Figure 
6). Co-administration of an excess unlabeled exendin (1 rat) reduced the pancreatic uptake to 
similar uptake levels observed in alloxan-treated rats, suggesting no or very low non-specifi c 
[111In]In-DTPA-exendin uptake in the exocrine pancreas. Furthermore, autoradiographical 
analysis showed similar results: high, specifi c tracer uptake in the islets of Langerhans and 
low, non-specifi c uptake in the exocrine pancreas (Figure 5B) resulting in an endocrine-to-
exocrine uptake ratio of 57.1 ± 12.5 (Table 4). These results indicate high beta cell specifi city of 
[111In]In-DTPA-exendin in these rats.
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Figure 5. a) Biodistribution of [111In]In-DTPA-exendin in Sprague Dawley, F344, Wag/Rij and Brown Norway 
rats. Values are expressed as percentage injected dose per gram tissue (n=2 rats). Rats were dissected 
four hours after injection. b) Autoradiography of pancreatic section of Sprague Dawley, F344, Wag/Rij and 
Brown Norway rats showing focal hotspots of tracer accumulation representing the islets.
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Figure 6. Pancreatic uptake of [111In]In-DTPA-exendin in Brown Norway rats treated with vehicle (control) 
(n=2) and alloxan (60 mg/kg) (n=2). Values are expressed as percentage injected dose per gram tissue. 
Blocking was performed by co-injection of 25 µg unlabeled exendin (n=1).
Quantitative PCR
Since receptor mediated [111In]In-DTPA-exendin uptake was observed in exocrine pancreas of 
mice, Glp-1r mRNA expression was compared in endocrine and exocrine pancreatic tissue 
of rats and mice. Quantitative RT-PCR revealed similar Glp-1r mRNA expression levels in 
endocrine and exocrine tissue of rat and mouse (Figure 7A and B) with endocrine-to-exocrine 
ratios of 45.8 and 55.6, respectively. Individual expression levels of all cell markers (Glp-1r, 
Pdx1, Ins and Amy2b) in endocrine and exocrine tissue are provided in Figure 8.
Immunohistochemistry
To investigate GLP-1R expression in endocrine and exocrine pancreatic tissue, GLP-1R staining 
was performed on rat, mouse and human pancreatic tissue. Figures 7C, D and E show the 
results of the immunohistochemical analysis. In all pancreatic tissues analyzed, the islets of 
Langerhans showed clear GLP-1R staining while no, or very limited, staining was observed in 
the exocrine portion of the pancreatic tissue.
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Figure 7. Quantitative PCR for the Glp-1r in endocrine and exocrine pancreatic tissue of rat (a) and mouse 
(b) and immunohistochemical analysis of GLP-1R expression in pancreatic tissue (embedded in paraffin) 
of rat (c), mouse (c) and human (c). Both analyses show high GLP-1R expression in the islets and no, or 
very low expression in exocrine tissue. For quantitative PCR, paired t-test was performed and p <0.05 was 
considered as significant.
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Figure 8. Quantitative PCR of the glucagon-like peptide 1 receptor (Glp-1r) mRNA expression in pancreatic 
islets and exocrine tissue with additional pancreatic endocrine and exocrine cell markers for mouse (Mm, 
Mouse musculus); A) Glp-1r, B) Pdx1 (Pancreatic and duodenal homeobox 1), and C) Ins1 (insulin) and D) 
Amy2b (pancreatic α-Amylase), and for rat (Rn, Rattus novergicus); E) Glp1r, F) Pdx1, G) Ins2 (Insulin) and H) 
Amy2b. In both species the pancreatic islets were positive for Glp-1r and the endocrine cell markers Pdx1
and Ins, while the exocrine material was positive for the exocrine cell marker Amy2b but had a decreased 
expression of Glp-1r, Pdx1 and Ins. N=3 in all experimental conditions. Paired t-test was performed and 
p<0.05 was considered signifi cant (**).
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In this study, we assessed differences between rodent models for non-invasive in vivo BCM 
assessment via GLP-1R targeting. We investigated the biodistribution of [111In]In-DTPA-exendin 
in various rat and mouse strains and determined the specificity of tracer accumulation in the 
beta cells. Our present findings indicate that Brown Norway rats display the most favorable 
characteristics for non-invasive BCM assessment using radiolabeled exendin as a tracer. Mice 
seem to display receptor mediated tracer uptake in the exocrine pancreas, an observation 
explaining the limited reduction of exendin uptake in the pancreas of mouse models after beta 
cell destruction 22, 24. 
In view of the spatial resolution of present imaging modalities and the small size of the islets, 
preventing visualization of single islets in vivo, the optimal model for in vivo BCM determination 
must display high and specific [111In]In-DTPA-exendin accumulation in the endocrine pancreas 
29, 30 with no or low uptake in the exocrine pancreas and surrounding tissues, in particular 
stomach and duodenum that are localized in the vicinity of the pancreas. Since [111In]In-DTPA-
exendin is excreted via the kidneys, high tracer uptake is observed in this  organ, which renders 
accurate quantification of pancreatic tracer uptake challenging in rodents. However, spill over 
signal from the kidneys can be excluded by analyzing a particular region of interest in the 
pancreas localized cranial and anterior of the kidneys 14. Another option to overcome spillover 
effects of the kidneys is co-injection of a second radiotracer, specifically targeting the exocrine 
tissue such as [99mTc]Tc-demobesin and [123I]I-L-phenylalanine in combination with [111In]In-
DTPA-exendin, which facilitates exact delineation of the pancreas and therefore improves 
accurate quantification of pancreatic [111In]In-DTPA-exendin uptake 22. Of all investigated rat 
strains, WAG/Rij rats showed the highest pancreatic [111In]In-DTPA-exendin uptake. However, 
due to their less favorable pancreas-to-stomach and pancreas-to duodenum ratios, WAG/Rij 
rats are expected to be less suited for in vivo BCM determination using [111In]In-DTPA-exendin 
SPECT than Brown Norway rats. 
To evaluate the beta cell specificity of the tracer, ex vivo autoradiography was performed. In 
rats, focal hotspots of tracer accumulation, representing the beta cells, were observed while 
there was a low background signal in the exocrine tissue (Figure 5B). Beta cell depletion by 
alloxan injection resulted in disappearance of the tracer accumulating hotspots, confirming 
beta cell specificity of GLP-1R targeting using [111In]In-DTPA-exendin allowing accurate 
BCM determination of BCM. Based on autoradiographic analysis, we showed endocrine-to-
exocrine ratios of 105.7 ± 29.8 in WAG/Rij rats, 57.1 ± 12.5 in Brown Norway rats, 44.0 ± 13.3 
in Sprague Dawley rats and 44.8 ± 2.9 in F344 rats, which is in line with previous observations 
23. Furthermore, pancreatic [111In]In-DTPA-exendin uptake in Brown Norway rats is similarly 
decreased after alloxan-induced beta cell depletion and co-injection with an excess unlabeled 
exendin, confirming beta cell specific tracer accumulation in this model. We have previously 
shown  clear differences in [111In]In-DTPA-exendin uptake in the pancreas of Brown Norway 
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rats treated with various concentrations of alloxan, resulting in a linear correlation of SPECT 
signal and BCM 14. These observations confi rm that this rat strain provides an optimal model 
for in vivo BCM assessment via GLP-1R targeting.
Several groups have reported a decrease in pancreatic tracer uptake in mice after alloxan or 
streptozotocin-induced beta cell destruction 22, 24. However, the maximum decrease did not 
exceed 40%, an observation which can be explained by our data. After co-injection of an excess 
unlabeled exendin in mice, tracer uptake was much lower than the remaining uptake observed 
after alloxan-induced beta cell depletion. These results strongly suggest that the limited 
decrease in tracer uptake after alloxan-induced beta cell destruction is caused by receptor 
mediated [111In]In-DTPA-exendin uptake in the exocrine pancreas of mice. Nevertheless, 
there was no detectable GLP-1R expression in exocrine pancreatic tissue of mice by 
immunohistochemistry and only very low Glp-1r mRNA expression was observed by RT-PCR. 
Furthermore, endocrine-to-exocrine ratios of Glp-1r mRNA expression are similar in mice 
and rats. These observations suggest that [111In]In-DTPA-exendin probably binds to a receptor 
other than the GLP-1R in the exocrine pancreatic tissue of mice, which could also explain the 
observations of Nalin et al. 31. These fi ndings preclude the use of this model for additional 
characterization of [111In]In-DTPA-exendin uptake. In contrast with observations in mice after 
beta cell destruction 22, 24 (present data), and similar to the above described rat data, patients 
with long standing type 1 diabetes can show very low [111In]In-DTPA-exendin uptake similar to 
background values 14, suggesting no or negligible uptake in the exocrine pancreas. Therefore, 
the situation in humans appears to be better refl ected by rat models than by mouse models. 
At this point in time, it remains unclear which receptor is responsible for exendin uptake in the 
exocrine pancreas of mice but it is highly likely that this receptor shows differences with the rat 
and human receptors in a way that only the variant expressed in mice can bind exendin. 
CONCLUSION
The choice of a certain rodent model can greatly infl uence studies investigating BCM 
dynamics. The present fi ndings indicate that mice have binding in the exocrine pancreas which 
is mediated by a receptor that is not the GLP-1R, rendering them an inadequate model for BCM 
assessment by radiolabeled exendin. On the other hand, rats do not show receptor mediated 
exendin binding in the exocrine pancreas, and are therefore a better suited model for further 
studies. Among the investigated rat models, Brown Norway rats are the optimal model for non-
invasive GLP-1R targeting given their favorable pancreas-to-background uptake ratios. In view 
of these results and the very low remaining uptake in patients with T1D, rats appear to display 
better characteristics for in vivo investigation of BCM dynamics when compared to mice, and 
are thus considered a suitable model better refl ecting the human situation than other animal 
models.
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Measuring the pancreatic beta cell mass 
in vivo with exendin SPECT during  
hyperglycemia and severe insulitis
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ABSTRACT
Targeting the glucagon like peptide-1 receptor (GLP-1R) with radiolabeled exendin is a very 
promising method to non-invasively determine the beta cell mass in the pancreas, which 
is needed to unravel the pathophysiology of type 1 and type 2 diabetes. The present study 
aimed to explore the effects of both hyperglycemia and insulitis on the uptake of exendin in a 
spontaneous type 1 diabetes mouse model: Non-Obese Diabetic (NOD) mice.
NOD mice (n = 75,  7-21 weeks old) were injected intravenously with [111In]In-DTPA-exendin-3 
and SPECT images were acquired 1 hour p.i.. The pancreatic accumulation of [111In]In-DTPA-
exendin-3 was quantified in vivo using SPECT and by ex vivo counting and correlated to the 
beta cell mass (BCM). The influence of insulitis and hyperglycemia on the exendin uptake were 
assessed.  
The pancreas could be visualized longitudinally using SPECT. A linear correlation was found 
between the BCM (%) and pancreatic uptake (%ID/g) as measured by ex vivo counting (Pearson 
r = 0.64, p < 0.001), which was not affected by either insulitis (Pearson r = 0.66, p = 0.83) or 
hyperglycemia (Pearson r = 0.57, p = 0.51). Biodistribution and ex vivo autoradiography revealed 
remaining [111In]In-DTPA-exendin-3 uptake in the pancreas despite total ablation of BCM.
Despite hyperglycemia and severe insulitis, we have found a good correlation between BCM 
and pancreatic exendin uptake, even in a suboptimal model with relatively high background 
activity.
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Type 1 diabetes (T1D) is characterized by islet-specifi c autoimmunity, followed by progressive 
depletion of the insulin-producing beta cells leading to hyperglycemia 1. Complete destruction 
of beta cells in patients with long-standing type 1 diabetes has been believed to be the single 
cause of hyperglycemia for a long time, however, this theory has been challenged lately. In 
the last few years, several studies have found evidence of residual insulin-positive beta cells 
in patients with longstanding T1D 2, 3. Furthermore, some patients with recent-onset T1D or 
patients positive for autoantibodies (ICA, GADA and IA-2-Ab) but not (yet) diabetic showed lack 
of insulitis 4-6, which has been considered to be the pathophysiological key feature required for 
development of T1D. Insulitis is defi ned as the presence of lymphocytes infi ltrating the islets of 
Langerhans 4 leading to destruction of the beta cells.
The evidence of remaining but functionally impaired beta cells in longstanding T1D patients 
and the presence or absence of insulitis underline the population heterogeneity of T1D and 
with that the crucial need for a non-invasive method to determine the beta cell mass. Beta 
cell function can be measured by clinical tests determining insulin production capacity 
following stimulation, but it appears that beta cell mass and functional beta cell mass are 
not identical 7, emphasizing the relevance for individual monitoring of the beta cell mass in 
relation to functional capacity. Such a method allows for monitoring of therapies targeting the 
autoimmune response to protect the beta cells or therapies to increase BCM.
The beta cells can be visualized non-invasively using radiolabeled exendin and SPECT or PET 8, 9.
Exendin is a stable analog of GLP-1 and targets the GLP-1R receptor with high affi nity, which 
is highly expressed on beta cells.
Previously, we have shown the feasibility of radiolabeled exendin to monitor the beta cell mass in 
a rat model with chemically induced beta cell destruction 8, and in a rat model for spontaneous 
type 1 diabetes 10. In both studies a strong good linear correlation between exendin uptake and 
the beta cell mass was found.
The expression of the GLP-1R can change during the development of diabetes. During insulitis, 
several cytokines (like Il-1ß and IFN-γ) are released by immune cells, which in turn alter the 
expression of many genes, amongst which the GLP-1R 11. Furthermore, previous studies in 
mice showed that hyperglycemia reduced the expression of the GLP-1R and thereby the beta 
cell function 12, 13. 
To address the effects of longstanding hyperglycemia and longstanding infl ammation of the 
islets on the GLP-1R expression and thus uptake of exendin in the pancreas, we performed a 
study using Non-Obese Diabetic (NOD) mice. This mouse model is the only well-characterized 
spontaneous mouse model for studying T1D 14. The development of diabetes in this model 
shows a variety of similarities with that in human patients, like the presence of particular 
immune cells and cytokines (like Il-1ß and IFN-γ) in the diabetic pancreas, and the presence 
of insulitis 14-16, although the insulitis is much more severe in mice than in men. Furthermore, 
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this model is suitable to study the effects of hyperglycemia, since these mice do not necessarily 
require insulin treatment.
Here, we determined the correlation between the BCM and pancreatic uptake of radiolabeled 
exendin under conditions of severe insulitis and hyperglycemia.
MATERIALS AND METHODS
Animals
All animal experiments were approved by the Animal Ethical Committee of the Radboud 
University, Nijmegen, The Netherlands, and all experiments were performed according to the 
Institute of Laboratory Animal Research Guidelines.
Non Obese Diabetic (NOD) female mice were purchased from Charles River Laboratories 
(L’Arbresle, France). Unilateral nephrectomy of the left kidney had been performed at the 
age of 5 weeks under isoflurane anesthesia using Buprenorphine as analgesic and the mice 
arrived at our facility between 6 and 9 weeks of age. One group of mice (n = 6) did not undergo 
nephrectomy and was euthanized at an age of 12 weeks to determine the distribution of the 
tracer, without any further measurements. Mice were housed in a pathogen-free environment 
in ventilated filter-topped cages (5 mice per cage), required to maintain diabetes incidence, 
and had ad libitum access to sterile water and chow. Mice were allowed to adapt to laboratory 
conditions for 1 week before the start of the experiments.
At least twice a week the body weight of the mice was measured, blood was drawn by venous 
puncture and blood glucose was measured using a blood glucose meter (Accu-Chek Sensor, 
Roche Diagnostics, Almere, The Netherlands). Every week a group of 5 mice was studied using 
SPECT, starting at 7 weeks old until 21 weeks old. Mice were considered diabetic when glucose 
levels exceeded 11.1 mmol/l 17.
Radiolabeling of DTPA-exendin-3 with 111In
 [Lys40(DTPA)]exendin-3 was purchased from Peptide Specialty Laboratories (PSL, Heidelberg, 
Germany) and referred to as DTPA-exendin-3. DTPA (diethylene triamine penta acetic acid) 
was conjugated to the ε-amino group of C-terminal Lysine. 111InCl3 was obtained from 
Mallinckrodt Medical (Petten, The Netherlands). DTPA-exendin-3 was labeled with 111In as 
described previously 18. Briefly, DTPA-exendin-3 (1 µg, 200 pmol) was incubated for 20 min 
with 150 MBq 111InCl3 and two volumes of 0.1 M MES buffer, pH 5.5. Subsequently, 50 mM 
EDTA (ethylenediaminetetraacetic acid) (Sigma Aldrich, St. Louis, MO, USA) and 10% Tween-80 
(Sigma Aldrich, St. Louis, MO, USA) to a final concentration of 5 mM and 0.1% respectively 
were added. The radiolabeled peptide was separated from the unbound 111In using solid-phase 
extraction using an HLB (hydrophilic-lipophilic balance reversed-phase sorbent) cartridge 
(Waters Oasis©, Milford, MA, USA) as described previously 19. Pure ethanol was used for 
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activation of the cartridge and 0.1 M MES buffer was used for conditioning and washing. Quality 
control was performed by Instant Thin Layer Chromatography (ITLC) on silica gel ITLC strips 
(ITLC-SG Biodex, Shirley, NY, USA). As a mobile phase 0.1 M EDTA in 0.1 M NH4Ac, pH 5.5 was 
used (Rf [
111In]In-DTPA-exendin-3 = 0, Rf
111In-EDTA = 1).
Biodistribution and SPECT
Every week 5 mice were injected intravenously with 19.7±1.3 MBq (20 pmol). One hour p.i. mice 
were anesthetized and subjected to SPECT/CT. Images were acquired with an acquisition time 
of 50 minutes using a dedicated small animal SPECT scanner (U-SPECT-II, MILabs, Utrecht, 
The Netherlands) and a 0.1 mm pinhole mouse collimator. 
Mice were euthanized after SPECT/CT using CO2/O2 suffocation. Blood, muscle, heart, lung, 
spleen, pancreas, stomach, intestine, kidney and liver were dissected, weighed and the 
radioactivity concentration was determined in a gamma counter (Wallac 1480-Wizard, Perkin-
Elmer, Boston, MA, USA). Pancreata were fi xed overnight in formaldehyde, dehydrated and 
embedded in paraffi n.
The U-SPECT-Rec software (MILabs, Utrecht, The Netherlands) was used to reconstruct the 
SPECT images (OSEM with 16 subsets, 1 iteration and a voxel size of 0.4 mm). The pancreatic 
uptake of [111In]In-DTPA-exendin-3 was quantifi ed using Inveon Research Workplace (Preclinical 
Solutions, Siemens Medical Solutions USA, Inc., Knoxville, TN, USA). A volume of interest over 
the pancreas was drawn manually and corrected for overlapping kidney uptake. For each 
mouse a volume of 100 mm3, including the voxels with the highest value, was measured by 
thresholding.
Macroautoradiography
Pancreatic sections of 5 µm were cut (one mouse per group). Two sections per mouse were 
exposed to a phosphor screen Fuji Film BAS-SR 2025, Raytest, Straubenhardt, Germany) for 
7 days, images were acquired with a radioluminography laser imager (Fuji Film BAS 1800 II 
System, Raytest) and analyzed using Aida Image Analyzer software (Raytest).
Beta cell mass measurement and insulitis
Four μm thin sections were cut, mounted on glass and stained. Pancreatic sections were 
stained with guinea pig anti-insulin polyclonal antibody (1:3,000; Van Schravendijk, Brussels) 
and species-matched Cy3-conjugated secondary antibody (Jackson ImmunoResearch, 
Cambridgeshire, UK), and counterstained with Hoechst (Sigma Aldrich). Images were acquired 
with a Carl Zeiss multi-photon confocal laser scanning microscope LSM710 and analyzed using 
IPLAB pathway 4.0 software. Beta cell mass was estimated morphometrically by quantifying 
total insulin immunoreactive area within a pancreatic section area of at least 100 mm2 for each 
mouse multiplied by the pancreatic weight as previously described 20. Insulitis was examined 
histologically after hematoxylin and eosin staining using a bright fi eld microscope (Zeiss 
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Axioskop, Oberkochen, Germany) and the degree of insulitis was scored as the percentage of 
islets that were infiltrated. The observer was blinded for the origin of the sections.
Immunohistochemistry
Four µm thin sections were cut, mounted on glass and stained. Pancreatic sections were 
treated with 10 mM citrate, pH 6.0 for 10 min at 96°C to reverse epitope masking. Blocking 
was performed by incubating for 10 min at room temperature in 3% H2O2, followed by 30 min 
at RT in 20% normal goat serum. Subsequently, sections were stained with guinea pig anti-
insulin (1:3,000; A0564; DAKO, Agilent, Ca, USA) for 60 min at room temperature, followed by 
goat-anti-guinea pig-HRP (1:1,000; A18775, Thermo Fisher, Massachusetts, USA) for 30 min at 
RT. Adjacent sections underwent antigen retrieval by a 10 min incubation step at 37°C in 0.1% 
pronase, followed by blocking in 3% H2O2 for 10 min at room temperature and 10 min at room 
temperature in 1% bovine serum albumin (BSA). Next, sections were stained with mouse-anti-
GLP-1R (1:100; 7F382A, Novo Nordisk, Bagsvaerd, Denmark) overnight at 4°C, followed by a 
30 min incubation at room temperature with Opal Polymer HRP Ms + Rb (ARH1001EA: Perkin 
Elmer). Sections were counterstained with hematoxylin and images were acquired using a 
Leica DM3000 microscope and Leica DMC2900 camera (Leica, Wetzlar, Germany) and Leica 
Application Suite software (v 4.11, Leica).
Statistical analysis
GraphPad Prism software version 5.03 for Windows was used for data analysis: One-way 
ANOVA followed by a Tukey test was used to determine significance. A p -value below 0.05 was 
considered significant. All correlation coefficients were calculated with a Pearson correlation 
coefficient using SPSS (IBM SPSS Statistics 22). To calculate the influence of insulitis and 
hyperglycemia on the correlation between the beta cell mass and the uptake of radiolabeled 
exendin, a partial correlation analysis was performed, with hyperglycemia and insulitis as 
confounding factors. The statistical difference between these correlations was examined by a 
two-tailed Fisher r-to-z transformation.
RESULTS
Blood glucose
The blood glucose level of the mice was measured at least twice a week. In Figure 1 all 
measured blood glucose values from 7 to 21 weeks of age of all mice are summarized. During 
the first 14 weeks all mice were able to control their glucose levels, which ranged between 
3.8 and 11.1 mmol/l (normoglycemic). From week 15 onwards elevated glucose levels were 
measured, that increased rapidly, indicating hyperglycemia.
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Figure 1. Blood glucose levels (mmol/l) in NOD mice up to 21 weeks of age. Blood glucose was measured 
twice a week. The duration of hyperglycemia was classifi ed for every mouse: Euglycemic (< 11.1 mmol/l) 
(open circles) or hyperglycemic (≥ 11.1 mmol/l) for 1 to 14 days (yellow circles) (n=8), 15 – 28 days (brown 
circles) (n=4) and ≥ 29 days (red circles) (n=3).
Biodistribution and SPECT/CT
The highest pancreatic uptake was found in the group of mice at an age of eight weeks (16.4 
± 3.3 %ID/g), whereas the lowest average uptake was observed in mice of 17 weeks old (6.7 ± 
2.0 %ID/g) (p=0.0005). Overall, a clear decrease in exendin uptake was observed over time. The 
comparative biodistribution between mice that were nephrectomised and mice that were not, 
is shown in Figure 2.
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Figure 2. Biodistribution of [111In]In-DTPA-exendin-3 in NOD mice of 12 weeks old. Mice that underwent 
unilateral nephrectomy are indicated with black bars (n=5), mice without nephrectomy are indicated with 
white bars (n=6). Values are expressed as a percentage of the injected dose per gram of tissue (error bars 
is SD).
SPECT with [111In]In-DTPA-exendin-3 clearly visualized the pancreas. Figure 3 shows examples 
of three mice of different ages and with a different BCM. The decline in [111In]In-DTPA-exendin-3 
uptake in the pancreas is clearly visible in these images. Image 3a was obtained from a healthy 
mouse of 7 weeks old, with an [111In]In-DTPA-exendin-3 uptake in the pancreas of 18.1 %ID/g 
and a BCM of 0.13 %. Image 3b shows a mouse of 13 weeks old, a pancreatic uptake of 12.2 
%ID/g and a BCM of 0.06 %. Both mice had normal blood glucose levels. Finally, image 3c is 
from a 19-weeks old mouse, with an uptake of 4.5 %ID/g, a BCM of 0.00 % and with high blood 
glucose levels during several weeks. Notably, there was still uptake of exendin detected in 
the diabetic mouse. Next to pancreatic uptake, also high uptake of exendin in the kidney was 
observed.
A linear correlation of 0.68 (Pearson r, p < 0.001) between the exendin uptake in the pancreas, 
measured by ex vivo counting and the SPECT signal was found (Figure 4). When the SPECT 
signal declined, also a decline in the pancreatic uptake measured by ex vivo counting was 
found.
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Figure 3. Coronal slices of SPECT images of NOD mice of 7, 13 and 19 weeks old, respectively, with a 
pancreatic uptake and BCM of (A) 18.1 %ID/g and 0.13 % respectively, (B) 12.2 %ID/g and 0.06 % respectively 
and (C) 4.5 %ID/g and 0 % respectively. Uptake in kidney is indicated with K and the pancreatic uptake with 
a green arrow.
Figure 4. Correlation between the quantifi ed SPECT signal in the pancreas and the uptake of exendin in 
the pancreas. The uptake is expressed as the percentage injected dose per gram of tissue (%ID/g) and 
determined by ex vivo counting of the pancreas.
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Beta cell mass measurement and insulitis
Figure 5 shows that the beta cell mass is linearly correlated with the exendin uptake in the 
pancreas (Pearson r = 0.64, p < 0.001). A decline in beta cell mass corresponded with a decline 
in pancreatic uptake. Furthermore, all mice that were mild (11.1 – 22.2 mmol/l) or severe 
hyperglycemic (> 22.2 mmol/l) at the end of the experiment had a low beta cell mass. However, 
in mice that had complete absence of beta cells, still uptake of exendin in the pancreas was 
measured.
Figure 5. Correlation between the uptake of exendin in the pancreas and the BCM. The uptake is shown as 
percentage injected dose per gram of tissue (%ID/g) and determined by ex vivo counting of the pancreas, 
the BCM is presented as percentage of the total pancreas and determined by morphometric analysis after 
immunohistochemical staining with an anti-insulin antibody. The level of glycemia was determined at the 
endpoint and classified for every mouse: Euglycemic (< 11.1 mmol/l), mildly hyperglycemic (11.1 – 22.2 
mmol/l) and severely hyperglycemic (> 22.2 mmol/l).
Already at an early age the first leukocyte infiltrated islets became apparent, and in the few 
islets that were infiltrated, infiltration was already very severe. With increasing age, more islets 
were infiltrated by immune cells and from 11 weeks of age onwards more than half of the islets 
were inflamed (Figure 6).
To investigate if inflammation of the islets influenced the exendin uptake, the correlation 
between the exendin uptake determined ex vivo and the beta cell mass was corrected for 
insulitis and was found to be 0.66 (Pearson r, covariant analysis) and was not statistically 
significant (p = 0.83). Insulitis did not significantly affect the uptake of exendin in the beta cells. 
Furthermore, there was no correlation whatsoever (p = 0.40) between insulitis and exendin 
uptake (Figure 7).
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Correction for the blood glucose value at the time of SPECT imaging resulted in a correlation 
coeffi cient of 0.57 (Pearson r, covariant analysis), which was not signifi cantly different than the 
uncorrected correlation coeffi cient (p = 0.51). There was, however, a slight negative correlation 
between blood glucose (at the time of SPECT imaging) and uptake of radiolabeled exendin 
(Pearson r = -0.44, p < 0.01) (Figure 8).
Figure 6. Insulitis score in NOD mice (n=75). The degree of insulitis was scored as the percentage of islets 
that were infi ltrated and was measured at the endpoint (n=5 mice per week).
Figure 7. Correlation between insulitis and the uptake of exendin in the pancreas. The degree of 
insulitis was scored as the percentage of islets that were infi ltrated. The uptake is expressed as the 
percentage injected dose per gram of tissue (%ID/g) and determined by ex vivo counting of the pancreas. 
The correlation coeffi cient between insulitis and the pancreatic uptake was calculated with a Pearson 
correlation coeffi cient (Pearson r = -0.10, p = 0.40).
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Figure 8. Correlation between the blood glucose and the uptake of exendin in the pancreas. The blood 
glucose depicted here was measured at the endpoint (mmol/l). The uptake is expressed as the percentage 
injected dose per gram of tissue (%ID/g) and determined by ex vivo counting. The correlation coefficient 
between the blood glucose levels and pancreatic uptake was calculated with a Pearson correlation 
coefficient (Pearson r = -0.44 (p < 0.01).
Macroautoradiography and immunohistochemistry
Figure 9 illustrates the high uptake of radiolabeled exendin in the islets of Langerhans and 
moderate uptake in the exocrine pancreas. The images depicted here show a decline of 
endocrine exendin uptake and thus beta cell mass over time, as diabetes was progressing. 
When no insulin positive cells were present in the section, there was still radioactive signal 
detected by macroautoradiography in the exocrine pancreas (Figure 9C).
To confirm the findings in the autoradiography, we have performed immunohistochemical 
analyses on a mouse with a high exendin uptake (17.7 %ID/g) and with a low exendin uptake 
(5.1 %ID/g). Figure 10 demonstrates high insulin and GLP-1R expression in the mouse with 
high exendin uptake (A and B respectively), in contrast to the mouse with low exendin uptake, 
where the endocrine pancreas was nearly complete negative for both insulin and GLP-1R (D 
and E respectively). Furthermore, in both mice there was no positive GLP-1R signal in the 
exocrine pancreas, which verifies that exendin binds to a different receptor than the GLP-1R.
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Figure 9. Macroautoradiography of pancreas of NOD mice of 11, 14 and 19 weeks respectively, with a 
pancreatic uptake and BCM of (A) 15.7 %ID/g and 0.29 % respectively, (B) 8.53 %ID/g and 0.09 % respectively 
and (C) 5.1 %ID/g and 0.01 % respectively.
Figure 10. Immunohistochemistry of pancreatic sections of an NOD mouse with high (A-C) and an NOD 
mouse with low (D-F) exendin uptake. Anti-insulin staining (A+D), anti-GLP-1R staining (B+E) and blanc 
controls (C+F).
DISCUSSION
In this study, we have validated [111In]In-DTPA-exendin-3 SPECT for determination of the BCM in 
a type 1 diabetic mouse model. In NOD mice, we were able to visualize the pancreas with SPECT 
and to quantify the radioactive signal during the progression of the disease. Furthermore, we 
have found a linear correlation between the BCM and the exendin uptake as determined by ex 
vivo counting, which was not signifi cantly altered by hyperglycemia or insulitis.
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A study of Ortis et al. demonstrated that the GLP-1R was downregulated upon stimulation of 
primary rat beta cells with pro-inflammatory cytokines 11. Although this was an in vitro study, 
it is reasonable that in human T1D or in animal models for T1D, insulitis could also influence 
the expression of the GLP-1R. We have previously demonstrated in BBDP rats that insulitis 
has no influence on the strong correlation between BCM and exendin uptake 10. In the present 
study we confirm these findings in a mouse model with even stronger insulitis 4. In nearly 
all mice insulitis was found, while in diabetic patients the incidence of insulitis is much less. 
Furthermore, the amount of islets that is infiltrated is hugely different between mice and 
human 4, 21. Based on these results, we presume that the weaker insulitis in humans will not 
have a significant influence on the uptake of exendin. Clinical evaluation is needed to address 
the influence of insulitis on the uptake of exendin in human, since the cytokines involved in 
insulitis are not completely identical between mice and human. 
The present study demonstrates that despite long term hyperglycemia, there is a good correlation 
between the beta cell mass and the uptake of exendin. Xu et al. and more recently Rajan et al. 
reported the downregulation of the GLP-1R both in vitro and in vivo after hyperglycemia 12, 13. We 
did not observe a significant difference in the correlation between beta cell mass and exendin 
accumulation when corrected for the blood glucose levels, indicating that the observation of 
Rajan and co-workers may not be relevant for beta cell quantification by GLP-1R imaging. 
However, as the duration of hyperglycemia varied in our study, and the blood glucose values 
at the time of [111In]In-DTPA-exendin-3 and BCM measurement were mainly concentrated at 
the high and low blood glucose levels, one might consider to perform in vivo experiments 
specifically designed to determine the influence duration and severity of hyperglycemia have on 
GLP-1R expression and radiolabeled exendin accumulation in the pancreas.
With immunohistochemical staining of insulin we have confirmed a near complete ablation of 
the beta cells in diabetic mice. However, uptake of the tracer was still found by ex vivo counting 
of the total pancreas in these mice, as well as the presence of a signal on SPECT. Furthermore, 
autoradiographic images of the pancreas of these mice confirmed the presence of a radioactive 
signal also in the exocrine pancreas. On the contrary, the validation of this tracer in BBDP rats 
demonstrated that when the amount of beta cells dropped to zero, also no radioactive signal 
could be detected with either SPECT or autoradiography 10.
Since there is exendin accumulation in the pancreas of diabetic mice, while 
immunohistochemistry shows a total depletion of the beta cells, it is plausible that exendin is 
binding to the exocrine tissue of the pancreas. These data are in line with a previous study, in 
which we compared GLP-1R targeting using exendin in various mouse and rat strains 22. We 
report that in mice the pancreatic uptake of exendin after chemical beta cell destruction is 
higher than after coinjection of an excess of unlabeled exendin. This stands in contrast to rats, 
where the accumulation of exendin is similar after beta cell ablation and blocking of uptake 
by an excess of unlabeled exendin. Because the endocrine-to-exocrine mRNA ratio of GLP-1R 
was similar in mice and rats, it is likely that in mice exendin has cross-reactivity in the exocrine 
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tissue with another protein. In accordance, the GLP-1R staining of the murine exocrine tissue 
was negative in the alloxan study as well as in this study. Similar fi ndings are described by 
Eriksson et al., who report that the exendin uptake in islets has a larger contribution to the total 
pancreatic uptake in rats than in mice 23. Furthermore, we have shown before that the uptake 
of exendin in patients with T1D drops to background levels, indicating that this cross-reactivity 
most probably does not play a role in human exocrine pancreas 8.
Diabetes imaging in the NOD mouse model has been described using two different approaches, 
namely immune imaging 24 or imaging the pancreatic beta cells 25, but thus far none of these 
approaches were suffi cient for proper in vivo use. To the best of our knowledge, to date no study 
reported successful non-invasive in vivo imaging of the beta cells using a radioactive tracer in 
the NOD mouse model. Thus, the NOD mouse model can be used for studying the beta cell 
mass with radiolabeled exendin, but the uptake of exendin in the exocrine pancreas should be 
taken into account. In the present study the mice underwent unilateral nephrectomy in order to 
visualize the pancreas in vivo, otherwise the left kidney would mask the pancreas. For clinical 
SPECT or PET imaging this is not an issue, because there is a larger distance between the 
pancreas and the kidneys. 
Population heterogeneity in T1D and new insights about beta cells underline the necessity to 
determine the BCM non-invasively 2, 3, as currently all knowledge about beta cells is obtained 
via autopsies. Detection of remaining beta cells opens possibilities for therapy in which these 
beta cells could be preserved, regenerated or even activated to proliferate. Immune therapy in 
diabetic NOD mice revealed recovery of beta cells, while at time of diagnosis no beta cells were 
detected immunohistochemically 26. In men, immunotherapy thus far cannot replace standard 
insulin treatment, due to safety reasons of the therapy or lack of (long term) effects, but shows 
great potential 27, 28. Based upon imaging and other (phenotypic) markers patients could be 
categorised in order to provide patients with optimal therapy. Furthermore, monitoring the 
effi cacy of novel immune-based therapeutic strategies would be of crucial value, especially in 
an individual-dependent manner 27.
Despite hyperglycemia and severe insulitis, we have found a good correlation between BCM 
and pancreatic exendin uptake, even in a suboptimal model with relatively low differences in 
uptake due to high background activity.
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ABSTRACT
The changes in beta cell mass (BCM) during the development and progression of diabetes 
could potentially be measured by radionuclide imaging using radiolabeled exendin. In this study 
we investigated the potential of [111In]In-DTPA-exendin in a rat model that closely mimics the 
development of type 1 diabetes in humans: BioBreeding Diabetes Prone (BBDP) rats. BBDP 
rats of 4-18 weeks of age were injected intravenously with [111In]In-DTPA-exendin and SPECT 
images were acquired. The accumulation of the radiotracer was measured as well as the beta 
cell mass and grade of insulitis by histology. [111In]In-DTPA-exendin accumulated specifically in 
the islets, resulting in a linear correlation with the BCM (%) (Pearson r = 0.89, p < 0,0001, r=0.64 
for SPECT). Insulitis did not have an influence on this correlation. These results indicate that 
[111In]In-DTPA-exendin is a promising tracer to determine the BCM during the development of 
type 1 diabetes, irrespective of the degree of insulitis.
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Type 1 diabetes (T1D) is the result of autoimmune destruction of the insulin-producing beta 
cells in the islets of Langerhans in the pancreas. It was long believed that a homogeneous 
and near-complete destruction of the beta cells occurs, but it has recently been shown that 
the autoimmune destruction of beta cells is a heterogeneous and chronically ongoing process 
during the course of T1D 1-3. As a result, beta cells and insulitic regions were found in pancreatic 
specimens many years after diagnosis of T1D 2. In the pancreata of T1D patients, various 
degrees of beta cell destruction in different areas of the pancreas could be found, including 
simultaneous detection of apparently healthy islets, early abnormalities, insulitic regions, and 
islets completely depleted from beta cells and absence of immune cells 3. More importantly, 
these studies showed that the degree and pattern of beta cell destruction and immune cell 
infi ltration are unique in every individual. The simultaneous appearance of different states of 
disease within one pancreas and the highly individual course of T1D would require a method to 
non-invasively measure the beta cell mass to provide additional information about the number 
and intrapancreatic distribution of beta cells during T1D and for the selection of patients 
eligible for novel (immune regulatory based) treatments . 
We previously showed that radiolabeled exendin accumulates specifi cally in the beta cells and 
could potentially be used to measure the beta cell mass by SPECT in rodents and humans 4. 
Despite these promising data, questions remain about the effectiveness of radiolabeled 
exendin for the determination of the BCM in the complex pathogenesis of diabetes. A concern 
is the potential variation in the expression of the glucagon-like peptide-1 receptor (GLP-1R), 
the receptor targeted by radiolabeled exendin, during the course of diabetes including the 
infl ammation-induced physiological changes in the pancreas. For example, it was shown that 
cytokine treatment of cell sorter-purifi ed rat beta cells reduced the GLP-1R mRNA expression 
5. Furthermore, hyperglycemia results in lower GLP-1R expression in isolated rat islets in vitro 
and in a rat model of partial duct ligation 6. These results suggest that possibly the GLP-
1R expression might change during the progression of T1D, which might result in changes 
of radiolabeled exendin accumulation impairing the correlation between tracer uptake and 
BCM. Besides the effects of infl ammation and metabolic disease on the GLP-1R expression, 
changes in blood fl ow and enhanced vascular permeability due to infl ammation could also 
affect accumulation of the tracer in the pancreas. However, the effect of potential changes in 
receptor expression on the accumulation of radiolabeled exendin in the beta cells is diffi cult 
to predict. We have previously demonstrated a linear correlation between radiolabeled exendin 
uptake and BCM in an alloxan-induced diabetes model of beta cell reduction4, 7, but this model 
does not show the typical patterns of infl ammation/insulitis found in T1D. Therefore, for 
determination of the feasibility of accurately measuring the BCM during T1D, the use of the 
tracer to determine the BCM noninvasively should be tested in a rodent model mimicking all 
aspects of the human disease progression.
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In the current study, we examine the correlation between the pancreatic uptake of [111In]In-
DTPA-exendin and the BCM and the influence of insulitis on the tracer uptake in a rat model for 
spontaneous T1D: the BioBreeding Diabetes Prone (BBDP) rat. These rats are characterized by 
severe insulitis, followed by rapid onset of T1D, making this an ideal model to study the effects 
of insulitis and inflammation and short-term fluctuations in blood glucose levels on the uptake 
of [111In]In-DTPA-exendin in the pancreas.
MATERIALS AND METHODS
Animals, nephrectomy and housing
Forty-five female Biobreeding Diabetes Prone rats of 3-5 weeks old were obtained from 
Biomedical Research Models (Worcester, MA, USA). The rats were housed in individually 
ventilated cages and were fed with sterilized chow and drinking water to maintain their 
microbiological status to ensure diabetes development. After one week acclimatization in our 
facility, unilateral nephrectomy (left kidney) was performed to allow accurate estimation of 
tracer uptake in the pancreas, under inhalation anesthesia with isoflurane (Abbott Laboratories, 
Toronto, Canada) in O2:Air (1:4). Carprofen (Rimadyl
®, Pfizer Animal Health B.V., Capelle aan de 
IJssel, The Netherlands) was used as analgesia for two days after surgery, twice daily (5 mg/
kg). As from one week after surgery the rats were used for SPECT studies. Every week three 
rats were subjected for SPECT studies.
Blood glucose levels and body weight were monitored at least twice weekly and the frequency 
of monitoring was intensified when blood glucose levels rise or body weight drops. For blood 
glucose level measurements a drop of blood was drawn by puncturing the tail vein with a 25G 
needle (BD Biosciences, Breda, The Netherlands). Blood glucose was measured with a glucose 
meter (Accu-Chek Sensor, Roche Diagnostics, Almere, The Netherlands). When rats were 
hyperglycaemic sustained release insulin implants (Linshin Canada Inc., Toronto, Canada) 
were injected subcutaneously with a 12G trocar needle to control blood glucose levels. 
SPECT
[111In]In-DTPA-exendin-3 was prepared as previously described8. Rats were injected intravenously 
with 15 MBq [111In]In-DTPA-exendin and SPECT scans were acquired 1 hour after injection on 
a dedicated small animal SPECT/CT scanner U-SPECT-II, MILabs, Utrecht, The Netherlands). 
SPECT images were acquired with a general purpose 1.0 mm pinhole rat and mouse collimator 
with an acquisition time of 50 min. The images were reconstructed with OSEM (3 iterations, 8 
subsets, voxel size 0.75) using the U-SPECT-Rec software (MILabs, Utrecht, The Netherlands). 
Mean uptake of [111In]In-DTPA-exendin in the pancreas was quantified using Inveon Research 
Workplace (Preclinical Solutions, Siemens Medical Solutions USA, Inc., Knoxville, TN, USA). A 
548546-L-bw-Joosten
Processed on: 22-9-2020 PDF page: 173
BETA CELL MASS DETERMINATION IN BBDP RATS
173
9
volume of interest was drawn over the pancreas and mean uptake (per voxel) was corrected 
for the injected dose.
After SPECT/CT acquisition the pancreas was dissected, fi xed in formalin and embedded in 
paraffi n for autoradiography and histological evaluation.
Histology, autoradiography, immunohistochemistry and beta cell mass determination
Sections (4 µm) were prepared of the paraffi n embedded pancreata at 3 levels with an interlevel 
distance of 100 µm. The sections were mounted and dried and one section per level was exposed 
to a phosphor imager screen (Fuji Film BAS-SR 2025, Raytest, Straubenhardt, Germany) for 
1 week. Images were acquired with a radioluminography laser imager (Fuji Film BAS 1800 II 
system, Raytest, Straubenhardt, Germany) and analyzed with Aida Image Analyzer software 
(Raytest, Straubenhardt, Germany).
A consecutive section of the one used for autoradiography was stained for insulin as follows: 
Deparaffi nation and antigen retrieval was performed as previously described4. Blocking was 
performed by incubation with PBS containing 1% BSA for 30 min at room temperature. After 
removal of PBS-BSA, 50-150 µl rabbit-anti-insulin antibody (4 µg/ml diluted in PBS containing 
1% BSA, sc9168, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was added and 
incubated for 1 hour at room temperature in the dark. The sections were washed three times 
with PBS and the sections were incubated with Alexa Fluor 594 Donkey Anti-Rabbit IgG (10 µg/
ml, Invitrogen, Bleiswijk, the Netherlands) for 30-60 minutes at room temperature in the dark. 
The sections were counterstained with DAPI. After washing three times with PBS the sections 
were mounted with Fluoromount (Sigma-Aldrich, St. Louis, MO, USA).
Insulin-stained sections were scanned with an automated microscope (Zeiss Axioskop 2 
plus) using a 100 x magnifi cation and a green light fi lter set. Thresholding was performed on 
pancreatic tissue in order to determine total pancreatic area semi-automatically using ImageJ 
(version 1.47, National Institutes of Health, USA). Also a threshold was set for the fl uorescently 
stained beta cells, to discriminate between the endocrine and exocrine tissue. Next, insulin 
positive beta cells were delineated in iVision (iVision-Mac™ (4.0.16), BioVision Technologies, 
USA) in order to select only islets and delete autofl uorescent regions. Finally, ImageJ was used 
to calculate the percentage of insulin positive beta cells within the pancreas automatically.
Insulitis score
One section per level was stained with hematoxylin-eosin (3 sections per rat). All islets in the 
sections were counted and scored for the presence of insulitis as follows: 0, no infl ammation; 1, 
intra-islet infl ammation occupying <50% within the islet; 2, intra-islet infl ammation occupying 
>50% within the islet; 3, complete or near complete obliteration of islets by infl ammation. The 
sections were read blindly by two independent observers. The index of insulitis of each rat was 
calculated according the following formula: I = (0  x n0) + (1 x n1) + (2 x n2) + (3 x n3) / 3 x (n0 + n1
+ n2 + n3)
9.
548546-L-bw-Joosten
Processed on: 22-9-2020 PDF page: 174
BETA CELL MASS DETERMINATION IN BBDP RATS
174
Statistical analysis
The correlation coefficient between the BCM and pancreatic uptake of [111In]In-DTPA-exendin 
was calculated with a Pearson correlation coefficient with SPSS (IBM SPSS Statistics 22). The 
influence of insulitis on this correlation was calculated by using insulitis as a covariant. The 
statistical difference between this correlations was examined by a two-tailed Fisher r-to-z 
transformation. The levels of significance was set to 0.05.
RESULTS
Blood glucose measurements and onset of diabetes
The results of the blood glucose measurements of BBDP rats during the complete 
experiments are summarized in Figure 1. All rats were normoglycemic until 8 weeks of age, 
and hyperglycemia occurred from 9 weeks of age. Hyperglycemic rats were treated with insulin 
to control the blood glucose levels. Despite insulin treatment, short-term fluctuations in blood 
glucose levels were observed.
Figure 1. Blood glucose values of BBDP rats. Blood glucose measurements performed twice weekly in 
BBDP rats (n=45 at 4 weeks of age). Rats were treated with insulin (implantation of an insulin pellet) when 
hyperglycemia occurred.
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[111In]In-DTPA-exendin accumulation and beta cell mass
In animals with a high beta cell fraction, [111In]In-DTPA-exendin accumulated in the pancreas, 
as measured by ex vivo counting. The pancreatic [111In]In-DTPA-exendin uptake decreased in 
rats with declining beta cell mass leading to a linear correlation between beta cell fraction and 
[111In]In-DTPA-exendin accumulation in the pancreas (Figure 2, Pearson r = 0.89, p<0.0001). The 
glycemia levels at the time point of imaging are presented in Figure 2B. The correlation between 
the beta cell mass and the pancreatic uptake, corrected for the blood glucose levels, was Pearson 
r = 0.89 and was not signifi cantly different than the uncorrected correlation (p<0.05).  
A restricted range correlation coeffi cient, excluding the animals with a BCM < 0.4%,  was 
calculated, resulting in a Pearson r=0.56.
Figure 2. Correlation between pancreatic [111In]In-DTPA-exendin accumulation and beta cell mass.(A). The 
uptake of [111In]In-DTPA-exendin in the pancreas (n=45), expressed as the percentage of the injected dose 
per gram of tissue (%ID/g, y-axis, determined y ex vivo counting of the entire pancreas) showed a strong 
correlation with the beta cell mass (expressed as percentage of the total pancreas, x-axis) determined 
by morphometric analysis (Pearson r = 0.89, p<0.0001). (B). The level of glycemia was plotted for every 
individual rat. The animals were categorized based on their non-fasting blood glucose levels at the time 
point of imaging as follows: 1) non-diabetic (<11.1mM) [open circles], mild hyperglycemia ( 11.1-22.2 mM) 
[open squares], moderate hyperglycemia (22.2-33.3 mM) [open triangles] and severe hyperglycemia (> 33 
mM). (C). The rats treated with insulin are represented as open squares and non-insulin treated rats with 
open circles.
Insulitis and [111In]In-DTPA-exendin accumulation
Insulitis scored by two independent observers showed a high level of agreement as determined 
by a Bland-Altman plot (Figure 3). There was no statistical correlation between the difference 
between the observers and the mean of the observers (One sample t-test, p=0.292). Therefore, 
there is no level of proportional bias between both observers and the mean insulitis score 
of both observers were used for further analysis. In young BBDP rats, no infi ltration of the 
islets was observed and fi rst signs of insulitis were observed after 7 weeks of age (Figure 
4), preceding the onset of hyperglycemia. The correlation between pancreatic [111In]In-DTPA-
exendin accumulation and the beta cell fraction, corrected for the insulitis score, was Pearson 
A B C
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r = 0.81 (partial correlation coefficient) and was not statistically different than the correlation 
coefficient when not corrected for insulitis (p=0.18).
Figure 3. Bland-Altman plot of insulitis score.
Figure 4. Presence of insulitis in BBDP rats.Insulitis was scored histologically on slides stained with H&E 
of BBDP rats (n=45) of various ages. Insulitis was observed as soon as 7 weeks of age.
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High accumulation of [111In]In-DTPA-exendin was observed in the islets of Langerhans in the 
autoradiographic images of rats with high beta cell mass (Figure 5A). Very low accumulation 
was observed in the exocrine pancreas, and the accumulation of [111In]In-DTPA-exendin 
colocalized with insulin expression (Figure 5D). The [111In]In-DTPA-exendin uptake decreased 
with declining amounts of beta cells (Figure 5B) and was not detectable in slides without any 
beta cells (Figure 5C), which was in line with the decline in insulin positive cells visualized by 
histology (Figure 5E and F). Furthermore, beta cell identity was verifi ed by Nkx6.1 staining 
(Figure 6).
BCM 0,60% BCM 0,20% BCM 0,00%
Figure 5. Autoradiography and immunohistochemical staining of pancreatic slides. High accumulation of 
[111In]In-DTPA-exendin was observed in rats with high BCM (A) where abundant staining for insulin was 
present (D). In rats with reduced beta cell content (E), lower accumulation of [111In]In-DTPA-exendin was 
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Figure 6. Histological analysis of beta cell identity. Pancreatic sections of a rat with normal (A-D), 
intermediate (E-H) or no beta cell mass (I-L) were stained for insulin (red), glucagon (green) and an 
additional marker for beta cells Nkx6.1 (purple). The sections were counterstained with DAPI. The images 
clearly show co-staining of insulin with Nkx6.1 indicating that a low beta cell mass is not caused by insulin 
depletion rather than beta cell destruction.
SPECT
SPECT images of rats with a high beta cell mass showed a clear [111In]In-DTPA-exendin 
accumulation in the pancreas (Figure 7A, beta cell fraction 0.6%). Besides [111In]In-DTPA-
exendin accumulation in the pancreas, a high signal was observed in the kidney. The signal in 
the pancreas decreased in rats with declining beta cell mass (Figure 7B and C). The pancreatic 
uptake of [111In]In-DTPA-exendin, determined by quantitative analysis of the SPECT images, 
correlated linearly with the [111In]In-DTPA-exendin accumulation as determined by ex vivo 
counting (Figure 8, Pearson r = 0.64, p<0.0001). The pancreatic uptake of [111In]In-DTPA-exendin 
determined by SPECT analysis showed a linear correlation with the beta cell fraction (Pearson 
r = 0.50, p = 0.0006).
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Figure 7. SPECT images of BBDP rats. Coronal images of BBDP rats with normal beta cell mass (A, 
0.23%), intermediate (B, 0.13%) and low beta cell mass (C, 0.03%). Pancreatic uptake of [111In]In-DTPA-
exendin (indicated with a red arrow) is clearly visible in healthy rats (A) and decreases with declining BCM. 
Besides pancreatic accumulation, uptake was observed in kidney (K) and lung (L).
Figure 8. Correlation between pancreatic signal measured by ex vivo counting and quantitative analysis of 
the SPECT images (Pearson r = 0.64, p<0.0001). Due to the low signal in rats with a low beta cell mass the 
SPECT based quantifi cation is challenging in these animals, as large variation is seen in these animals.
548546-L-bw-Joosten
Processed on: 22-9-2020 PDF page: 180
BETA CELL MASS DETERMINATION IN BBDP RATS
180
DISCUSSION
In this study we validated [111In]In-DTPA-exendin as a method to determine the beta cell mass 
noninvasively in BBDP rats, a model for spontaneous type 1 diabetes. We demonstrated a 
strong correlation between pancreatic [111In]In-DTPA-exendin accumulation, as determined by 
ex vivo counting, and the beta cell mass in this T1D rat model. Moreover, autoradiography 
revealed that the accumulation is restricted to the islets with very low signal in the exocrine 
pancreas. Importantly, the signal from the islets completely disappeared when no beta cells 
were present, while alpha cells could still be observed histologically. These observations 
indicate high specificity of [111In]In-DTPA-exendin for beta cells and are in line with our previous 
studies in a rat model for chemically induced beta cell loss, where a strong correlation between 
pancreatic exendin accumulation and BCM, but not alpha cell mass, was found4, 7. 
The expression of the GLP-1R in the presence of an immune response remains a matter 
of debate. Previous studies showed a decrease in GLP-1R expression in islets treated with 
cytokines in vitro 5 or after partial duct ligation in vivo 6. Our data clearly demonstrate that 
in the presence of insulitis also there is a strong linear correlation between the pancreatic 
uptake of the tracer and the BCM, comparable with the correlation found in chemically induced 
diabetes without insulitis (Pearson r = 0.89 uncorrected vs. Pearson r = 0.81 corrected for 
insulitis, p=0.18). This non-significant difference indicates that insulitis has no relevant effect 
on the correlation between these parameters. The use of the sophisticated rat model for T1D, 
representing a complete biological system, should reflect the complex pathophysiological 
processes better than a rather crude in vitro model of cytokine treated beta cells. It should be 
noted that in humans insulitis is described by the infiltration of 3 or more islets with more than 
15 leukocytes10, which is a much milder inflammatory process than the massive infiltration of 
the islets in rat and mouse models. It is therefore expected that the effect of insulitis on the 
accumulation of radiolabeled exendin is of even less importance in humans.
Also, changes in GLP-1R expression during hyperglycemia were observed in previous studies. 
It should be noted that the marked decrease in GLP-1R expression after near complete 
pancreatectomy was observed after 4 weeks of hyperglycemia 6. Similar results were observed 
by glucose infusion experiments, where hyperglycemia was present for 4 days. In our study, 
the blood glucose levels were controlled by insulin treatment and a strong correlation between 
radiotracer accumulation and the BCM was observed. Although the rats were treated with 
insulin, fluctuations in blood glucose were observed (Figure 1), closely mimicking the clinical 
situation. The strong correlation between 111In-exendin accumulation and BCM suggests 
a negligible effect of fluctuating glycemic levels in T1D on radiotracer uptake. However, the 
effects of long term hyperglycemia on the GLP-1R expression and radiolabeled exendin 
accumulation could not be elucidated in this model.
Besides promising results with radiolabeled and fluorescent exendin analogs for the 
measurement of the beta cell mass, other radiotracers have been evaluated in animal models 
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and clinical trials. The fi rst tracer that was evaluated for targeting of the beta cells was DTBZ 
(which targets VMAT2). Studies in BBDP rats, a spontaneous model for T1D, showed a decrease 
of 65% in pancreatic standardized uptake value (SUV) of [11C]C-DTBZ in severely diabetic rats11, 
12. Similar results were obtained with the same radiotracer in streptozotocin induced beta cell 
loss in Lewis rats: reduced specifi c binding index (pancreas-to-kidney ratio) in diabetic rats 
with a variation in degree of reduction between rats12. Clinical evaluation of [18F]FP-(+)-DTBZ 
revealed  a reduction of 38% in SUV and 40% in binding potential between healthy subjects 
and subjects with longstanding type 1 diabetes (>9 years)13. Moreover, a linear correlation 
between arginine stimulated c-peptide and DTBZ binding parameters was observed. A more 
recent publication  showed VMAT2 expression on pp cells and cells of the nervous system 
in the exocrine part of the pancreas14, which should be taken into account in evaluating the 
imaging studies using DTBZ. Recently, Eriksson et al. showed that accumulation of the 
serotonin receptor tracer [11C]5-HTP is reduced by 66% in the pancreas of C-peptide negative 
T1D subjects as compared to healthy volunteers implying that this tracer could also be a useful 
non-invasive marker to determine the total mass of endocrine cells in the pancreas15. Since 
the serotonin receptor is expressed in all endocrine cells, a combination of [11C]5-HTP imaging 
of serotonin activity and [111In]In-DTPA-exendin imaging could provide useful complementary 
information about the beta cell and total endocrine mass as well as changes in endocrine cell 
conformation during the development of diabetes.
Previous studies suggest GLP-1R expression in other endocrine and exocrine cells of the 
pancreas 16-19. In the BBDP rat model the accumulation of [111In]In-DTPA-exendin appears to be 
restricted to beta cells, based on the observation that no signal is observed in autoradiographic 
images of rats without any beta cells while alpha cells were still present. These observations 
are in line with our previous fi ndings of a lack of correlation between alpha cell mass and 111In-
exendin accumulation in the pancreas7. 
The pancreatic uptake measured by quantitative analysis of the SPECT images showed a linear 
correlation with the pancreatic uptake as measured by ex vivo counting of the activity in the 
pancreata. The relatively high background activity in the SPECT images represents a challenge 
for accurate quantifi cation of [111In]In-DTPA-exendin in the pancreas of rats with a low beta cell 
mass, reducing the correlation coeffi cient. This phenomenon is of less importance in clinical 
SPECT or PET imaging, since the background in these images is low and the distance between 
the pancreas and the kidneys is larger.
The results of this study clearly indicate that radiolabeled exendin imaging represents a reliable 
technology for the noninvasive determination of the BCM in type 1 diabetes, and the potential of 
this method should clearly be exploited to study the changes in BCM in clinical studies.
In conclusion, the strong correlation between pancreatic accumulation of [111In]In-DTPA-
exendin and the BCM observed in BBDP rats is independent of insulitis and fl uctuations in 
blood glucose levels, suggesting that this non-invasive imaging method holds great promise 
for clinical determination of BCM in individuals with T1D.
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BETA CELLS ARE THE GUARDS OF GLUCOSE BALANCE
Beta cells play a crucial role in the development of diabetes. However, during many years 
of research the cause of the disease has not yet fully been elucidated. Several possible 
mechanisms have been proposed that could be involved in its etiology: genetic predisposition 
(for instance certain variation in HLA genes)1, infl ammation, metabolism, viruses, diet, and 
environmental factors. Together these factors contribute to the development of diabetes, a 
very complicated disease. During the course of the disease, beta cells lose their capacity to 
produce insulin, and fi nally induced cell death occurs, leading to a reduced beta cell mass. For 
many years, it was believed that there was total depletion of beta cells in patients suffering 
from longstanding type 1 diabetes. However, several studies have found evidence of residual 
insulin-positive beta cells in these patients2, 3. In fact, new insights into the survival of beta cells 
in longstanding T1D patients2 and proliferating beta cells in recent-onset T1D patients4 have 
opened a window of opportunities for possible treatments to re-activate beta cells, to stimulate 
proliferation of beta cells, or to stimulate differentiation of beta cells from other cells.
A non-invasive method to determine the beta cell mass in a living organism could aid in 
unraveling the pathophysiology of beta cell loss, diabetes development, and monitoring the 
effect of new therapies. Current data on beta cells is being obtained via either functional tests 
(c-peptide, oral glucose tolerance test) or post-mortem studies (based on insulin staining), 
providing information about beta cell function or beta cell mass, respectively. Up to now very 
little data is available about the dynamics of beta cell mass during the progression of diabetes.
A few years ago, our group has shown the potential of [111In]In-DTPA-exendin-3 to non-invasively 
monitor the beta cell mass in a chemically-induced model for diabetes. Furthermore, our 
group showed that the uptake of radiolabeled exendin directly correlated with the beta cell 
mass. In addition, we have shown that the uptake of exendin was lower in patients with T1D 
than in healthy subjects5. Besides, many studies with radiolabeled exendin have been pursued 
to detect beta cell-derived tumors (insulinomas), with great successes6.
In this thesis we have explored the feasibility of two additional beta cell markers for imaging 
beta cells: maxadilan and GIP. In addition, we have modifi ed exendin to enhance its molar 
activity and to overcome the high kidney uptake. Furthermore, we have defi ned an optimal 
rodent model to determine the beta cell mass, and fi nally, the feasibility of exendin as a non-
invasive beta cell marker was investigated in two rodent models for type 1 diabetes.
EXENDIN BEATS MAXADILAN AND GIP
The involvement of beta cell-related incretin receptors in the maintenance of the blood glucose 
levels makes them interesting targets for imaging beta cells. In this thesis we have shown 
that targeting the GIP receptor using radiolabeled GIP resulted in specifi c uptake in GIPR 
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expressing tumors. Similarly, PAC1 receptor targeting using radiolabeled maxadilan showed 
specific uptake in PAC1 receptor expressing INS-1 tumors. Therefore, both tracers seem to be 
suitable ligands for visualizing beta cell-derived tumors. 
Radiolabeled exendin showed specific uptake in INS-1 tumors, which was almost four times 
higher than the uptake of maxadilan. Yet, we cannot make a fair judgement which tracer would 
perform best in detecting insulinomas. We have used a different tumor model for GIP, a model 
with artificial expression levels of the receptor, since the GIPR expression in our insulinoma 
model is very low. In human insulinomas, the incidence of the GLP-1R expression is more than 
92%7. Interestingly, Wild et al reported that malignant insulinomas often lack the GLP-1R, 
whereas benign insulinomas do express the GLP-1R8. To date, there are no studies describing 
the expression of the PAC1 receptor in human insulinomas. They only show VPAC1 receptors in 
more than 95% of the cases, but no VPAC2 receptor expression7. Remarkably, a study of Waser 
and colleagues revealed that 100% of insulinomas were GIPR positive, whereas only 50% of 
insulinomas where positive for SST receptors9. While the latter is currently the most widely 
used molecular imaging technique for the detection of insulinomas and other NETs.
How about imaging (native) pancreatic beta cells using either radiolabeled maxadilan, GIP or 
exendin? For radiolabeled maxadilan we have found specific uptake in the pancreas in mice. 
Although we did observe specific uptake of radiolabeled GIP in isolated human islets, we did 
not demonstrate specific uptake in mouse pancreas in our biodistribution study. Furthermore, 
with radiolabeled maxadilan and GIP we were not able to visualize the mouse pancreas with 
SPECT in vivo. Regarding imaging insulinomas, in our tumor models virtually all cells have 
receptor expression, which leads to a high concentration of the tracer in the tumor. On the 
contrary, in the pancreas there are less receptor-expressing cells, they are spread throughout 
the tissue and therefore the concentration of the tracer is lower. In contrast to maxadilan 
and GIP, it was possible to visualize the pancreatic beta cells using radiolabeled exendin and 
SPECT in rodents, which is supported by the higher uptake in the pancreas (3 times and 65 
times higher for exendin compared with maxadilan and GIP, respectively). The differences in 
the performance of these ligands may reflect a difference in receptor expression in the islets 
and/or in the exocrine tissue, receptor affinity, internalisation rate, or stability of the peptide. 
Based on these findings, exendin would be the first tracer of choice for imaging beta cell 
related diseases, as it shows high and specific uptake in both insulinomas and in pancreatic 
beta cells, which could both be visualized using SPECT.
EXENDIN IS THE CRÈME DE LA CRÈME
 
In addition to the beta cell targets investigated in this thesis, many other receptors have been 
studied for imaging insulinomas and islets of Langerhans (Figure 1). A tracer that is currently 
being studied for this application is the serotonin precursor, 5-hydroxytryptophan (5-HTP). 
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Figure 1. An overview of the most promising targets for beta cell imaging discussed in this chapter. 
Abbreviations: GIP, glucose-dependent insulinotropic polypeptide; LAT, L-type amino acid transporter; 
5-HTP, 5-hydroxytryptophan; PAC1, pituitary adenylate cyclase-activating polypeptide type I; max, 
maxadilan; VMAT2, vesicular monoamine transporter 2; DTBZ, dihydrotetrabenazine; SST, somatostatin; 
oct, octreotide; GLP-1, glucagon-like peptide 1; ex, exendin.
5-HTP is taken up by both pancreatic endocrine and exocrine cells, but it is only processed to 
serotonin and subsequently trapped in vesicles in the endocrine cells. Therefore, it leads to a 
higher accumulation in endocrine cells than in exocrine cells and it is a potential tracer for 
islet imaging. However, contradicting results have been reported using radiolabeled 5-HTP as 
a marker for endocrine cells. Di Gialleonardo et al. questioned the feasibility of [11C]5-HTP to 
image islets, because of the low target-to-background ratio10. In contrast, Eriksson et al. showed 
that uptake of [11C]5-HTP in isolated human islets correlated with islet purity. Furthermore, 
they showed a reduced uptake of [11C]5-HTP in diabetic rats compared to healthy rats, 
demonstrating the potential of this tracer for noninvasive imaging of the endocrine pancreas11. 
After [11C]5-HTP was used in various clinical studies for diagnosis of neuroendocrine tumors12, 
it was more recently also introduced as an imaging biomarker for the islets of Langerhans in 
the pancreas. In a prospective study, Eriksson et al. demonstrated reduced uptake of [11C]5-
HTP in the pancreas of T1D patients compared to healthy volunteers. Pancreatic uptake of 
radiolabeled 5-HTP showed overlap between diabetic patients and healthy volunteers, and 
showed large variation within these groups. However, the use of the tracer is not only restricted 
to beta cells, since alpha cells have also been described to take up 5-HTP 13. It is therefore a 
tracer for total endocrine mass14, 15.
Another tracer is based on vesicular monoamine transporter 2 (VMAT2), which is responsible 
for transporting monoamines (especially neurotransmitters, such as dopamine, histamine and 
serotonin) from the cytoplasm into synaptic vesicles and is expressed within chromaffi n cells, 
neuron cells and endocrine cells16, 17. The use of the VMAT2 antagonist dihydrotetrabenazine 
(DTBZ) has been extensively studied, with variable results. Several studies, in spontaneous rat 
models for type 1 diabetes as well as in streptozotocin-induced diabetes, reported a reduced 
pancreatic uptake of [11C]DTBZ, which was related to progression of diabetes18-20. However, 
the attribution of beta cell related uptake was estimated to be ~25%, as there was signifi cant 
specifi c and nonspecifi c binding of DTBZ to other pancreatic cells21. On the contrary, Eriksson 
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et al. showed no difference in 18F-labeled DTBZ uptake between diabetic and healthy pigs, 
as uptake in the islets did not exceed the uptake in exocrine tissue20. This was confirmed by 
Fagerholm and colleagues, who reported the same findings in rat and human pancreata22. 
Because of these contradictory results, a study was conducted in different species. VMAT2 
expression was identified in islets of pig and human islets, but not in rat and mouse islets, 
indicating that DTBZ may be suitable for beta cell mass measurements in the clinic23. While 
preclinical studies on the applicability of radiolabeled DTBZ as a tracer for measuring the beta 
cell mass revealed contradictory results, clinical studies have been performed using this tracer. 
Goland et al. investigated the feasibility of [11C]DTBZ quantification in pancreata of individuals 
with T1D and healthy controls by dynamic scanning and found a decreased uptake of [11C]
DTBZ in T1D patients. However, the functional binding capacity was decreased by a maximum 
of 40% in patients with longstanding T1D, who almost completely lost the BCM (determined 
by postmortem analysis), indicating substantial nonspecific VMAT2 uptake in the pancreas24. 
Similarly, 18F-labeled DTBZ showed a reduced uptake in (long-term) T1D patients, compared 
to healthy individuals25, 26. Tracer uptake correlated with stimulated c-peptide levels and a 
high overlap between insulin and VMAT2 expression was found in human pancreata27. Despite 
encouraging results, the relevance of VMAT2 as an imaging marker for beta cell mass remains 
a matter of debate, because nonspecific uptake of DTBZ in the exocrine pancreas could limit 
the ability of the tracer to measure small changes in beta cell mass and expression of VMAT2 
is not present in all beta cells 23, 27. Furthermore, VMAT2 expression has been found in rodent 
pancreatic mast cells and nerve fibres23.
Currently, the most widely used tracers for the detection of insulinomas are based on 
somatostatin (SST) receptor targeting. Reubi et al. have shown that 50-70% of insulinomas 
express the SST2 receptor, and 60% express the SST1 receptor
7. In addition, Wild and colleagues 
showed that malignant insulinomas express the SST2 receptor more often than the GLP-1R 
and benign insulinomas express the GLP-1R more often than the SST2 receptor
8. Furthermore, 
following SST1 receptor targeting, a lower uptake in diabetic NOD mice pancreata was found 
compared with normal mice28. However, the expression of the five subtypes of SST receptors 
has extensively been studied on human pancreatic islets, which showed that there is great 
overlap of these subtypes in alpha, beta, and delta cells29.
After careful evaluation of the above mentioned ligands, the performance of exendin seems to 
best comply the requirements that are needed for an optimal tracer for imaging of beta cells 
in humans and rats. Exendin seems to exclusively target beta cells, and not other endocrine 
cells. Furthermore, the uptake of exendin in the exocrine tissue is negligible, since uptake of 
exendin in severely diabetic rats is corresponding to uptake after receptor blockade5. Moreover, 
exendin is able to visualize insulinomas as well as native beta cells in the pancreas. Yet, using 
radiolabeled exendin has some drawbacks that we would like to tackle.
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DRESSED-UP EXENDIN LIKES TO PERFORM
High molar activity
A number of different factors make native beta cell imaging (compared to tumor imaging) 
very challenging. First, the beta cell mass represents only 1-2% of the total pancreas and 
the islets of Langerhans are scattered throughout the pancreas. Second, the targeting agent 
should be highly specifi c for the beta cells, since it is surrounded by other endocrine and 
exocrine cells. Third, the beta cells have lower expression levels of the GLP-1 receptor than 
tumor cells. As there are less receptors available for binding, these receptors can be more 
rapidly saturated upon binding of ligands. Thus, to prevent saturation of the beta cell specifi c 
receptors, only low doses of exendin can be applied and a high molar activity is required. 
Therefore, we aimed to increase the molar activity of exendin by adding multiple chelators to 
incorporate more radioactive molecules per exendin molecule. This has resulted in a massive 
increase in absolute uptake of radiolabeled exendin in the pancreas of Brown Norway rats and 
a better visualization of the pancreas using SPECT. Whether this new exendin-based tracer is 
able to improve the sensitivity of detecting small changes in beta cell mass requires further 
examination. The methods that have been used so far for increasing the molar activity are 
mainly based on optimizing labeling conditions30, 31. Furthermore, simple purifi cation methods 
have been described, which separate the unlabeled from the labeled compound before in vivo 
use to prevent receptor saturation by the unlabeled compound32. On par with this and our study 
are the fi ndings of Keller et al.33 They showed that an increased molar activity enabled them 
to administer a lower [18F]F-DPA dose in vivo. In their study this resulted in a higher tracer 
binding and retention in the respective organ. In addition, a higher molar dose could allow 
administration of a reduced peptide dose to patients, thereby preventing pharmacological side-
effects.
High kidney uptake
The biggest drawback of radiolabeled exendin and many other small molecules as imaging 
agents, is the clearance and subsequent reabsorption in the kidneys. Since the kidneys and 
pancreas are located in close proximity to each other in mice and rats, the high kidney uptake 
may impair visualization of the pancreas, especially in diabetic animals were the amount of 
beta cells is very low. When it comes to imaging diabetes in human, the spill-over signal of 
the kidneys can lead to an overestimation of the signal in the pancreatic tail. For insulinomas, 
several studies have shown that patients that do have an insulinoma could be diagnosed false 
negative at early time points after injection, because high uptake in the kidneys could mask the 
insulinoma in the pancreatic tail in these patients.
Furthermore, if one would like to translate exendin from a diagnostic to a therapeutic agent to 
treat patients with for example metastasized insulinomas, high renal uptake is a dose limiting 
factor.
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To tackle the problem of high renal uptake, we have modified exendin by incorporating a 
cleavable linker, namely methionine-isoleucine, between the chelator and the peptide, 
resulting in NOTA-MI-exendin. Normally, when exendin is cleared from the blood and enters 
the kidneys, reabsorption in the proximal tubuli causes accumulation of exendin in the kidneys. 
However, NOTA-MI-exendin showed a massive reduction in renal retention compared to 
NOTA-exendin, presumably as a consequence of enzymatic cleavage of the linker at the brush 
border membrane in the kidneys34. Very recently, a similar study was carried out, but with a 
different linker. Introducing a Met-Val-Lys linker to NOTA-exendin resulted in an even faster 
renal clearance than our compound, NOTA-MI-exendin. Worth noting is that overall, NOTA-
Cys40-Leu14-exendin-4 already had a much lower kidney uptake than NOTA-exendin34. Another 
approach is based on introducing an albumin-binding motif (ABM) to exendin. Upon binding 
to albumin in blood, the circulation time of the radiotracer will be prolonged. Consequently, 
the ligand has an increased chance of binding the target receptor and the binding to albumin 
presumably leads to an altered route of clearance. Kaeppeli and colleagues have used this 
strategy to successfully reduce kidney accumulation35.
To the best of our knowledge, there is only one clinical study that addressed the high kidney 
uptake of exendin. In healthy volunteers, succinylated gelatin (Gelofusine) reduced the kidney 
accumulation of [111In]In-exendin by approximately 18%. Furthermore, in 30% of the patients 
that received gelofusine, an improved distinction between the pancreatic tail and kidneys was 
observed, if compared to no Gelofusine administration36. To which extend a combination of 
Gelofusine, a cleavable linker exendin compound, or exendin with an albumin-binding motif 
would further improve the fast kidney clearance would be an interesting follow-up to these 
studies.
If we would be able to decrease the accumulation of radiolabeled exendin in the kidneys, this 
would open a window for exendin to serve as a therapeutic agent. Of course, additional studies 
are needed to determine the pharmacokinetics of this cleavable exendin labeled with a beta-
emitter like Lu-177, and to explore its therapeutic efficacy on insulinomas. Interestingly, one 
study describes [177Lu]Lu-DOTA-Ahx-Lys40-exendin-4 having specific pancreatic uptake and 
high kidney uptake in healthy Swiss mice37 (Guleria 2019), showing that it is feasible to use 
177Lu-labeled exendin for targeting GLP-1R expressing organs.
Taken together, a strategy to reduce renal uptake of exendin using a cleavable linker could be 
of interest for radionuclide therapy using exendin, but for other tracers as well. Actually, this 
may be the key to develop radiolabeled exendin from a diagnostic to a theranostic agent.
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TRANSLATABILITY FROM ANIMAL TO HUMAN (FROM HIGH 
CUDDLINESS TO HIGH IMPACT)
Are animal studies a reliable predictive surrogate for human studies? Although some animal 
models are very well-defi ned, the metabolism, receptor expression and disease progression 
can greatly vary between species. Critical evaluation of data obtained in animal studies are 
needed in order to be able to translate them to human application. We have seen that rats 
seem to be a more suitable model for beta cell imaging than mice, because there is exendin 
uptake in the exocrine tissue as well. With these exendin results in rodents, the importance of 
a reliable model has been underlined. Also, for other compounds that have been used for beta 
cell targeting, large variations between different species have been described. As described 
previously, VMAT2 expression has been found in human and pig islets, but not in rat and mouse 
islets23.
In addition, also the translation of results obtained in subcutaneous tumor models should be 
evaluated carefully. Often tumor models with artifi cially high receptor expression are used, 
which do not always adequately refl ect the situation in humans. Furthermore, the tumor 
location, tumor vasculature, tumor stroma and (lack of) infi ltration of immune cells can 
infl uence the uptake of the tracer. However, these models can still give a good indication when 
comparing different tracers.
Stress conditions
In addition to reliably measure the beta cell mass in an appropriate animal model, metabolism 
plays a crucial role. Changes in the metabolism should not interfere with the expression of 
the target receptor in order to reliably measure the beta cell mass. Hyperglycemia, which is a 
consequence of the inability of the beta cells to produce enough insulin, is the hallmark of type 
1 and type 2 diabetes. In previous studies, it has been demonstrated that the GLP-1R expression 
was down-regulated during chronic hyperglycemia38, 39. Furthermore, near-normalization of 
blood glucose levels in patients with type 2 diabetes improved the beta cell sensitivity to GLP-1. 
These studies indicate that elevated blood glucose levels could infl uence the expression of the 
GLP-1R and subsequent quantifi cation of the beta cell mass and imply that close to normal 
blood glucose levels are needed to reliably measure the beta cell mass40, 41.
Besides hyperglycemia, also the secretion of certain cytokines has been described to alter 
GLP-1R expression. Cytokines are released by activated macrophages and T-cells during 
insulitis, which is known as infl ammation of the beta cells. The prevalence and appearance of 
insulitis in patients with type 1 diabetes and in non-diabetic patients positive for autoantibodies 
is very heterogeneous42. It is important to determine whether (chronic) hyperglycemia and 
insulitis hamper a reliable beta cell mass quantifi cation using exendin. Our data indicate that 
severe insulitis and hyperglycemia do not seem to infl uence the uptake of exendin in preclinical 
models. Therefore, it is not likely that it infl uences the determination of the beta cell mass. 
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Insulitis is less severe in humans than in mice, albeit clinical studies are needed to confirm 
these findings.
A BRIGHT FUTURE FOR EXENDIN
I believe the use of exendin as a tracer is still in its infancy. The use of exendin in detecting 
NETs, together with octreotide analogs is becoming a clinical routine in some hospitals. Yet, 
the role of exendin in diabetes imaging is still not (fully) investigated. In this thesis we have 
demonstrated the feasibility of exendin to determine the beta cell mass in rodent models for 
type 1 diabetes, with negligible influence of hyperglycemia and insulitis. A possible next step 
could be a similar study in an animal model for type 2 diabetes, as the underlying mechanisms 
for the development of both types differ. Subsequently, it would be of interest to study the beta 
cell mass in larger patient populations suffering from either type 1 or type 2 diabetes, and 
relate this to beta cell function. Actually, in a previous study we have shown that there is still 
exendin uptake in the pancreas of individuals with longstanding type 1 diabetes that have no 
measurable C-peptide5. In this regard, it would be of great interest to find out whether we are 
detecting non-functional beta cells in these individuals, because this would allow personalized 
treatment. Stratification of patients, depending on the presence and/or the level of functional 
beta cells, could aid in choosing the most suitable treatment. For example, patients that still 
have non-functional beta cells, could possibly benefit from therapies aiming at restoration of 
beta cell function, rather than regeneration of beta cell mass.
Another approach of radiolabeled exendin is visualization of transplanted islets with SPECT. 
It has been shown that the accumulation of radiolabeled exendin correlated linearly with 
transplant size43. Therefore, it may qualify to monitor (intrahepatic) islet transplantation in 
human44, as exendin shows specific uptake in the beta cells in the islets of Langerhans and 
has low liver uptake. Transplantation of human donor islets of Langerhans into the liver is one 
of the explorative treatments that are studied nowadays to restore the insulin production in 
patients with type 1 diabetes45. Visualizing transplanted islets would aid in understanding the 
spread and survival of these transplants and could give insight into the effectiveness of new 
therapies aiming at improving intrahepatic islet survival and function.
In this thesis, we have also shown that we are able to reduce the kidney uptake of radiolabeled 
exendin, which evokes two major questions. First, does the reduced kidney uptake lead to a 
higher sensitivity in detecting insulinomas, especially the lesions in the vicinity of the kidneys? 
Second and even more exciting, peptide receptor radionuclide therapy with exendin could now 
be within reach. Do patients with unresectable or multiple lesions possibly benefit from this 
new treatment? Both questions need to be further investigated in (pre)clinical studies. So, the 
road map for exendin (as a theranostic) is yet to be explored.
548546-L-bw-Joosten




Finding the most appropriate tracer for beta cell imaging does not necessarily have to be a 
competition. There is a higher chance on success when working together, and that should be 
the aim of any research. Using different tracers subsequentially would presumably narrow 
the area of undetected insulinomas. Furthermore, combining a tracer that detects functional 
beta cells with a tracer that detects non-functional beta cells, could possibly allow patient 
stratifi cation, and as such, could offer a personalized treatment.
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Diabetes is one of the leading causes of death worldwide, according to the WHO. Type 1 diabetes 
develops as a result of an autoimmune attack directed towards the insulin-producing beta 
cells. Type 2 diabetes is characterized by an ineffective use of insulin by the peripheral organs. 
Little is known about beta cell dynamics during the onset and progression of diabetes. A non-
invasive imaging method would allow monitoring of the beta cell mass longitudinally and could 
identify changes in the beta cell mass during development of diabetes. Subsequently, it could 
provide information to individualize diabetes treatment. The ideal tracer should meet certain 
prerequisites to qualify as a suitable tracer for beta cell imaging, for example, specifi c uptake 
in the beta cells and not in non-target cells, high target affi nity, and fast blood clearance. In 
the recent years, several tracers for beta cell imaging have been proposed and some have 
been tested in clinical trials. Yet, none of these tracers has been implemented for routinely 
visualizing beta cells in diabetic patients. 
Preferably, the tracer should also be able to visualize insulinomas, tumors in the pancreas 
derived from insulin-producing beta cells. Currently, the most widely used imaging method to 
diagnose insulinomas is based on somatostatin receptor targeting using radiolabeled octreotide 
visualized by PET or SPECT. However, it has been shown that only part of insulinomas express 
the somatostatin receptor, and it is not a suitable tracer to image beta cell mass. Therefore, the 
search for new agents that are able to image beta-cell related diseases is ongoing. Currently, 
the glucagon-like peptide 1 receptor (GLP-1R) targeting peptide exendin is the most promising 
tracer for imaging beta cells. Peptides, targeting specifi c receptors on beta cells, best comply 
the requirements for a suitable tracer. Hence, the search for new beta cell imaging agents, as 
described in the next studies, have been focused on peptides.
THE SEARCH FOR NEW TRACERS FOR BETA CELL IMAGING
Insulinomas have high expression of the pituitary adenylate cyclase-activating polypeptide 
type I (PAC1) receptor and the glucose-dependent insulinotropic polypeptide receptor 
(GIPR). In chapter 3 we have investigated the feasibility of radiolabeled maxadilan, a PAC1 
receptor targeting agent, to detect insulinomas by SPECT imaging in a mouse model with 
subcutaneous insulinomas (INS-1 tumors). Maxadilan-DTPA-[111In]In accumulated specifi cally 
in INS-1 tumors and in the pancreas. Furthermore, we were able to clearly visualize INS-1 
tumors using SPECT/CT. Next, another promising tracer has been investigated as a beta cell 
imaging agent. Chapter 4 describes the characterization of 111In-labeled GIP for visualizing 
neuroendocrine tumors. [111In]In-DTPA-GIP1-42 showed receptor-mediated binding to BHK-
GIPR positive cells, NES2Y cells (human beta cell-like insulin secreting cell line) and isolated 
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islets in vitro. Furthermore, the in vivo studies showed that GIP receptor transfected tumors 
and NES2Y tumors could be visualized with SPECT/CT using [111In[In]-DTPA-GIP1-42 as a tracer.
Exendin has been shown to specifically target the GLP-1R on beta cells in the pancreas and is 
able to visualize GLP-1R expressing insulinomas. Native beta cells, in contrast to tumor cells, 
display physiological levels of the receptor and are spread throughout the pancreas. As there 
are less receptors available for binding, a low peptide dose should be administered to avoid 
receptor saturation. Hence, to be able to be detected, a high molar activity is needed in order 
to get a sufficient amount of radioactive signal in the beta cells. This issue has been addressed 
in chapter 5, which focusses on the improvement of the molar activity of 111In-labeled exendin. 
In this study, exendin has been modified by addition of six lysine residues and by conjugation 
of one, two or six DTPA moieties to these lysine residues, resulting in five new compounds. 
Addition of multiple DTPA molecules increased the molar activity, and was most pronounced for 
hexendin(40-45), which has six DTPA moieties. As a result of the enhanced molar activity, the 
absolute pancreatic uptake of hexendin(40-45) in Brown Norway rats increased considerably, 
enabling an improved visualization of the pancreas with SPECT/CT.
Chapter 6 is devoted to one of the main challenges when using radiolabeled exendin in vivo. 
Radiolabeled exendin accumulates at high concentrations in the kidneys, which could hamper 
the detection of small insulinomas in the vicinity of the kidneys. Reduction of the accumulation 
in the kidney would greatly improve the visualization of insulinomas. In this study, exendin-4 
was extended with a Met-Ile-linker and subsequently conjugated with NOTA. Biodistribution 
studies in BALB/c nude mice bearing a subcutaneous INS-1 tumor showed stable tumor 
uptake over time for [68Ga]Ga-NOTA-MI-exendin-4 and the INS-1 tumor was clearly visualized 
using SPECT/CT. Most importantly, kidney uptake was significantly lower for this extended 
exendin analog compared to [68Ga]Ga-NOTA-exendin-4.
BETA CELL IMAGING APPLIED IN RODENT MODELS
To validate the clinical potential of radiolabeled exendin as a native beta cell imaging agent, 
we first determined the most suitable animal model for non-invasive determination of the beta 
cell mass using [111In]In-DTPA-exendin-3 (chapter 7). The most important finding of this study 
was that rats seem to represent a more adequate model for beta cell mass assessment than 
mice. In rats, the uptake of exendin after alloxan treatment was similar to the uptake after 
a blocking dose, whereas in mice there was a considerable amount of exendin uptake after 
alloxan treatment. These results indicate that there was exendin uptake in the exocrine tissue 
as well. Considering the fact that exocrine GLP-1R expression measured on mRNA and protein 
level was very low, it is likely that [111In]In-DTPA-exendin-3 binds to a binding site, other than 
the GLP-1R, in exocrine mouse pancreas. Therefore, determination of the beta cell mass using 
radiolabeled exendin may be more specific for the beta cells in rats than in mice.
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Next, we have examined the use of [111In]In-DTPA-exendin-3 for determining the beta cell mass 
in two rodent models for spontaneous type 1 diabetes. In chapter 8 nonobese diabetic (NOD) 
mice were monitored until 21 weeks of age by measuring blood glucose and performing SPECT/
CT after injection of [111In]In-DTPA-exendin-3. A linear correlation was found between the beta 
cell mass in these mice and the uptake of exendin in the pancreas, which was not affected 
by either insulitis or hyperglycemia. However, there was remaining [111In]In-DTPA-exendin-3 
uptake in the pancreas, despite total ablation of the beta cells, rendering this a suboptimal 
animal model for exendin imaging as mentioned above. A more favorable correlation between 
exendin uptake and the beta cell mass was found in BioBreeding Diabetes Prone rats (Chapter 
9). Also, in this model we have shown that the correlation between radiolabeled exendin uptake 
and beta cell mass was independent of insulitis and fl uctuations in blood glucose levels. The 
results of this study clearly indicate that imaging with radiolabeled exendin represents a 
reliable and robust technology for non-invasive determination of the beta cell mass in type 1 
diabetes.
In chapter 10 the results of the studies described and the future perspectives of beta cell and 
insulinoma imaging are discussed.
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Diabetes is een chronische, metabole ziekte, waarbij het lichaam niet in staat is om de 
bloedglucose in goede balans te houden. De beta cellen, gelokaliseerd in de eilandjes van 
Langerhans in de pancreas zorgen voor deze balans door het produceren van insuline. Onder 
invloed van insuline wordt glucose in het bloed opgeslagen in onder andere spieren en de 
lever, waardoor de concentratie glucose daalt naar normale waarden. Type 1 diabetes ontstaat 
als gevolg van een auto-immuunreactie gericht tegen de beta cellen, waarbij deze cellen 
sterven. Type 2 diabetes kenmerkt zich door insuline-resistentie  van weefsels die normaliter 
wel gevoelig zijn voor insuline. Beide oorzaken leiden tot verhoogde bloedglucosewaarden 
(hyperglycemie). Er is weinig bekend over de hoeveelheid beta cellen (beta cel massa) tijdens het 
ontstaan en de ontwikkeling van diabetes. Momenteel wordt alleen de beta cel functie gemeten 
door het bepalen van bijvoorbeeld bloedglucosewaardes of glucose tolerantie. Vaak wordt de 
beta cel functie gezien als een maat van de beta cel massa, maar de beta cel massa en functie 
komen niet per defi nitie overeen. Wanneer de beta cel massa op een niet-invasieve manier 
gevisualiseerd kan worden, geeft dit de mogelijkheid om de beta cel massa langdurig te volgen 
en zo mogelijke veranderingen in de beta cel massa waar te nemen tijdens de ontwikkeling van 
diabetes. Om beta cellen te kunnen visualiseren is een merkstof (tracer) nodig die specifi ek 
bindt aan de beta cellen. De beta cellen zijn geclusterd in de eilandjes van Langerhans, welke 
verspreid liggen over de pancreas. Dit maakt het moeilijk om de beta cellen af te beelden. De 
ideale beta cel tracer moet aan bepaalde eisen voldoen. De tracer moet bijvoorbeeld I) specifi ek 
accumuleren in de beta cellen en niet in andere organen, II) hoge affi niteit hebben voor de 
receptor op de cellen waar de tracer specifi ek aan kan binden en III) snel uit het bloed worden 
geklaard. Er is een verscheidenheid aan beta cel tracers onderzocht, waarvan sommigen in 
klinische trials zijn getest. Toch is er tot op heden nog geen beta cel tracer die routinematig 
wordt gebruikt om de beta cel massa in mensen met diabetes te bepalen.
Naast het in beeld brengen van diabetes, zou het van toegevoegde waarde zijn als de tracer ook 
insulinomen kan detecteren. Insulinomen zijn tumoren in de pancreas, die zijn ontstaan door 
ongeremde groei van de insuline-producerende beta cellen. De meest gebruikte nucleaire 
methode voor het visualiseren van insulinomen is gebaseerd op somatostatine receptor 
targeting met behulp van radioactief octreotide en PET of SPECT. Het is echter aangetoond 
dat niet alle insulinomen de somatostatine receptor tot expressie brengen, en octreotide is ook 
geen geschikte tracer voor het visualiseren van de beta cel massa, omdat octreotide ook bindt 
aan andere endocriene cellen. De vraag naar nieuwe tracers voor het zichtbaar maken van beta 
cel gerelateerde aandoeningen blijft dus bestaan. In dit proefschrift wordt de toepasbaarheid 
van nieuwe en geoptimaliseerde tracers voor het visualiseren van beta cellen en insulinomas 
en voor het bepalen van de beta cel massa onderzocht.
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DE ZOEKTOCHT NAAR NIEUWE TRACERS VOOR BETA CEL IMAGING
In deel 1 (H3 – H6) van dit proefschrift onderzoeken we nieuwe en geoptimaliseerde radioactieve 
tracers voor beta cel imaging. Insulinomen brengen de pituitary adenylate cyclase-activating 
polypeptide type I (PAC1) receptor en de glucose-dependent insulinotropic polypeptide receptor 
(GIPR) verhoogd tot expressie. In hoofdstuk 3 hebben we onderzocht of het PAC1 receptor 
bindende peptide maxadilan toepasbaar is voor het detecteren van insulinomen. In muizen met 
een subcutane insulinoom (INS-1 tumor) werd receptor gemedieerde tumor opname gezien na 
injectie van maxadilan-DTPA-[111In]In. Ook in de pancreas werd PAC1-gemedieerde opname van 
deze tracer waargenomen. Verder hebben we laten zien dat de INS-1 tumoren konden worden 
afgebeeld met SPECT/CT na injectie van maxadilan-DTPA-[111In]In. Hoofdstuk 4 beschrijft 
de karakterisatie van 111In-gelabeld GIP voor het visualiseren van neuroendocriene tumoren. 
[111In]In-DTPA-GIP1-42 liet receptor gemedieerde opname zien in BHK-GIPR positieve cellen, in 
NES2Y cellen (humane insuline-secreterende (beta)-cellijn) en in geïsoleerde eilandjes van 
Langerhans in vitro. Daarnaast toonden in vivo studies aan dat GIP getransfecteerde tumoren 
en NES2Y tumoren konden worden afgebeeld met SPECT/CT na injectie van [111In]In-DTPA-
GIP1-42. Deze resultaten tonen aan dat zowel maxadilan als GIP veelbelovende tracers zijn voor 
het afbeelden van neuroendocriene tumoren.
Momenteel is het peptide exendin de meest veelbelovende tracer voor het in beeld brengen van 
beta cellen. Eerdere studies hebben aangetoond dat exendin specifiek bindt aan de glucagon-
like peptide-1 receptor (GLP-1R), welke tot expressie komt op beta cellen in de pancreas en 
dat exendin gebruikt kan worden om GLP-1R expresserende tumoren in beeld te brengen. 
In tegenstelling tot tumorcellen, waar bepaalde receptoren/eiwitten tot overexpressie worden 
gebracht, hebben de beta cellen in de pancreas fysiologische expressie van de GLP-1R. Omdat 
deze niet-neoplastische beta cellen minder receptoren beschikbaar hebben waar gelabeld 
exendin aan kan binden (ten opzichte van tumoren), is er een lage peptide dosis nodig om 
verzadiging van de receptoren te voorkomen. Om deze cellen toch zichtbaar te kunnen maken, 
is het dus belangrijk om voldoende radioactiviteit toe te dienen. Dit kan door middel van het 
behalen van een hoge molaire activiteit (de hoeveelheid radioactiviteit per massaeenheid van 
de tracer). In hoofdstuk 5 richten we ons op een betere visualisatie van de pancreas door 
het verbeteren van de molaire activiteit van 111In-gelabeld exendin. In deze studie worden 
vijf nieuwe exendin verbindingen beschreven waarbij exendin werd gemodificeerd door het 
toevoegen van zes lysines (hexendin) en de conjugatie van één, twee of zes DTPA moleculen. 
In Brown Norway ratten hebben we de visualisatie van de pancreas met deze tracers met 
elkaar vergeleken. Het toevoegen van meerdere DTPA moleculen resulteerde in een verhoogde 
molaire activiteit, vooral voor hexendin(40-45), welke in totaal zes DTPA moleculen heeft. Als 
gevolg van de verhoogde molaire activiteit konden we een grotere hoeveelheid radioactiviteit 
in de beta cellen in de pancreas krijgen. Hierdoor zagen we een verbeterde visualisatie van de 
pancreas in Brown Norway ratten met SPECT/CT na injectie van 111In-gelabeld hexendin(40-45).
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Kleine hydrofi ele moleculen, zoals exendin, worden via de nieren uit het bloed geklaard. Een 
deel hiervan zal via de urine worden uitgescheiden, maar een signifi cant deel zal door middel 
van reabsorptie via bepaalde receptoren in de nieren blijven. Het exendin zelf wordt daar 
afgebroken, maar het radionuclide zal in de nieren blijven, wat leidt tot hoge concentraties 
radioactiviteit in de nieren. Dit kan de aanwezigheid van kleine insulinomen in de nabijheid van 
de nieren maskeren. Maar ook de beta cel massa bepaling met behulp van radioactief exendin 
kan bemoeilijkt worden, doordat de staart van de pancreas dichtbij de nieren ligt. Een reductie 
van de exendin opname in de nieren zou daarom de visualisatie van bepaalde insulinomen 
sterk kunnen verbeteren. In hoofdstuk 6 hebben we exendin-4 verlengd met een methionine-
isoleucine (Met-Ile) linker, waaraan NOTA is geconjugeerd. Bepaalde enzymen in de nieren 
zullen deze linker in het radioactieve exendin knippen, waardoor er twee delen ontstaan. Het 
exendin deel zal in de nieren worden opgenomen en daar worden afgebroken, terwijl het 
radioactieve deel niet zal worden gereabsorbeerd, maar via de urine worden uitgescheiden. 
Biodistributie studies in muizen met een subcutane INS-1 tumor lieten stabiele tumor opname 
van [68Ga]Ga-NOTA-MI-exendin-4 zien gedurende vier uur na injectie. Ook met behulp van 
SPECT/CT konden de INS-1 tumoren duidelijk zichtbaar worden afgebeeld. Het toevoegen van 
de Met-Ile linker tussen exendin en NOTA leidde tot 70 procent minder nier opname vergeleken 
met [68Ga]Ga-NOTA-exendin-4.
BETA CEL IMAGING IN DIERMODELLEN
Deel 2 van dit proefschrift richt zich op de validatie van radioactief exendin voor het niet-invasief 
bepalen van de beta cel massa in verschillende diermodellen. Om de klinische toepasbaarheid 
van radioactief exendin te onderzoeken, hebben we eerst gezocht naar de meest optimale 
diersoort voor het bepalen van de beta cel massa met behulp van [111In]In-DTPA-exendin-3 
(hoofdstuk 7). We hebben de opname en distributie van [111In]In-DTPA-exendin-3 in muizen en 
ratten pancreas bepaald door middel van biodistributie en autoradiografi e. Deze resultaten 
hebben we vervolgens vergeleken met de GLP-1R expressie op basis van immunohistochemie 
en qPCR. Met autoradiografi e zagen we hotspots in de pancreas (de eilandjes van Langerhans), 
die verdwenen na alloxaan geïnduceerde depletie van de beta cellen. In ratten ging de depletie 
van beta cellen gepaard met een 80% afname van radioactief exendin in de pancreas, in 
tegenstelling tot in muizen, waar we na het toedienen van alloxaan nog steeds een fl inke 
pancreas opname van exendin zagen. Deze resultaten impliceren dat er in muizen, naast 
opname in de beta cellen, er ook opname is in de exocriene pancreas. Aangezien er met 
immunohistochemie en qPCR geen expressie van de GLP-1R is aangetoond in de exocriene 
pancreas, is het aannemelijk dat [111In]In-DTPA-exendin-3 in muizen exocrien pancreasweefsel 
aan een andere receptor bindt dan de GLP-1R. Deze resultaten leiden tot de bevinding dat voor 
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het bepalen van de beta cel massa met behulp van exendin ratten een geschikter model zijn 
dan muizen.
Vervolgens hebben we het gebruik van [111In]In-DTPA-exendin-3 voor het bepalen van de 
beta cel massa onderzocht in twee type 1 diabetes diermodellen. Hoofdstuk 8 beschrijft 
het monitoren van nonobese diabetic (NOD) muizen. Type 1 diabetes ontwikkelt zich bij de 
NOD muizen als gevolg van een spontane auto-immuunreactie tegen de beta cellen, wat 
gekarakteriseerd wordt door hyperglycemie (verhoogde bloedglucose) en insulitis (ontsteking 
van de eilandjes van Langerhans). Bij deze muizen is gedurende een leeftijd van 21 weken 
wekelijks de bloedglucose bepaald en wekelijks een SPECT/CT uitgevoerd 1 uur na injectie van 
[111In]In-DTPA-exendin-3. In deze muizen is een lineaire correlatie gevonden tussen de beta 
cel massa en de opname van exendin in de pancreas. Insulitis en hyperglycemie leken geen 
invloed te hebben op deze correlatie. Terwijl we na immunohistochemische analyse geen beta 
cellen meer zagen in de pancreas, maten we wel nog opname van [111In]In-DTPA-exendin-3 in 
de pancreas. Deze bevindingen bevestigen dat muizen een suboptimaal model zijn voor het 
bepalen van de beta cel massa met exendin imaging.
Er is ook een ratten model waarbij type 1 diabetes spontaan ontwikkelt na een auto-
immuunreactie tegen de beta cellen. Diabetes wordt in deze BioBreeding Diabetes Prone 
(BBDP) ratten gekarakteriseerd door ernstige insulitis, waarna diabetes zich snel ontwikkelt. 
In hoofdstuk 9 staat beschreven hoe deze ratten zijn gemonitord tot een leeftijd van 18 
weken, waarbij wekelijks de bloedglucose werd gemeten, en wekelijks een SPECT/CT werd 
uitgevoerd 1 uur na injectie van [111In]In-DTPA-exendin-3. Door middel van autoradiografie 
zagen we specifieke accumulatie van radioactief exendin in de eilandjes van Langerhans. 
Wanneer we met autoradiografie geen signaal in de eilandjes zagen, kwam dit overeen met de 
immunohistochemische analyse, waar ook geen beta cellen werden aangetoond. We hebben 
een goede correlatie tussen de pancreas opname van radioactief exendin en de beta cel massa 
aangetoond. Ook in dit model hebben we laten zien dat deze correlatie niet werd beïnvloedt 
door insulitis en bloedglucose waarden. De resultaten van deze studie tonen aan dat imaging 
met radioactief exendin een veelbelovende methode is om niet-invasief de beta cel massa in 
type 1 diabetes te bepalen.
In hoofdstuk 10 worden de resultaten van de beschreven studies en het toekomstperspectief 
van beta cel en insulinoom imaging besproken.
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Hoi! Leuk dat je het dankwoord leest. Neem een kopje thee en ga er even voor zitten. Het is vrij 
lang namelijk, want ik heb het werk wat hier beschreven staat natuurlijk niet alleen gedaan. 
Zonder het enthousiasme, harde werk en goede input én output van vele anderen is het ee n 
compleet boekwerk geworden. Met zoveel samenwerkingen en zoveel collega’s waar ik mee 
heb mogen samenwerken, weet ik zeker dat ik personen ga vergeten te bedanken. Dus bij 
deze: voel je je ook maar enigszins aangesproken, dan wil ik je graag bedanken voor hetgeen 
jij voor mij hebt gedaan. Ik heb mezelf vast ingedekt. Mocht je je overigens niet aangesproken 
voelen, dan evengoed bedankt. We hebben vast een keer samen gelachen. Voor jullie allemaal 
een bloemetje!
Ten eerste wil ik mijn beide promotoren, Martin en Otto, bedanken voor de mogelijkheid om op 
deze wijze promotieonderzoek te doen. Naast mijn analistenfunctie en ook nog eens parttime 
hebben jullie het nodige geduld moeten hebben.
Lieve Otto, mijn woord van dank aan jou gaat heel ver terug. Door jouw enthousiaste rondleiding 
op het lab wilde ik niets liever dan mijn afstudeerstage bij jullie uitvoeren. Toen ik ook nog de 
mogelijkheid kreeg om na mijn studie als analist te mogen blijven hoefde ik daar niet over na 
te denken. Voor mijn gevoel heb jij de basis gelegd voor de open en goede sfeer die er op de 
afdeling heerst. Samenwerken met jou was heel fi jn, mede door je razendsnelle correcties, 
enthousiasme en positieve kijk op dingen. Ook al waren de resultaten niet altijd zoals verwacht, 
dan wist jij er toch iets positiefs uit te halen. Ik ben blij dat je, ondanks je vertrek naar een 
andere afdeling, toch mijn promotor wilt zijn. Dankjewel!
Lieve Martin, het is fi jn om met je samen te werken. Jouw grapjes en anekdotes over de meest 
uiteenlopende (soms vieze) onderwerpen zijn een welkome afwisseling met werk. Jouw ideeën 
voor nieuw onderzoek tijdens werkbesprekingen werken aanstekelijk. Meestal dan, ik heb 
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inmiddels geleerd om de ideeën die je hebt te filteren en heb me er ook bij neergelegd dat ik 
niet alles meteen hoef te begrijpen wanneer je hardop aan het brainstormen bent over waar 
exendin mogelijk nog meer voor ingezet kan worden. Jouw pad van logica kan ik dan niet altijd 
volgen, en laat me des te meer inzien dat dus ook niet iedereen mijn, voor mij zeer logische, 
denkwijze kan volgen. Ook jouw rake vragen: ‘Lieke, gaat het echt goed met je?’ waren af en 
toe nodig. Waar jij vaak met wilde ideeën kwam, wist Otto dit in kleinere stapjes te hakken om 
te weten waar te beginnen. Voor mij waren jullie een goede aanvulling op elkaar. Dankjewel!
Lieve Maarten, jij hebt me wegwijs gemaakt op zowel het nucleaire lab, het celkweeklab en 
het dierenlab en hebt me de fijne kneepjes van het vak geleerd. Wat ook wel nodig was, gezien 
ik vond dat de mannetjes muizen toch wel rare billen hadden… We hebben veel gelachen op 
het lab, met name onze kleurrijke josti-codering maakte de mega experimenten enigszins 
overzichtelijk en haalbaar. Je functioneerde tevens als mijn externe harde schijf, want ik moest 
dikwijls aan jou vragen welke experimenten ik alweer had gedaan en wat daar de uitkomst van 
was. Mede dankzij jou heb ik nu een mooie vervolgfunctie die bij me past. Ik vind het jammer 
dat we geen collega’s meer zijn, maar ik hoop dat we toch nog eens kunnen samenwerken. 
Dankjewel!
Lieve Sandra, we zijn beiden begonnen als student in het Aquarium op de Nucleaire en hebben 
een heel ander pad bewandeld. Je gaat als een trein, en je neemt onderweg heel veel personen 
mee in deze trein, om ze op een verder traject in hun carrière netjes af te zetten, met een koffer 
vol bruikbare bagage. Ik vraag me vaak af hoe je het toch allemaal doet. Ik vind het fijn dat je 
deel uitmaakt van mijn promotieteam en dat we nu samen een nieuw project aan gaan. Een 
project waar ik met veel plezier aan werk. Ik ga nog ontzettend veel van je leren de komende 
jaren. Je bent een voorbeeld voor velen. Dankjewel!
Lieve Peter, je verdient het om een apart stukje te krijgen in het dankwoord. In het verleden 
hebben we bij veel studies mogen samenwerken, wat geleid heeft tot mooie resultaten. Ik vind 
het dan ook leuk om in mijn nieuwe onderzoek weer nauw met je te kunnen samenwerken. Met 
jouw kritische en vooruitkijkende blik gaan we dit project ook tot een succes maken. Bovenal 
wil ik je bedanken voor je luisterend oor, als ‘papa’ van de afdeling kunnen we wel bijna zeggen. 
Het is niet altijd even makkelijk geweest, en je nam tijd om ook over niet-werk gerelateerde 
dingen te praten. Dankjewel!
Lieve analisten, Gerben, Cathelijne, Desirée, Janneke, Danny, Annemarie, Milou en Hanneke, 
jullie houden de afdeling draaiende. Ik heb het altijd fijn gevonden om één van jullie te zijn, 
en zo voelt het nog steeds een beetje. Iets met niet kunnen loslaten. Ik moet eraan wennen 
om nu ‘aan de andere kant’ te staan en jullie om hulp moet vragen voor het uitvoeren van 
experimenten. Niet dat ik geen vertrouwen in jullie heb, want dat heb ik zeker wel, maar… ik 
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weet eigenlijk niet waarom. Jullie staan altijd voor iedereen klaar en zonder jullie is er geen 
nucmed. Gerben, ik kan je geen hele bladzijde in mijn boekje geven, dus ik hoop dat ik je 
niet teleurstel. Ik hoop nog lang van jouw kennis gebruik te mogen maken, en dat we samen 
het ‘lood-project’ tot een mooi resultaat kunnen brengen. Hanneke, je kwam als geroepen 
ons ‘beta’ team versterken. Er liepen veel grote projecten door elkaar heen, waardoor we 
nauwelijks tijd over hadden om tussendoor goed bij te praten. Ik realiseer me dat we af en 
toe veel van je verwachtten, je werkte immers nog maar net bij ons op de afdeling. Mede 
door jouw zeer nauwkeurig bijgehouden labjournaal en je mega tabellen die overigens heel 
overzichtelijk waren, kon ik uiteindelijk alle resultaten bundelen. Ik hoop dat je geen muisarm 
(haha) of nachtmerries hebt overgehouden aan het eindeloos tekenen van ontplofte eilandjes. 
Desirée en Cath, uren en uren hebben we gepland, gelabeld, gescand, geofferd, geperfuseerd, 
geïsoleerd, gekleurd, getekend, geanalyseerd. Maar altijd met gezellig geklets. Cath, meestal 
heb jij een experiment al uitgevoerd voordat ik mijn vraag af heb. Je werkt super effi ciënt en 
doet alles met evenveel enthousiasme. Samenwerken met jou is een plezier, dus ik hoop dat 
we dat ook nog veel kunnen blijven doen. Desirée, dat je mijn schets van een celmembraan met 
receptoren, getekend met mijn uitzonderlijke (verreweg van goede) tekentalent, hebt weten om 
te zetten in mooie digitale plaatjes (zie H2 en H10), laat toch wel enig talent aan jouw zijde zien. 
Ik zou er niet raar van opkijken als de aanvragen nu binnenstromen (sorry?). Naast de fi jne 
samenwerking hebben we ook veel goede gesprekken gehad. Ik ben blij dat je mijn paranimf 
bent, want je verdient het. Dankjewel!
Lieve Erik, ik wil je toch even apart bedanken voor je geduld en afl eiding tijdens het vliegen. 
Zelfs toen ik op weg naar San Sebastian al een afscheidsberichtje naar mijn familie wilde gaan 
versturen omdat de steward iets te hard van de achterkant van het vliegtuig naar voren rende 
en ik dacht dat we via de glijbaan de zee in zouden moeten duiken. Uiteindelijk had jij gelijk en 
had de piloot waarschijnlijk gewoon graag een kauwgumpje. Dankjewel!
Lieve Beta-groep, Martin, Maarten, Tom, Sanne, Cath, Estel, Daphne D, Marti, ook al zijn onze 
meetings niet altijd effi ciënt (meestal wel uiteraard), ze zijn wel altijd gezellig. Het is erg fi jn 
om met jullie samen te werken, ik denk dat we een goede aanvulling zijn op elkaar. Tom en 
Daphne L, zonder jullie hulp had ik de ingewikkelde dosimetrie berekeningen nooit voor elkaar 
gekregen. Dankjewel!
Lieve Stefanie, het was ontzettend fi jn om met jou samen te werken en dat heeft ook twee 
mooie hoofdstukken opgeleverd. Maar nog meer waardeer ik de tijd buiten werk. We hebben 
samen veel gelachen, gedronken, geluisterd en gepraat. Jammer dat we geen collega’s meer 
zijn, maar erg dankbaar dat we nog steeds contact hebben. Ik kijk uit naar ons volgende 
weekendje naar Leuven! Want dat gaat er zeker komen! Dankjewel!
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Lieve kamergenoten, Sanne, René en Marti, opeens zit ik bij jullie op de kamer, bij de seniors, 
wat een serieuze bedoeling. Nooit eens tijd voor een praatje of een grapje. Altijd volledige 
concentratie op het werk, alle deadlines worden gehaald, nooit wordt er geklaagd. Niets is 
minder waar. Toch fijn dat thuiswerken, anders krijg ik niks gedaan ;-). Ik vind het leuk met 
jullie en goed dat we toch nog enige tijd onze ‘ellende’ samen kunnen delen. Dankjewel!
Lieve (oud) collega’s van de nucleaire, studenten, laboranten, hotlab, staf, artsen, PhD’s, 
seniors, mede dankzij jullie heerst er een ontzettend fijne sfeer op de afdeling. De vele borrels 
(soms iets teveel voor mij als moeder en forens), dagjes uit, research lunch, weekendjes weg, 
workshop vlaai bakken, workshop paaldansen, dagje Volendam (nee, ik ben niet zo goed in 
onverwachte dingen) en vooral ook de memorabele congressen (hét IBA-feest in Milaan is 
nooit meer geëvenaard), één en al gezelligheid. Ik ben blij dat ik hier deel van uitmaak en hoop 
dat nog lange tijd te mogen doen. Dankjewel!
Dear Martin Schäfer, Eberhard Weihe, Decio Eizirik, Alexander Balhuizen, Fritz Andreae, 
Martin Béhé, it was a real pleasure working with you. Thank you for your scientific input for 
several of my chapters. I hope we will get the chance to work together again. Thank you!
Lieve Monica van Zanten, Luc Bouwens en Eddy Himpe, ik heb onze samenwerking als zeer 
prettig ervaren. Ook al lag het werk een hele tijd stil, ik vind het fijn dat we het zo vlug weer 
konden oppakken en waardeer jullie input enorm! Dankjewel!
Lieve collega’s van pathologie, urologie en radiotherapie, ik heb vele uurtjes doorgebracht op 
jullie afdelingen, waar ik me altijd welkom heb gevoeld. Jullie gastvrijheid en behulpzaamheid 
stel ik zeer op prijs. Dankjewel!
Lieve collega’s van PRIME, Bianca, Kitty, Iris, Henk, Wilma, jullie zijn onmisbaar voor ons 
onderzoek. Door jullie flexibiliteit, meedenkendheid (is dat een woord? Bij deze), vaardigheid, 
oplettendheid en uiteraard gezelligheid is het fijn om met jullie samen te werken. Ik ben blij 
dat we dit in de toekomst kunnen voortzetten. Dankjewel!
Lieve carpoolers, Cindy, Claudia, Hanneke, Najat, José. We hebben het er vaak over gehad. 
Is je dankwoord nou al af? We komen er wel in he? Tadaa, hier staan jullie dan! Welverdiend! 
We kletsen wat af tijdens onze ritjes, al doe ik ook graag even mijn ogen dicht in de auto. Alle 
ins en outs worden besproken en het is fijn om mijn ei kwijt te kunnen bij jullie. De meest 
hilarische momenten waren toch vaak wanneer we in een file terecht kwamen en spijt hadden 
dat we geen snoepjes in de auto hadden liggen of probeerden met een foto op het nieuws 
te komen. Helaas is dat één keer wel gelukt, maar toch hebben we toen ook veel gelachen. 
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Waarschijnlijk van de schrik. Ook Nico, Alice, Bart, Suzanne, Marian, Ria, Karen, Monique en 
Kim wil ik bedanken voor de gezellige ritjes. Dankjewel!
Dear Bridget Collins (Flora Forager), your work inspires me. I am really grateful that I could 
use your botanical artworks to illustrate my book. They are a perfect match with the work that 
I have done. Thank you!
Lieve Bregje, jij voelde precies goed aan welke kant ik op wilde met de lay out van mijn boekje, 
vooral omdat het toch iets afwijkt van de meeste boekjes. Ik ben blij dat je mijn ‘More is more’ 
hebt weten in te dammen. Het moest herkenbaar zijn als een echt ‘Lieke-boekje’, en ik geloof 
dat dat is gelukt. Dankjewel!
Het leven draait niet alleen om werken, en ik mag me gelukkig prijzen dat ik zoveel mensen om 
me heen heb voor de nodige ontspanning en afl eiding.
Lieve Lay’s, spreekt voor zich. Dankjewel!
Lieve familie, ik kijk altijd weer uit naar onze familiedagen, weekendjes weg en op zondagochtend 
chocola eten bij Omi. Dankjewel! 
Lieve vrienden, René, Cindy, Sjors, Sonja, Tom, Anda, Erik, Sandra, Johan, Christel, Roos, 
Niels, Leonie, Rob, Aniek (Buisbubs 2.0), Richard en Veerle, een feestje, verhuizen, klussen of 
gewoon een gezellig avondje, we kunnen altijd op elkaar rekenen. Op handen en voeten door 
tunnels kruipen, met kleren aan in de sloot vallen of een ouderwets potje beugelen. Ik vind het 
fi jn om samen te zijn. Hopelijk kan dat snel weer, dan gaan we proosten en dan zeggen we net 
zo vaak: “Nog eine dan”,  tot we er bij neervallen. Christel, je staat altijd voor ons klaar, “doe 
bis de leefste”. Dankjewel!
Lieve Golden Girls (volgens Remco de Grey Girls) Marloes, Christine en Leonie, we hebben 
al vele mooie herinneringen gemaakt sinds we elkaar hebben leren kennen op de Bouwens. 
Ons plan om elk jaar een Escape Room te gaan doen is niet helemaal gelukt, en het is al een 
puzzel op zich om een avondje te prikken om te daten. Ik denk graag terug aan onze jaarlijkse 
(wat ging er mis?) kermis date (waar ik me niet alles van kan herinneren), de PM-sessies in 
Panningen, etentjes (met en met zonder kinderen en aanhang), en het eten van ijsjes met 
alcohol. Ik hoop nog meer mooie herinneringen met jullie te maken. Dankjewel!
Lieve Thom en Chris, ik geniet van de spontane etentjes en gezellige avonden samen (en 
zwempartijtjes die onze dochters regelen). Dankjewel!
Lieve Leonie en Niels, we kenden elkaar al toen we nog niet konden lopen. We raken nooit 
uitgepraat, terwijl we eigenlijk aan één woord genoeg hebben. Als we samen zijn is het altijd 
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gezellig, moet er altijd een etentje bij en wordt het altijd te laat. En dat is fi jn. Laten we hiermee 
doorgaan tot we niet meer kunnen lopen. Dankjewel!
Lieve schoonfamilie, Leo, Jeanne, Lotte, Lucas, Pien en Richard, alweer 19 jaar geleden stapte 
ik bij jullie naar binnen. Een beetje onwennig in het begin, maar ik ben blij met zo’n lieve 
schoonfamilie. Dankjewel!
Lieve papa en mama, de grootste dank gaat uit naar jullie! Jullie hebben de basis gelegd, en 
dat is denk ik het halve werk. Dankzij jullie heb ik het zover kunnen schoppen. Jullie liefde en 
steun is onvoorwaardelijk. Niet alleen voor mij, maar ook voor de kinderen. De wetenschap 
dat jullie altijd voor ons klaar staan geeft rust. Op de kindjes passen, verbouwen, huis op orde 
houden, op de kindjes passen, tuin op orde houden, op de kindjes passen. Het is nooit teveel 
voor jullie en daarom kon ik met een gerust hart aan mijn promotie werken. Dankjewel!
Lieve Rob, Aniek en Evy, ik vind het ontzettend fi jn dat we elkaar nu vaker zien, ondanks dat 
we niet bij elkaar in de buurt wonen. Ik ben trots op jullie, als kersvers gezin. Evy, wat gaan 
we samen nog vele leuke dingen meemaken. Ik kan niet wachten om je weer te knuffelen. 
Aniek, het lijkt alsof ik je al jaren kent en dat voelt goed. Rob, ik ben ontzettend trots dat jij hier 
vandaag bij me staat. Dankjewel!
Lieve Zsofi  en Timo, als er iets is wat ik jullie wil leren, is dat je nooit moet opgeven en 
vertrouwen moet hebben in jezelf. Die woorden krijg ik ook meteen van jullie terug als ik 
me weer druk maak om de verdediging. Door onze momenten samen kan ik echt alles even 
loslaten en genieten. Genieten, dat doe ik van jullie, met volle teugen. Dankjewel voor jullie 
knuffels, ondeugendheid, gekkigheid, eerlijkheid, vertrouwen en liefde. Jullie zijn mijn alles! 
De tijd staat jullie goed! Dankjewel!
Lieve Remco! Mijn liefje, mijn maatje, mijn best vriend, mijn rem… Dankjewel voor je 
onvoorwaardelijke steun. Je kent me door en door. Je kent me beter dan dat ik mezelf ken. 
Wanneer ik weer eens meerdere achtbanen in mijn hoofd heb, weet jij ze in goede banen te 
leiden, zodat er geen kan ontsporen. Je begrijpt het als geen ander wanneer ik toch even moet 
werken om mijn hoofd leeg te krijgen, of wanneer ik echt even tijd voor mezelf nodig heb. We 
hebben ontzettend veel meegemaakt samen, en dat heeft ons alleen maar sterker gemaakt. 
Je hebt me tevens het allermooiste gegeven wat er bestaat, ons gezin. Ik kijk er heel erg naar 
uit om samen met jullie mooie nieuwe herinneringen te maken. Dankjewel lief!
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Radiology and Nuclear Medicine to work as a research technician. While working as a senior 
research technician, she started her PhD project at the same department. Her project is 
focused on the development and characterization of novel beta cell tracers. From September 
2019 she continues her work at the Department of Radiology and Nuclear Medicine as a 
Scientifi c Researcher on the project ‘Development of a new alpha-based-PSMA therapy for 
prostate cancer’.
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Training activities Year(s) ECTS
a) Courses & Workshops
- Statistics
- Within sight of my PhD
- FIJI microscopic imaging
- RIMLS PhD Retreat
- How to write a medical scientifi c paper
- Scientifi c integrity
- RIMLS PhD Retreat*
- InDesign course
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All raw and processed data obtained during my PhD and described in this thesis have been 
stored on the hard drive of the department of Radiology, Nuclear Medicine and Anatomy at 
the Radboud university medical center. This hard drive is password protected and automatic 
back-ups are made several times a day. Most of the data is captured in notebooks and a digital 
copy of these notebooks is stored on the hard drive as well. A small part of the data in chapters 
6 and 8 is captured and stored on Labguru, a digital lab book client, which is centrally stored 
and daily backed-up on the local Radboudumc server. Raw data from equipment (e.g. SPECT/
CT, gamma counter) are backed-up on university servers belonging to the department. Big 
data, for example SPECT/CT images and immunohistochemical images are stored on external 
hard-drives and are located at the department of Radiology, Nuclear Medicine and Anatomy.
All mouse studies were performed according to the Institute of Laboratory Animal Research 
Guidelines. Animal experiments were approved by the Animal Ethical Committee of the 
Radboud University, Nijmegen, The Netherlands.
Accessible
All protocols and data are accessible by contacting the corresponding author or one of the 
researchers involved in these studies.
Interoperable
All protocols and data are documented in English.
Reusable
All data will be saved for at least 15 years after publication of the respective study. All 
used methods and data analyzed during these studies are available upon request from the 
corresponding author.
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